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Zusammenfassung 
 
Adenosin zu Inosin Editierung von Ribonukleinsäuren (RNA) ist eine konservierte 
post-transkriptionelle Modifikation in höheren Metazoen. Die hydrolytische 
Desaminierung von Adenosin zu Inosin wird von einer Enzymfamilie durchgeführt, 
welche als Adenosin-Deaminasen bekannt sind (ADARs) und doppelsträngige RNA 
desaminieren. Durch RNA-Editierung wird die Sequenz eines primären Transkriptes 
verändert, was dramatische Auswirkungen haben kann: Editierung der mRNA eines 
kodierenden Transkriptes kann zu alternativem Splicing und 
Aminosäurensubstitutionen im translatierten Protein führen. Abgesehen davon 
gehören nicht-codierende RNAs und repetitive Sequenzen, wie Alu-Elemente und 
micro RNAs, zu den Hauptsubstraten von ADARs. Editierung dieser Substrate kann 
Einfluss auf die Expression von Genen haben, weil die Sequenz regulatorischer 
Elemente und kleiner RNAs verändert wird.  Durch aktuelle Studien wurden bereits 
viele Substrate für ADAR-vermittelte Editierung identifiziert. Jedoch sind 
Auswirkungen der Editierung auf die Funktion vieler prozessierter Substrate noch 
nicht bekannt. Zusätzlich zu den unbekannten Konsequenzen der RNA-Editierung 
gibt auch die Regulation dieses Mechanismus Rätsel auf.  
In den vergangenen Jahren wurden in unserer Arbeitsgruppe einige Kandidaten 
identifiziert, welche als mögliche Regulatoren für RNA-Editierung in Frage kommen. 
In diesem Projekt haben wir versucht, diese Kandidaten stabil in Säugerzellen zu 
exprimieren, um durch Aufreinigungsmethoden und anschließende 
massenspektrometrische Analyse Interaktionsnetzwerke dieser Kandidaten 
aufzuklären. Der zweite Teil dieser Arbeit behandelt zwei Substrate für RNA-
Editierung: das zytoskelettale Protein Filamin A und BLCAP, ein Protein, assoziiert 
mit der Entstehung von Blasenkrebs. Editierte und nicht editierte Versionen dieser 
Proteine wurden stabil in Säugerzellen exprimiert. Durch Aufreinigungsexperimente 
unter nativen Bedingungen und anschließender massenspektrometrischer Analyse 
konnten einige Proteine identifiziert werden, welche mit diesen ADAR-Substraten 
interagieren. 
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Abstract 
 
Adenosine to inosine RNA editing is a posttranscriptional modification highly 
conserved in higher metazoa. The hydrolytic deamination of adenosine to inosine is 
catalysed by a family of enzymes, known as adenosine deaminases that act on double-
stranded RNA (ADARs). Changing the sequence of a primary transcript by RNA 
editing can have dramatic consequences: Editing of the pre-mRNA of a coding 
transcript can lead to alternative splicing events and may cause amino acid 
substitutions in the translated protein, as the triplet codon becomes changed. Apart 
from that, most of the known substrates of RNA editing are non-coding RNAs and 
repetitive elements, as Alu elements in untranslated regions of the transcript, and 
micro RNAs. These editing events can influence gene expression, as the sequence of 
regulatory elements or the target specificity of small RNAs is altered. To date, on-
going studies have identified many targets of ADAR editing. However, very little is 
known about the consequences of the editing events. In addition to the consequences 
of editing on its targets, mechanisms of regulation of A to I editing are still unclear.  
In the last few years several candidates for regulators of ADAR activity have been 
identified in our lab. In this thesis we stably expressed these candidates in mammalian 
cell lines for purification assays.  Subsequent mass spectrometric analysis of purified 
complexes led to the identification of proteins interacting with editing regulator 
candidates, what may help to clarify regulatory networks involved in A to I RNA 
editing. The second part of this project deals with two protein-coding targets of RNA 
editing: The effect of RNA editing on the interaction profiles of the cytoskeletal 
cross-linker Filamin A, and the bladder cancer associated protein BLCAP is 
investigated. Edited and unedited versions of both proteins were stably expressed in 
mammalian cell lines. Purification of the two targets of RNA editing under native 
conditions led to the identification of interacting proteins after mass spectrometric 
analysis.  
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1. Introduction  
 
After eukaryotic transcription the produced RNA transcript is still immature and has 
to undergo several processing steps to fulfil its destined function. The primary 
transcript of a coding region gets modified by 5’ capping and 3’ processing (e.g. 
polyadenylation) what stabilizes the transcript (Darnell, 1979; Darnell et al., 1971; 
Shatkin, 1976). Splicing removes introns from a primary transcript (Konarska and 
Sharp, 1987; Kruger et al., 1982). Lastly, RNA editing induces sequence changes 
(Benne, 1992; Cattaneo et al., 1988; Melcher et al., 1996b; Visomirski-Robic and 
Gott, 1997). These processing steps together with posttranslational mechanisms are 
thought to be very important for the complexity of higher organisms, to generate a 
diversity of products from a minimal set of coding regions. The mechanism I focus on 
in this thesis is RNA editing, a posttranscriptional mechanism, where single 
nucleotides get selectively inserted, deleted or chemically modified (Aphasizhev et 
al., 2003; Kapushoc and Simpson, 1999; Navaratnam et al., 1995; Polson et al., 1991; 
Visomirski-Robic and Gott, 1995).  
 
 
1.1. RNA editing 
 
Several subtypes of RNA editing exist where bases are changed (C to U/ A to I 
deamination), deleted or inserted. Nucleotide insertion or deletion editing generally 
affects mitochondrial and plastid RNA in lower eukaryotes. This subtype of RNA 
editing was discovered in Trypanosomes. These protozoa insert and delete uridines 
extensively in mitochondrial messenger RNAs by an editing mechanism, involving 
guide RNAs (Aphasizhev et al., 2003; Kapushoc and Simpson, 1999; Visomirski-
Robic and Gott, 1995). Another subtype of RNA editing is the modification type 
found in nuclear-encoded RNA. One of these modifications, which occurs in plants 
and animals, is the deamination of cytidine to form uracil. The first C to U editing 
reaction identified in mammals was found in the Apolipoprotein B transcript. Here the 
primary mRNA gets edited to convert a CAA codon into a UAA stop codon to 
generate the two versions of Apolipoprotein B, type 48 and type 100, which both play 
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important roles in cholesterol metabolism (Navaratnam et al., 1995; Takenaka et al., 
2008). 
 
The conversion of adenosine into inosine in double-stranded RNAs is catalysed by a 
family of enzymes called adenosine deaminases that act on double-stranded RNA 
(ADARs) (Bass et al., 1997). During this editing reaction the C-6 position of an 
adenine base becomes hydrolytically deaminated to generate inosine (Polson et al., 
1991; Wagner et al., 1989). As depicted in figure 1, inosine is recognized as 
guanidine by cellular machineries, because it forms Watson-Crick base pairs with 
cytosine (Polson et al., 1991). RNA editing may be a powerful mechanism for the 
generation of protein diversity, because the edited and the unedited version of the 
transcript are present within a cell, regulated in a tissue- and temporal-specific 
manner. The first member of the ADAR family was discovered and isolated from 
Xenopus laevis in 1987 as a double-stranded RNA unwinding activity (Bass and 
Weintraub, 1987; Rebagliati and Melton, 1987). Later it was found, that the enzyme 
does not actively unwind RNA but the duplexes are destabilized by inosine : uracil 
base pairs (Wagner et al., 1989). To date several other members of ADARs have been 
identified and isolated from many metazoa, like from mammals, birds, flies and 
worms (Herbert et al., 1995; Melcher et al., 1996b; O'Connell et al., 1995; Palladino 
et al., 2000b; Tonkin et al., 2002).  
    A)   B)        
Figure 1) RNA editing. A) Hydrolytic deamination of adenosine into inosine. B) Base-pairing properties before 
and after RNA editing (Nishikura, 2010). 
 
Due to the fact that the conversion of adenosine into inosine alters the primary 
sequence and structural features of a RNA transcript, RNA editing may also effect 
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functional activities of the mature RNA. Several cellular mechanisms affected by 
RNA editing are depicted in figure 2 and discussed in the following section. 
  
 
Figure 2) Mechanisms affected by RNA editing. Since inosine forms Watson-Crick base pairs with cytosine, 
RNA editing leads to a nucleotide substitution in the primary RNA transcript. A to I RNA editing can alter the 
meaning of a triplet codon and therefore lead to an amino acid substitution of the translated product. Pre-mRNA 
splicing is also affected by RNA editing if a conserved A of a splice site recognition sequence becomes edited. 
Editing of miRNA can influence the action of miRNA processing proteins. Additionally the target specificity of 
the mature miRNA can be altered if an A within the seed region becomes edited. Also RNA stability and structure 
are manipulated by RNA editing because I:U base pairs generate bulges within the RNA duplex and destabilize the 
molecule (Samuel, 2011). 
 
The change of the primary sequence of protein coding transcripts may lead to a 
substitution of the encoded amino acid since inosine is interpreted as guanosine by 
cellular machineries, like the translation machinery. Thus the translated product may 
show alternative activity features as was shown for example for HDV viral proteins 
(Chen et al., 2010) and several neuronal receptors as described in 1.5. Since RNA 
editing alters the primary transcript, also conserved RNA-encoded recognition sites 
can be altered, such as AU dinucleotides, which are highly conserved splice site 
recognition sites and intronic or exonic splicing enhancer or silencer sequences 
respectively. Thus RNA editing may be involved in regulating RNA processing. To 
mention one example, ADAR2 was found to autoregulate its own expression. By 
autoediting of ADAR2 pre-mRNA, an alternative 3’ splice site is generated what 
causes the insertion of 47 nucleotides into the mature transcript (Rueter et al., 1999). 
In addition to the effects of RNA editing on mRNA translation and splicing it also 
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affects replication of viral RNA, since A to G and U to C transitions are generated 
(Cattaneo and Billeter, 1992). A to I RNA editing leads to mutations in the viral 
genome after RNA-dependent RNA replication. As mentioned earlier, RNA editing 
was initially discovered as an RNA unwinding activity (Bass and Weintraub, 1987; 
Rebagliati and Melton, 1987). The reduced stability of RNA duplexes is due to the 
conversion of a A:U Watson-Crick base pair into a less stable I:U wobble base pair 
(Serra et al., 2004; Strobel et al., 1994). Micro RNAs are also known to be targets of 
ADARs (Kawahara et al., 2008; Kawahara et al., 2007a; Kawahara et al., 2007b). 
Thus by RNA editing the action of miRNA processing proteins, such as 
Drosha/DGCR8 or Dicer, can be inhibited (Kawahara et al., 2007a; Yang et al., 
2006). Additionally, the target specificity of the mature miRNA can be altered, if an 
A within the seed region becomes edited (Kawahara et al., 2007b). As mentioned 
before, RNA editing reduces the stability of the RNA by changing the base pairing 
properies of the transcript. Additionally, hyperediting leads to efficient degradation of 
the inosine containing RNA. The RISC subunit Tudor staphylococcal nuclease 
(Tudor-SN) is known to cleave hyperedited inosine-containing RNA, thus linking 
RNA editing to RNAi pathways (Scadden, 2005).  
 
1.2. The family of ADARs 
 
Enzymes with deaminase activity have been identified in several organisms (Herbert 
et al., 1995; Melcher et al., 1996c; O'Connell et al., 1995; Palladino et al., 2000a; 
Tonkin et al., 2002). These proteins, belonging to the family of ADAR enzymes, 
show a common domain structure. The deaminase domain is located at the C-terminus 
and highly conserved. The N-terminal structure by contrast varies in the amount of 
double-stranded RNA binding motifs (dsRBDs) (St Johnston et al., 1992) and several 
additional nucleotide binding domains, such as the Z-domain of ADAR1 isoforms, 
which enables them to bind DNA, and the arginine-rich R-domain in ADAR3, which 
is known to be a common single-stranded RNA binding motif (Chen et al., 2000; 
Herbert et al., 1997). Though, the functional significance of these additional 
DNA/RNA-binding domains remains largely unknown. Three variants of ADARs are 
highly conserved among vertebrates (Slavov et al., 2000). In humans, ADAR1 is 
expressed in two isoforms. The expression of the larger 150 kDa ADAR1 isoform is 
induced by interferon signalling, stimulated by cellular stress or viral infection and is 
	   13	  
known to be present within the cytoplasm and nucleus. The shorter p110-ADAR1 
isoform is constitutively expressed and exclusively nuclear located. Both ADAR1 
isoforms are able to bind double-stranded RNA through three dsRBDs (Patterson and 
Samuel, 1995). ADAR2 was found to be alternatively spliced to yield isoforms 
containing distinct C-termini and 3’ UTRs expressed abundantly in brain and heart 
tissues (Gerber et al., 1997). A third member of the human ADAR enzymes, ADAR3, 
was identified in 1996 (Melcher et al., 1996a). ADAR3 is expressed exclusively in 
brain tissues (Melcher et al., 1996a) and contains both, double- and single-stranded, 
RNA binding motifs (Chen et al., 2000). To date there is no evidence for the 
enzymatic activity of ADAR3. However, in vitro editing assays have shown inhibited 
editing activity of ADAR1 and ADAR2 in the presence of ADAR3 indicating a 
regulatory role of ADAR3, for the editing process (Chen et al., 2000).  
 
 
Figure 3) The family of ADARs. ADAR1, ADAR2 and ADAR3 are the three known vertebrate family members, 
where ADAR1 is expressed in two isoforms. Two squid, two C. elegans ADAR enzymes and one D. melanogaster 
ADAR enzyme are known. These ADAR family members show a highly conserved deaminase domain at their C-
termini and variable numbers of dsRBDs. Some members comprise additional nucleotide binding motifs such as a 
DNA-binding Z-motif in ADAR1 and a single-stranded RNA binding motif in ADAR3. ADAR: Adenosine 
deaminase that act on RNA; Sq: squid; Dm: Drosophila melanogaster; Ce: Caenorhabditis elegans; blue: 
deaminase domain; violet: dsRBD; green: Z-DNA binding domain; pink: R-motif (Nishikura, 2010). 
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1.3. Regulation of RNA editing 
 
RNA editing has a dramatic effect on protein function and the regulation of RNA 
meditated cellular mechanisms. However, little is known about the regulation of the 
editors, the ADARs. Nevertheless, some facts about ADAR expression pattern and 
known posttranscriptional and posttranslational modifications are discussed in this 
section. 
 
Expression of ADAR proteins is highly regulated during development and in a tissue 
specific manner (Gerber et al., 1997; Jacobs et al., 2009; Melcher et al., 1996a; 
Melcher et al., 1996c; O'Connell et al., 1995). The two active enzymes, ADAR1 and 
ADAR2, are expressed in many tissues. However, their expression was found to be 
highest in brain tissues (Melcher et al., 1996c). A different set of proteins becomes 
edited during brain development with increasing rates, where editing levels are 
highest in the adult brain. The target specificity and rate of editing during 
development cannot simply be explained by altered expression levels of ADARs 
(Wahlstedt et al., 2009). ADAR1 is expressed in two isoforms, a full-length 
ADAR1p150, driven by an interferon-inducible promoter, and a N-terminally 
truncated ADARp110, which is constitutively expressed (George and Samuel, 1999; 
Patterson and Samuel, 1995). The ADAR1 gene comprises three alternative 
promoters, whereas, one of them is induced by interferon signalling. The produced 
transcripts comprise alternative first exons (George and Samuel, 1999; Kawakubo and 
Samuel, 2000). Both isoforms of ADAR1 contain three dsRBDs and the C-terminal 
deaminase domain (O'Connell et al., 1995). However, ADAR1p110 contains just one 
DNA-binding motif, the Z-binding domain, whereas ADAR1p150 encodes two Z-
binding domains, Zα and Zβ, as a N-terminal extension of the short isoform, where 
only the Zβ domain is found (Herbert et al., 1997). The p150 isoform of ADAR1 
comprises nuclear export and nuclear import sequences (Eckmann et al., 2001), which 
enable it to shuttle between nucleus and cytoplasm, regulated by the binding of 
transportin-1 and exportin-5 respectively, where binding of dsRNA would interfere 
with transportin-1 binding (Fritz et al., 2009). Additionally it was found earlier, that 
another nuclear export signal is located within one Z-binding domain of 
ADAR1p150, which is bound by the nuclear export receptor Crm1, what is another 
indication for a shuttling activity of ADAR1p150 (Poulsen et al., 2001). Also 
	   15	  
posttranslational modifications of the editing enzymes have been shown to be 
important for their enzymatic function. Sumoylation of lysine residues of ADAR1 by 
SUMO-1 reduces the editing activity of ADAR1 in vitro and in vivo. ADAR1 co-
localizes with ADAR2 in the nucleolus. However, only ADAR1 gets modified by 
SUMO-1, because ADAR2 lacks the N-terminal sumoylation site (Desterro et al., 
2005). 
ADAR2 is predominantly located within the nucleus, where it accumulates and co-
localizes with ADAR1 within defined compartments of the nucleolus (Desterro et al., 
2003). Sansam et al. have shown in 2003, that ADAR2 is able to shuttle rapidly from 
the nucleolus to other nuclear compartments. This concentration of ADAR2 within 
the nucleolus is rRNA-dependent, where ADAR2 translocation is targeted by direct 
interactions with rRNA. In order to become enzymatically active ADAR2 translocates 
out of the nucleolus to the nucleoplasm to edit its nuclear encoded RNA substrates, 
suggesting an important impact of localization of the enzyme on the regulation of 
editing (Sansam et al., 2003). Various isoforms of ADAR2 are generated by 
alternative splice events in a tissue-specific manner (Agranat et al., 2010; Gerber et 
al., 1997; Maas and Gommans, 2009). ADAR2 selectively modifies its own pre-
mRNA and thereby auto-regulates its expression by generating various alternatively 
spliced products. This editing event happens as a co-transcriptional process 
(Laurencikiene et al., 2006). One of these editing events converts an intronic AA into 
an AI dinucleotide, generating an alternative proximal 3’ splice site acceptor. 
Alternative splicing of the ADAR2 pre-mRNA leads to an alternative transcript, 
including additional nucleotides and thus results in a frame shift. By changing the 
reading frame of the ADAR2 mRNA the translated protein lacks the dsRBDs and 
zinc-coordination motifs required for deaminase activity. Hence RNA editing is a 
possible mechanism for the regulation of alternative splicing and protein expression 
(Rueter et al., 1999).  Another alternative splice event within the ADAR2 primary 
transcript leads to the generation of an ADAR3-like nuclear localization sequence 
bound by importins. This splicing event alters the binding specificity of importins and 
may play an important role during localization of the protein, thus could be another 
way of regulating ADAR activity (Maas and Gommans, 2009). Structural studies of 
the ADAR2 deaminase domain have illustrated the requirement of one zinc atom and 
one molecule of inositol hexakisphosphate in the catalytically active centre of the 
ADAR2 deaminase domain. The zinc atom may help the enzyme to localize the 
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adenosine to be edited, located in the major groove of the dsRNA. The inositol 
hexakisphosphate molecule is required as cofactor for the catalytic activity of the 
deaminase and for protein folding. However, ADAR1 does not need inositol 
hexakisphosphate for its enzymatic activity (Macbeth et al., 2005). In addition it was 
found that ADAR1 and ADAR2 both predominantly form homodimers. Functional 
protein-protein interactions between the molecules seem to be important for their 
enzymatic activity and for choosing the adenosine to be edited (Cho et al., 2003; 
Jaikaran et al., 2002). The formation of homodimers is RNA-independent, but two 
ADAR monomers with functional dsRBDs are required for the editing reaction to 
occur (Valente and Nishikura, 2007). However, recombinant expressed ADAR3 does 
not form homodimers, what may explain its enzymatic inactivity. Whether brain 
specific posttranslational modifications or oligomerization of ADAR3 might lead to 
an enzymatically active enzyme is still not proven (Cho et al., 2003). As mentioned 
before, no enzymatic activity of the third member of the vertebrate ADAR family, 
ADAR3, has been shown so far. Though it contains a homologous deaminase domain, 
similar dsRBDs and an additional R-domain for binding of single-stranded RNA 
(Chen et al., 2000), no editing activity on known editing substrates could be 
demonstrated. ADAR3 also differs from its family members in its expression pattern 
since it its exclusively expressend in brain tissues (Melcher et al., 1996a). One nuclear 
localization signal was found within the arginine-rich R-domain of ADAR3, which is 
bound by importin alpha 1. Nevertheless, identification of this binding partner of 
ADAR3 does still not elucidate the functional role of this ADAR family member 
(Maas and Gommans, 2009). 
 
In the last few years several candidates for regulators of ADAR-mediated editing 
have been identified in our lab. In a new developed yeast screen the small acidic 
protein DSS1 (yeast ortholog SEM1) was found to be an activator of ADAR2 activity. 
In addition, some editing inhibiting candidates have been identified: The RNA 
helicase DDX15, the splice factor SRSF9 and the ribosomal protein RPS14. The 
regulatory role of these proteins was also confirmed in mammalian cells (Aamira 
Tariq, unpublished data). 
 
DSS1 is of 70 amino acids in length and seems to be a ubiquitous protein, present in 
the nucleus and the cytoplasm. This short protein is comprised of three alpha-helices 
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separated by two beta-sheets, containing a high number of acidic amino acids (Yang 
et al., 2002). As part of the small subunit of the 26S proteasome in yeast and 
mammals, the evolutionarily conserved DSS1 may play an important role in protein 
degradation (Coux et al., 1996; Funakoshi et al., 2004; Josse et al., 2006; Sone et al., 
2004). Additionally DSS1 may be involved in DNA repair, as it forms a 
stoichiometric complex with the repair protein BRCA2 (breast cancer associated 
protein 2). DSS1 is required for BRCA2 stability and regulates its ability to bind 
single-stranded DNA (Li et al., 2006). Other studies have indicated an important role 
of DSS1 during the recruitment of BRCA2-RAD51 complexes to sites of DNA 
damage (Dray et al., 2006; Gudmundsdottir et al., 2004). DSS1 seems to be a 
multifunctional player within the cell, as in addition to its role during protein 
degradation and DNA repair, studies in yeast indicated also an important role of 
DSS1 during splicing and mRNA export through interactions with nucleoporins 
(Thakurta et al., 2005; Wilmes et al., 2008). 
The DExD/H-box RNA helicase DDX15 (Imamura et al., 1997), the human ortholog 
of the yeast Prp43, has been identified as a possible negative regulator of ADAR 
activity. DEAH-box RNA helicases are involved in several cellular processes where 
they unwind double-stranded RNA in an energy dependent manner, reviewed in 
Rajkowitsch et al., (Rajkowitsch et al., 2007). DDX15 was found to localize to the 
nucleus, nuclear speckles and nucleoli, where it co-localizes with U snRNAs, and 
may play important roles during splicing of primary transcripts as its yeast ortholog 
Prp43 does. The N- and C-terminal regions of DDX15 contain localization signals. 
The N-terminal part of the protein is involved in localization of DDX15 to the nucleus 
and nucleolus, whereas C-terminal signal sequences are responsible for the 
localization to nuclear speckles. It was also shown that parts of the DDX15 DEAH-
box domain interact with the LA antigen, a putative RNA chaperone (Fouraux et al., 
2002). 
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Figure 4) Scematic domain structure of DDX15. The highly conserved DEAH domain of DDX15 (black) is 
flanked by N-and C-terminal extensions, which contain signal sequences important for DDX15 subcellular 
localization. At the N-terminus sequences for localization to the nucleus (Nu) and to the nucleolus (No) are found. 
The C-terminal signal sequences are involved in localization to nuclear speckles. The LA antigen binds within the 
helicase domain (La) (Fouraux et al., 2002). 
 
 
Another candidate, identified in an ADAR-inhibiting activity screen, is the ribosomal 
protein RPS14. RPS14 is a subunit of the 40S ribosomal part and is required for 18S 
pre-rRNA processing (Ebert et al., 2008; Ferreira-Cerca et al., 2005) and 40S 
ribosomal subunit formation (Chen et al., 1986; Rhoads et al., 1986). Heterozygous 
deletion of RPS14 leads to a decrease in the production of erythroid progenitors and 
blocks the production of terminally differentiated erythroid cells. The phenotype of 
this haploinsufficiency of RPS14 correlates with the 5q- syndrome or myelodysplastic 
syndrome, where heterozygous deletion of RPS14 was identified as a major cause of 
the disease (Ebert et al., 2008). 
 
The last putative candidate for a negative regulator of ADAR activity identified in the 
editing screens is the arginine/serine-rich splice factor SRSF9. SR proteins are 
characterized by their ability to interact simultaneously with RNA and protein 
components via an RNA recognition motif (RRM) and through a domain rich in 
arginine and serine residues, the RS-domain. Their functional roles in gene expression 
are surprisingly diverse, ranging from their classical involvement in constitutive and 
alternative pre-mRNA splicing to various post-splicing activities, including nuclear 
export of mRNA, nonsense-mediated decay, and mRNA translation, reviewed in 
Shepard et al., (Shepard and Hertel, 2009). Our candidate, SRSF9, also known as 
SRp30, is involved in alternative splicing of pre-mRNA (Screaton et al., 1995). 
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Figure 5) Scematic domain structure of SRSF9. The arginine/serine rich splice factor SRSF9 was initially 
named as SRp30c. It contains a RRM, RNA recognition motif, RRMH, RNA recognition motif homology, and an 
arginine/serine-rich domain (RS), taken and modified from Shepard et al, 2009 (Shepard and Hertel, 2009). 
 
 
 
 
1.4. Site-selectivity and substrate specificity of ADARs 
 
Several studies on A to I RNA editing have indicated that an RNA duplex, completely 
double-stranded or comprising single-strand bulges and loops, is required for the 
editing reaction to occur, whereat inter- and intra-molecular double-stranded regions 
can serve as substrates for editing. However, the modification efficiency is dependent 
on the length of the double-stranded region (Morse et al., 2002; Nishikura et al., 
1991). Long double-stranded viral RNAs become extensively edited during 
replication, presumably as mechanism for adaptation (Cattaneo et al., 1988).  By 
contrast, site selectivity of RNA editing is dependent on the RNA secondary structure, 
where mismatched bases, bulges or loops may determine which adenosine becomes 
edited (Lehmann and Bass, 1999). Overall, RNA editing seems not to be sequence 
specific. Nevertheless, in addition to the importance of the secondary structure of 
editing targets, several studies on specific substrates of ADARs have shown site-
selective editing events dependent on the sequence context of the edited RNA. Thus, 
structural elements and the sequence of the editing substrate determine the extent of 
editing in a given double-stranded RNA (Dawson et al., 2004; Maas et al., 1996). 
ADAR1 has a 5’ neighbour preference (A = U > C > G) but edits independent of the 
adenosine 3’ neighbour. Also the distance of the edited adenosine to strand termini 
was found to impact the probability of this adenosine to be edited (Barraud et al., 
2011; Eggington et al., 2011; Polson and Bass, 1994). ADAR2 has a similar 5’ 
neighbour preference as ADAR1 (A = U > C = G), but was found to have a 3’ 
neighbour preference too (U = G > C = A). In general, the nearest 5’ neighbour highly 
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influences the choice of the A to be edited (Eggington et al., 2011). Dependent on the 
structure and sequence of the substrate, the adenosine to be edited, may be flipped out 
of the helix (Hough and Bass, 1997). Studies on editing selectivity of both enzymes 
have shown an overlap in substrate specificity of ADAR1 and ADAR2 (Lehmann and 
Bass, 2000; Riedmann et al., 2008).   
 
 
1.5. Targets of ADARs 
 
Messenger RNAs expressed in the central nervous system have been the first 
identified substrates for A to I RNA editing (Sommer et al., 1991). Though on-going 
bioinformatical and biochemical studies have identified thousands of new editing sites 
within non-coding RNAs, untranslated highly repetitive regions and in some protein-
coding RNAs, little is known about the effect of RNA editing on the organism 
(Athanasiadis et al., 2004; Blow et al., 2006; Hundley and Bass, 2010; Kim et al., 
2004; Levanon et al., 2004; Levanon et al., 2005; Li et al., 2009; Riedmann et al., 
2008; Xia et al., 2005). However, knock out studies on worms, flies and mice have 
revealed a fundamental role for ADAR enzymes for the living organism. The 
expression of the Drosophila melanogaster homolog of ADAR, dADAR, is highly 
regulated during development (Chen et al., 2009). Flies lacking dADAR show a 
severe behavioural phenotype and have impaired coordinated locomotion (Palladino 
et al., 2000a, c). If the Caenorhabditis elegans homologs of ADAR, ceADAR1 and 
ceADAR2, are homozygously deleted, the worms show defects regarding chemotaxis 
and in development of the vulva (Tonkin et al., 2002). Mice carrying a homozygous 
deletion of ADAR1 die early during embryonic development between day E11.0 and 
E12.5. This severe ADAR1 knock out phenotype is accompanied by elevated levels 
of apoptosis (Hartner et al., 2004; Wang et al., 2004) liver disintegration and defects 
in haematopoiesis (Hartner et al., 2004; Hartner et al., 2009). Additionally, 
conditional knock-out studies with mice have indicated an essential role of ADAR1 
during fetal and adult hematopoietic stem cell maintenance and as a suppressor of 
interferon signalling in hematopoietic stem cells and fetal liver progenitor cells 
(Hartner et al., 2009). ADAR2 deficiency does not interfere with embryonic 
development, but mice lacking ADAR2 die early after birth due to recurrent epileptic 
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seizures (Brusa et al., 1995; Higuchi et al., 2000). This severe phenotype is due to 
underediting of one particular position in a protein-coding ADAR2 substrate, the 
Q/R-site of glutamate receptor B (GluR-B), what leads to an increased Ca2+ 
permeability of the AMPA receptor channel. Thus, the GluR-B Q/R-site may be the 
most important physiological substrate of ADAR2 (Higuchi et al., 2000).  
Non-coding RNAs and repetitive elements, like Alu elements, within transcripts are 
the most abundant substrates for RNA editing (Greenberger et al., 2010; Kim et al., 
2004; Levanon et al., 2004; Morse et al., 2002; Neeman et al., 2006). Nevertheless, 
also some protein-coding targets have been identifed, where editing of the pre-mRNA 
can lead to recoding of the edited transcript. Several proteins involved in 
neurotransmission have been some of the first identified editing substrates of this 
target group (Hoopengardner et al., 2003; Seeburg and Hartner, 2003). As mentioned 
earlier, A to I RNA editing of the AMPA receptor GluR-B subunits leads to an amino 
acid substitution from a glutamine into an arginine, what regulates Ca2+ influx into the 
cell (Sommer et al., 1991).  Editing of potassium channels within the ion-conducting 
pore leads to fast inactivation of the channel (Bhalla et al., 2004). Also one G-protein 
coupled seven-transmembrane-spanning receptor, the 5-HT2C  serotonine receptor, 
has been found to be an ADAR target (Niswender et al., 1998). In this case RNA 
editing also leads to amino acid substitutions, what decreases G-protein coupling 
interactions to the receptor (Burns et al., 1997) and thus silences constitutive activity 
of the serotonine receptor (Niswender et al., 1999). Anyhow, except from the lack of 
editing of the GluR-B subunit in ADAR2-deficient mice, to date there is no 
explanation for the embryonic lethal phenotype of ADAR1 knock-out mice on the 
molecular level. Hence several groups have developed new biochemical and 
bioinformatical methods to identify other targets of RNA editing (Hoopengardner et 
al., 2003; Levanon et al., 2005; Maas et al., 2011; Riedmann et al., 2008). Up to now 
many other protein-coding targets have been identified, but the effect of the amino 
acid substitutions happening in some of these proteins is unclear. In this thesis I focus 
on two protein-coding targets of RNA editing identified in 2005: the cytoskeletal 
cross-linker Filamin A and the bladder cancer associated protein BLCAP (Levanon et 
al., 2005). 
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1.5.1. Filamin A 
 
Filamin A (FLNA) was initially identified as actin filament cross-linker in non-
muscle cells (Hartwig and Stossel, 1975; Stossel and Hartwig, 1975). Three highly 
conserved mammalian Filamins are known, Filamin A, Filamin B and Filamin C, and 
are expressed in a developmental specific pattern (Sheen et al., 2002; Thompson et 
al., 2000).  FLNA is a multifunctional high molecular weight protein, of 280 kDa, and 
is involved in many cellular processes.  The structure of FLNA is comprised of a N-
terminal actin-binding domain, containing two calponin homology (CH) domains, 
followed by 24 beta-sheets folding into immunglobulin-like domains (Fucini et al., 
1997; Gorlin et al., 1990; van der Flier and Sonnenberg, 2001). The IgG-like repeats 
form two rod domains, separated by two calpain-sensitive hinge regions (van der Flier 
and Sonnenberg, 2001). The N-terminal actin binding domain plus the IgG-like 
repeats 9 to 15 are responsible for FLNA interactions to F-actin. IgG-like repeats 
located at the C-terminus of FLNA are docking sites for other FLNA-interacting 
proteins (Nakamura et al., 2007). The last IgG-like repeat, repeat 24 at the C-terminus 
of FLNA, is important for FLNA dimerization. FLNA dimers form a V-shaped 
structure, what mediates branching of actin filaments (Janmey et al., 1990; Pudas et 
al., 2005; Seo et al., 2009).  
 
 
 
Figure 6) Schematic representation of the overall structure of a FLNA dimer (Stossel et al., 2001). a) This 
figure shows the V-shaped dimer structure of two FLNA monomers. Dimerization is mediated via the IgG-like 
repeat 24 at the C-terminus. A filamentous actin-binding domain (yellow) is present at the N-terminus, followed 
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by 24 IgG-like repeats (blue). Repeats 1 to 15 form rod 1, repeats 16 to 23 form a more globular rod 2. The rod-
structures are separated by two hinge regions (red). b) Electron micrographs of tantalum-tungsten-cast rabbit 
macrophage FLNA dimers (Hartwig and Stossel, 1981; Tyler et al., 1980) 
 
 
By high-angle orthogonal branching of actin filaments, FLNA plays an important role 
for cell locomotion, as this cortical actin network is found at the leading edge of 
migrating cells (Matsudaira, 1994; Weihing, 1988). The V-shaped structure of FLNA 
allows it to be flexible and stiff at the same time, what is important for the 
maintenance and rearrangements of the cortical actin network (Gorlin et al., 1990; 
Hartwig and Stossel, 1981). Since the identification of FLNA as actin filament cross-
linker, many other FLNA interacting proteins, apart from F-actin, have been 
discovered. Among these proteins are trans-membrane receptors, such as integrin beta 
(Travis et al., 2004), but also cytoplasmic signalling molecules, like small GTPases 
(Bellanger et al., 2000; Ohta et al., 1999), and transcription factors (Sasaki et al., 
2001; Yoshida et al., 2005). Additionally, some studies have referred, that in some 
cases FLNA is also found within the nucleus and thereby maybe actively regulates 
transcription factors (Berry et al., 2005). Thus FLNA is involved in the regulation of 
many different cellular mechanisms, such as cell migration, polarization and stability, 
cell signalling and transcriptional regulation, reviewed in Zhou et al., (Zhou et al., 
2010). 
The importance of FLNA as a cytoskeletal cross-linker and signalling scaffold is 
highlighted in FLNA A null mice. The FLNA knockout phenotype is embryonic 
lethal, due to abnormal epithelial and endothelial cell junctions in developing blood 
vessels, heart and brain tissues (Feng et al., 2006). Apart from the studies on model 
organisms, several human diseases are linked to FLNA mis-function. Periventricular 
heterotopia is a X-linked brain malformation, caused by loss-of-function mutations of 
FLNA, where in most cases, truncated versions of FLNA are expressed (Eksioglu et 
al., 1996; Fox et al., 1998; Moro et al., 2002). This neuronal disease manifests as late-
onset epilepsy (Eksioglu et al., 1996). Since FLNA is important for cell migration, a 
lack of FLNA constricts migrating cerebral neurons from wandering out of the 
ventricular zone (Fox et al., 1998). A group of FLNA-associated disorders are 
otopalatodigital spectrum disorders (OPD), as OPD type 1, OPD type 2, 
frontometaphyseal dysplasia (FMD) and Melnik-Needles syndrome (MNS). In this 
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cases, point mutations within the actin-binding domain, or localized miss sense 
mutations in other regions of the protein lead to a high range of pathological 
manifestations (Robertson et al., 2003). Nevertheless, extended information about the 
FLNA interaction network will be necessary to declare these FLNA-associated 
syndromes. 
As mentioned earlier, FLNA was identified as one of the protein coding targets of 
RNA editing. ADAR1 and ADAR2 edit the FLNA transcript at one particular 
position, which is encoded in the IgG-like repeat 22. This editing event leads to an 
amino acid substitution from a glutamine into an arginine, what possibly changes the 
electrostatic features of the protein (Levanon et al., 2005; Riedmann et al., 2008). The 
IgG-like repeat 22 of FLNA is known to interact with integrin beta (Travis et al., 
2004) and small GTPases involved in signalling networks (Ohta et al., 1999). 
However, the biological effect of FLNA editing on the protein function is still 
unclear.  
 
 
 
 
1.5.2. BLCAP 
 
 
As described earlier, the bladder cancer associated protein (BLCAP) has been 
identified as human substrate for ADAR-mediated editing (Clutterbuck et al., 2005; 
Galeano et al., 2010; Levanon et al., 2005). BLCAP is also called BC10 (bladder 
cancer 10 kDa protein) and consists of 87 amino acids, generating two hypothetical 
membrane-spanning regions. Initially, BC10 was identified in a screen for proteins 
involved in bladder cancer tumour progression, where its expression was highly down 
regulated (Gromova et al., 2002; Moreira et al., 2010). In addition to its down 
regulation in bladder cancer tissues, BLCAP expression was also found to be reduced 
in renal cell carcinoma (Rae et al., 2000) and cervical carcinoma (Zuo et al., 2006). 
Very little is known about the function of this small protein. Nevertheless, BLCAP 
was found to be highly conserved among various species (Galeano et al., 2010; 
Makalowski and Boguski, 1998). 
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Figure 7) Alignment of BLCAP protein from mutliple species. Identical amino acids among all investigated 
species are indicated in black. Amino acids identical in most of the samples are gray. Red are edited amino acids. 
(hs, Homo sapiens; pt, Pan troglodytes; bt, Bos taurus; mm, Mus musculus; m, Rattus norvegicus; md, 
Monodelphis domestica; gg, Gallus gallus; xt, Xenopus tropicalis; tn, Tetraodon nigroviridis; ga, Gasterosteus 
aculeatus; dr, Danio rerio; ag, Anopheles gambiae; dm, Drosophila melanogaster; ce, Caenorhabditis elegans 
(Galeano et al., 2010) 
 
 
The BLCAP gene locus shows brain-specific imprinting, thus various transcripts are 
generated in a tissue-specific manner (Schulz et al., 2009). The gene encoding 
BLCAP consists of two exons separated by one single intron. Exon 1 encodes parts of 
the 5’ UTR and exon 2 comprises the remaining 5’ sequence, the coding region plus 
the 3’ UTR (Galeano et al., 2010). 
 
 
 
 
Figure 8) Schematic representation of the BLCAP pre-mRNA structure. Exon1 encodes parts of the 5’ UTR 
(lined box). Exon 1 and exon 2 are separated by one single intron (green line). The remaining parts of the 5’ UTR, 
the coding region (red box) plus the 3’ UTR are encoded by exon 2. Red dots indicate editing sites within the 
coding region of BLCAP. Red lines show editing sites within the intron (Galeano et al., 2010). 
 
It is known that multiple editing events occur within the coding region of the BLCAP 
exon 2, the 5’ UTR in exon 2 and within intronic sequences. In the non-coding parts 
of BLCAP, 11 editing events have been reported. Within the coding region 3 editing 
events occur within the highly conserved N-terminal part of BLCAP, that lead to 
amino acid substitutions, Y/C, Q/R, K/R. Additionally three editing sites have been 
identified to occur in the exon 2 encoded 5’ UTR (Clutterbuck et al., 2005; Galeano et 
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al., 2010; Levanon et al., 2005). Both enzymes, ADAR1 and ADAR2 have been 
found to act cooperatively on the editing sites in the BLCAP transcript where the 
level of editing is tissue-specific (Galeano et al., 2010). Due to the clustering of 
editing events within the pre-mRNA, a secondary structure formed between the intron 
and the coding regions has been predicted. The multiple editing positions of BLCAP 
are edited to different extents in different human tissues, whereby malignant tissues 
show less editing events in addition to a down regulated expression of BLCAP. Each 
of the editing events within the coding region of the protein leads to a dramatic 
change of the originally encoded amino acid. For example, the Q/R event substitutes 
an uncharged glutamine into a positively charged arginine whereas the K/R site lies 
within a hypothetical proline-rich region (Galeano et al., 2010). However, the 
particular function of this highly conserved and ubiquitously expressed protein is still 
unknown. 
 
 
 
1.6. RNA editing and disease 
 
As mentioned before, RNA editing can alter the coding potential of a triplet codon 
(Chen et al., 2010; Rueter et al., 1995), it can alter or generate a splicing recognition 
site (Rueter et al., 1999), or change splicing enhancer and silencer sites respectively 
(He et al., 2011). Other RNA processing mechanisms like the generation of mature 
miRNA (Yang et al., 2006) and the process of RNAi (Wu et al., 2011) can also be 
manipulated by RNA editing. In the following section, some examples are described 
how changes of RNA editing could possibly be involved in disease development. 
 
1.6.1. RNA editing and cancer 
 
A to I RNA-editing is known to occur frequently in the central nervous system 
(Jacobs et al., 2009; Melcher et al., 1996b; Sommer et al., 1991). Thus on-going 
studies focus on altered editing patterns in cancerous tissues of the brain. 
Astrocytomas are classified in four grades, where grade four, the glioblastoma 
multiforme (GBM), is one of the most dangerous forms of human tumours (Maher et 
al., 2001). Studies on cancerous tissues of patients suffering from malignant gliomas 
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have shown a decrease in editing of the GluR-B subunit of AMPA receptors (Maas et 
al., 2001). As described earlier, this editing event is important for the control of Ca2+ 
influx into the cell (Seeburg et al., 1998). As GluR-B is known to be the 
physiologically most important substrate of ADAR2 (Higuchi et al., 2000), analysis 
of paediatric and adult glioblastoma tissues have shown an overall down regulation of 
ADAR2 (Cenci et al., 2008; Paz et al., 2007). The long isoform of ADAR1 was found 
to be alternatively spliced in these tissues, leading to the expression of mainly the 
ADAR1p110 isoform. Excess of ADAR1p110 may be a main cause for ADAR2 
down regulation, as ADAR1 and ADAR2 form an inactive heterodimer (Cenci et al., 
2008). Further studies on A to I editing substrates were done in many cancerous 
tissues (Cenci et al., 2008; Galeano et al., 2010; Paz et al., 2007). In 2007, Paz et al. 
did a bioinformatic investigation on some human cancer tissues. They found a global 
hypoediting of Alu elements in brain cancer and in malignant tissues of prostate, lung, 
kidney and testis tumours. This overall reduction of A to I RNA editing was again 
found to be due to a highly reduced expression of ADAR1 and ADAR2 in the 
investigated tissues (Paz et al., 2007). However, it was also reported that over-
expression of ADAR1 in breast tumours leads to A to I editing of new RNA targets 
(Shah et al., 2009). An increase in substrate editing was also detected in 
neuroblastoma samples, where some miRNAs are more often edited than in normal 
healthy tissues (Schulte et al., 2010). These are just some observations gained from 
studies on cancerous tissues. Nevertheless, an overall deregulation of ADAR 
expression and subsequent changes in editing levels of important substrates may play 
a role during cancer development and tumour progression, reviewed in Gallo et al., 
(Gallo and Locatelli, 2011). 
 
1.6.2. RNA editing and diseases of the central nervous system 
 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease, 
caused by a gradual loss of functional motor neurons. Little is known about the 
pathological mechanisms leading to the disease. A major cause for the development 
of familiar ALS is a mutation in the gene of the radical scavenger SOD1 (superoxide 
dismutase). Progressive loss of motor neurons may be caused by excessive 
accumulation of SOD1 and other neurofilament proteins (Rosen, 1993). However, 
there are several other hypotheses that may explain the development of the disease. 
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One of these hypotheses, leading to death of motor neurons, concerns α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, a subtype of ionotropic 
glutamate receptors. Increased Ca2+ influx through AMPA receptors was repeatedly 
shown to play a pivotal role during motor neuron death (Lu et al., 1996). The Ca2+ 
permeability of these AMPA-receptors is dependent on the presence and properties of 
the GluR-B subunit (Hollmann et al., 1991). The properties of the GluR-B subunit are 
determined by RNA-editing, leading to an amino acid substitution where glutamine 
gets changed into arginine (Burnashev, 1992). The incorporation of unedited GluR-B 
into AMPA receptors causes high Ca2+ permeability of the receptors whereas the 
presence of the edited version of GluR-B blocks the Ca2+ influx into the cell (Swanson 
et al., 1997). It was found, that patients suffering from sporadic ALS show defects in 
editing the glutamate receptor GluR-B subunit.  Editing of the Q/R position was 
dramatically decreased in diseased neurons (Kawahara et al., 2004). In 2005 it was 
shown that the expression of a transgenic Ca2+ permeable GluR-B (N) version of the 
AMPA receptor in mice leads to the development of late-onset degeneration of motor 
neurons and neurons of the spinal cord, mimicking a neurodegenerative disorder. If 
those genetically modified mice express a mutated version of the superoxide 
dismutase gene (SOD1) additionally, disease progression and severity is enhanced 
(Kuner et al., 2005).  Nevertheless, the defect in RNA editing of the glutamate 
receptor subunit may be just an additional cause for neuronal death, as mainly spinal 
motor neurons show deficient RNA editing of the GluR-B (Kawahara et al., 2004).  
Recurrent unprovoked seizures are a main characteristic of a neurological disorder, 
called epilepsy. Hyperexcitability of neurons, caused by changes in AMPA receptor 
composition, expression, channel density and subsequent imbalanced intracellular 
levels of Ca2+, is thought to be one of the main causes of several epileptic phenotypes. 
These changes in glutamate receptor excitability can be caused by brain injuries, like 
stroke and traumatic brain damages, what eventually leads to neuronal death 
(Delorenzo et al., 2005). Efficiency of membrane conductance mediated by AMPA 
receptors is highly influenced by the subunit composition of the receptor. As 
mentioned earlier, the mRNA encoding glutamate receptor subunit GluR-B gets 
posttranscriptionally modified by RNA editing (Melcher et al., 1996c; Rueter et al., 
1995), where the conversion of adenosine into inosine leads to an amino acid 
substitution from glutamine into arginine. This editing event was shown to be critical 
	   29	  
for the Ca2+ permeability of the AMPA receptor (Burnashev, 1992; Sommer et al., 
1991). There are several indications for the impact of deregulated RNA editing at the 
GluR-B Q/R site for the development of at least some epileptic pathologies. Mice 
expressing a genetically altered editing-incompetent version of the GluR-B receptor 
subunit die early after birth caused by epileptic seizures (Brusa et al., 1995). Mice 
defecient in the RNA editing enzyme ADAR2 are also prone to seizures and die a 
view days after birth. Studies on the ADAR2 knock-out phenotype have illustrated, 
that the GluR-B pre-mRNA may be the physiologically most important substrate of 
ADAR2 as the lethal phenotype can be rescued by the expression of a transgenic 
AMPA receptor containing an arginine at the Q/R site (Higuchi et al., 2000). 
However, more studies on tissue specimen of diseased patients have to be done, to 
link deficient RNA editing to human disease development. 
Several missense, frame-shift, nonsense and splice site mutations in the human 
ADAR1 gene have been linked to the autosomal dominant inherited pigmenting 
disease Dyschromatosis symmetrica hereditaria (DSH) (Cui et al., 2005; Gao et al., 
2005; Miyamura et al., 2003; Zhang et al., 2004). One of these mutations leads to a 
frame-shift upstream of the ADAR1p110 translation initiation site thus eliminating 
the expression of the large p150 isoform of ADAR1 (Gao et al., 2005). Another 
mutation in the ADAR1 gene generates a premature stop codon, which leads to the 
production of a truncated ADAR1 protein lacking the deaminase domain (Xing et al., 
2005).  However, more information on the development of the disease is still missing, 
because the wide range of mutations in the ADAR1 gene lead to phenotypes of 
different severity suggesting an important role for environmental factors (Zhang et al., 
2004).  
  
 
2. Aims and project proposal 
 
The aim of this project is on the one hand to define the interaction pattern of four 
newly identified regulators of ADAR activity: DSS1, DDX15, RPS14 and the SRSF9 
protein. Little is known about the cellular function of these four proteins. By tandem 
affinity purification and following mass spectrometric analysis we want to generate an 
interaction profile of the possible regulators of ADAR activity on the one hand and on 
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the other hand we want to define a model how these proteins could possibly regulate 
ADAR activity. 
In the second part of this thesis we investigate the effects of RNA editing on the 
interaction behaviour of the two editing targets Filamin A and BLCAP. Several 
constructs of Filamin A and BLCAP, edited and unedited, were stably expressed in 
various cell lines. Immunoprecipitations and subsequent mass spectrometric analysis 
of pulled down interaction partners will bring new insights into the functional effects 
of RNA editing on these two investigated targets.  
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3. Material and Methods 
 
 
3.1. Expression vectors 
To investigate interaction proteomics of factors that modulate RNA editing, we had to 
generate appropriate expression vectors for stable expression of the identified 
candidates of activators and inhibitors of editing in mammalian cell lines. To improve 
the overall yield of protein purification, proteins of interest were tagged with a 6x c-
MYC-TEV-HA TAP tag, 6x c-Myc, TEV-protease cleavage site, Hemagglutinin, for 
tandem affinity purification. A TEV-HA fragment was designed in silico and cloned 
downstream to a 6x MYC-tag into a pcDNA 3.1 (-) (Invitrogen) expression vector. 
This 6x c-MYC-TEV-HA tag was cloned into a similar pcDNA vector containing a 
selection marker, hygromycin, for selection of stable transfectants, pcDNA 3.1 (-), 
Hygro (Invitrogen). The full-length versions of ADAR-affecting candidates were 
cloned into the generated TAP-tag expression vector by either BamHI or NheI/XhoI 
digestion.  
 
a)  b)  
Figure 9) pcDNA vectors. For the generation of an appropriate expression vector for tandem affinity purification 
the two listed vectors were used. The pcDNA (-) vector already contained a 6x myc tag, which was fused to an 
additional TEV-HA sequence N-terminally. a) pcDNA (-) containing Neomycin resistance gene. b) pcDNA (+) 
Hygro containing a Hygromycin resistance gene1. T7 = T7 RNA polymerase promoter; P CMV = CMV promoter; 
BGH pA = BGH polyadenylation signal; f1 ori = f1 origin; SV40 ori = SV40 promoter and origin; SV40 pA = 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Invitrogen	  (http://www.invitrogen.com/, 2012)	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SV40 polyadenylation signal; pUC = pUC origin; Ampicillin = Ampicillin resistance gene; Hygromycin = 
Hygromycin B resistance gene. 
 
For transient and stable expression of 3x c-Myc-tagged full length Filamin A, edited 
and unedited, we used a pREP4 expression vector 2  containing a Hygromycin 
resistance gene. Truncated versions of edited and unedited Filamin A, comprising 
immunoglobulin-like repeats 20 to 24, were kindly provided by Christina Godfried, 
Lehigh University of Pennsylvania, cloned into pCeMM expression vectors. For 
generation of stable transfected cells we co-transfected the pCeMM vectors with a 
helper plasmid containing a Hygromycin resistance gene3. 
 
 
 
 
Figure 10) pREP4 mammalian expression vector (Invitrogen) 
for transient and stable expression of full length edited and 
unedited Filamin A. Full length versions of edited and unedited 
Filamin A were cloned into a pREP4 expression vector to be 
tagged with a 3x c-MYC tag. PRSV = RSV LTR promoter; SV40 
pA = SV40 polyadenylation signal; OriP = origin; EBNA-1 = 
Epstein-Barr virus nuclear antigen; Ampicillin = Ampicillin 
resistance gene; pUC ori = origin; PTK = Tyrosine Kinase 
promoter; Hygromycin = Hygromycin B resistance gene; TK pA 
= Tyrosine Kinase polyadenylation signal. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  Invitrogen	  (http://www.invitrogen.com/, 2012)	  3	  MYC-­‐TEV-­‐HA	  TAP-­‐tag	  pcDNA	  3.1	  (-­‐)	  expression	  vector	  containing	  Hygromycin	  resistance	  gene	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a)     b)  
Figure 11) Expression vectors for stable and transient expression of full-length and truncated versions of 
edited and unedited Filamin A. a) pCeMM expression vector containing protein G plus a streptavidin tag 
separated by a TEV protease cleavage site for tandem affinity purification of N-terminally tagged inserts. b) 
pCeMM expression vector containing a c-Myc tag plus a protein G tag separated by a TEV-protease cleavage site 
for tandem affinity purification of C-terminally tagged inserts (C-e-M-M, Research Center for Molecular Medicine 
of the Austrian Academies of Sciences). protG = protein G; TEV = TEV-protease cleavage site; SBP = Streptavidin 
binding protein; IRES = internal ribosomal entry site; GFP = green fluorescent protein; 3’ LTR = 3’ long terminal 
repeat; APr = Alkaline phosphatase reporter gene; COLE1 ori = origin of replication of Escherichia coli; hCMV = 
human cytomegalovirus antigen; 5’ LTR = 5’ long terminal repeat; MYC = c-Myc. 
 
3.2. Tissue culture 
 
3.2.1. Cell lines 
 
-­‐ HeLa: derived from cervical cancer (Homo sapiens) 
-­‐ Hek293: human embryonic kidney cells (Homo sapiens) 
-­‐ U2OS: osteosarcoma (Homo sapiens) 
-­‐ SCaBER: squamous cell carcinoma (Homo sapiens) 
-­‐ STANB: St. Anna Neuroblastoma (Homo sapiens) 
-­‐ cN2A: neuroblastoma (Mus musculus) 
-­‐ C2C12: myoblasts (Mus musculus) 
 
3.2.2. Cultivating mammalian cells 
All cell lines were cultivated in DMEM (Dulbecco’s modified eagle medium, PAA 
Laboratories GmbH) containing 10% FCS (foetal calf serum, PAA Laboratories 
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GmbH), 1% L-glutamine (PAA Laboratories GmbH) and 1% penicillin/streptomycine 
(PAA Laboratories GmbH) on 3 to 10 cm dishes (PAA Laboratories GmbH) at 37°C, 
5% CO2, 95% humidity. Dense plates were split by washing with 1x PBS to remove 
all medium and incubation with 1x Trypsin/EDTA (PAA Laboratories GmbH) at 
37°C for 5’-10’. The reaction was stopped by dilution of the cells in DMEM. The 
cells were seeded on new plates. 
 
3.2.3. Mammalian Cell Transfection  
 
Material 
 
-­‐ 60% confluent cells on acid-edged cover slip (VWR®) on 3 cm/6 cm dish (PAA 
Laboratories GmbH), (seeded 24h to 48 h before transfection) 
-­‐ Nanofectin cell transfection Kit (PAA Laboratories GmbH) 
-­‐ Preparation for different cell culture formats: (Protocol for use: Nanofectin Kit4) 
Table 1) Nanofectin complex preparation for different cell culture formats (www.paa.com) 
Culture vessel DNA (µg] Diluent (µl) Nanofectin (µl) Diluent (µl) Final volume (µl) 
96 well 0.25 10 0.8 10 20 
48 well 0.5 25 1.6 25 50 
24 well 1 50 3.2 50 100 
12 well 2 50 6.4 50 100 
6 well 3 100 9.6 100 200 
25 cm2 5 250 16 250 500 
75 cm2 8 500 25 500 1000 
 
Method 
Cells were seeded on 3 cm dishes 24 h before transfection. Before use, DNA was 
cleaned by adding Chloroform, mixing, and spinning down for 5’ at maximum speed. 
The aqueous phase can directly be used for transfection. DNA and Nanofectin were 
mixed with diluents (according to the table above). As a next step the Nanofectin 
dilution was added to the DNA mix and incubated for > 30’ at RT. Afterwards the 
DNA-Nanofectin-Mix was added dropwise to the cells. 24 h later the medium was 
changed. 48 h after transfection the cells were fixed and stained or selection was 
started respectively. 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4	  Manufacturers’	  protocol:	  www.paa.com	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3.3. Immunofluorescence staining 
 
Material 
 
-­‐ 1x PBS (phosphate buffered saline) 
-­‐ 2% PFA/0.05% Triton X-100 (Fluka) in 1x PBS 
-­‐ Methanol (Riedel-de Haën) 
-­‐ 10% horse serum (PAA Laboratories GmbH) in 1x PBS-T (0.05% Tween 20, Fluka) 
-­‐ 2.5% horse serum in 1x PBS-T 
-­‐ Primary antibodies: 9E10 (anti-myc antibody from tissue culture supernatant)  
-­‐ Secondary antibodies: goat anti-mouse coupled to Alexa 568 (Invitrogen) / Alexa 488 (Invitrogen), Atto-
565 Biotin (ATTO-TEC GmbH) 
-­‐ DAPI 1:1000 in Antifade (1 g p-phenylenediamine/100ml phosphate buffer (150mM NaCl, 10mM 
KH2PO4, 10mM Na2HPO4), pH  8.0, 1:8 in glycerol)  
Method 
After washing the cells with 1x PBS (on ice) they were incubated for 5’ with ice cold 
2% PFA / 0.05% Triton X-100 in 1x PBS, to fix proteins. The cells were washed 
again with 1x PBS and incubated with ice-cold methanol for 1’. Before blocking for 
10’ with 10% horse serum in 1x PBS-T the cells were again washed with 1x PBS. 
When the blocking was done the cover slips were incubated on microscopy slides 
with a dilution of the primary antibody (9E10 1:1 in 2.5% horse serum in 1xPBST) at 
37°C in a humidity chamber for 1h. Before incubation with the secondary antibody 
the cover slips were washed three times for 5’ with 2.5% horse serum in 1x PBS-T. 
After incubation with the secondary antibody for 1h at 37°C the cover slips were 
again washed for three times with 2.5% horse serum, stained with DAPI-Antifade and 
stored at -20°C5 . For microscopic analysis of the immunofluorescence stained 
samples a Zeiss fluorescence microscope was used. Images were imported into 
Photoshop 4 (Adobe Systems, Mountain View, CA) with the help of a QED plug-in 
module (QED-Imaging, Pittsburgh, PA). 
 
3.4. Immunoprecipitation 
 
Material 
 
-­‐ Sepharose A beads (GE Healthcare), (2.5-5 mg beads per IP)  
-­‐ NET-2 lysis buffer: 150mM NaCl, 80mM Tris pH 7.4, 0.05% NP-40 (AppliChem GmbH) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5	  Method	  taken	  and	  modified	  from	  Current	  Protocols	  in	  Molecular	  Biology	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-­‐ For membrane-spanning BLCAP a solubilisation buffer was used containing 0.1% Triton-X 100, 140 
mM NaCl, 10 mM KCl, 20 mM Hepes pH 7.4 
-­‐ TAP-Lysis Buffer, for purification of proteins expressed from pCeMM vectors: 50 mM Tris pH 7.4, 150 
mM NaCl, 1 mM EDTA, 7.5% Glycerol, 25 mM NaF, 0.2% NP-40 (AppliChem), 1 mM Na3VO4 
(Burckstummer et al., 2006)  
-­‐ 9E10 anti-c-Myc antibody (2mg / 10-15 µl per reaction or undiluted tissue culture supernatant) 
-­‐ 0.2 M Sodium borate pH 9 (neoLab) 
-­‐ Dimethylpimelimidate (Sigma), (final concentration 20 mM) 
-­‐ 0.2 M Ethanolamine pH 8 
-­‐ 1x PBS 
-­‐ 2x SDS sample buffer (220mM Tris-HCl pH 6.8, 1.8% SDS, 29% glycerol, 0.03% bromophenol-blue, 
0.03% β-mercaptoethanol) 
Method 
For 10 immunoprecipitations 25mg Sepharose A beads were incubated with NET-2 
lysis buffer for 1‘, spinned briefly and the supernatant was removed. The beads were 
dissolved in 5 ml of 9E10 tissue culture supernatant and incubated on a rotation wheel 
at 4°C o/n. On the next day the antibody-coupled beads were spinned and washed 4 
times with NET-2 before a next washing step with 10 vol. of 0.2 M sodium borate pH 
9. After this washing step a first aliquot was taken. Finally the beads were suspended 
in 20 mM dimethylpimelimidate in 10 vol. of 0.2 M sodium borate and incubated for 
30’ at RT on a rotation wheel. The cross-linking reaction was stopped by washing the 
beads with 0.2 M ethanolamine, pH 8, and incubating in 0.2 M ethanolamine for 2 h. 
The beads can be stored in PBS containing sodium azide (0.1%). 
For immunoprecipitation the cells were prepared by scraping off of the tissue culture 
plate, washing with 1x PBS (2000 rpm) and diluting in the appropriate lysis buffer 
(1ml per 10 cm dish). Cell lysis was done by sonication (30% output, 50% pulse) 3 
times for 15’’ on ice. The lysate was spinned at full speed at 4°C for 10’. The 
supernatant was spinned a second time for 3’ at full speed. An aliquot of total cell 
lysate was taken. The gained supernatants were aliquoted to the cross-linked 
sepharose A beads and incubated for 1-2 h on a rotation wheel at 4°C. Finally the 
beads were washed 4 to 8 times with ice cold lysis buffer and resuspended in 2x SDS 
sample buffer. After heating the samples at 95°C for 5’ the samples can be loaded on 
a SDS PAGE gel or stored at -20°C. 
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3.5. Tandem Affinity Purification  
 
Material 
 
- 1-3 10 cm dishes (AppliChem GmbH) of stable cells of 80% confluency 
- Lysis buffer: Purification of regulators of editing/Filamin A constructs:     
 0.5x RIPA-buffer: 150 mM NaCl, 50 mM Tris/HCl pH 8.0, 1% NP-40, 1mM MgCl2, 0.05% 
 SDS, 0.25% DOC 
- NET-2 lysis buffer: 150mM NaCl, 80mM Tris pH 7.4, 0.05% NP-40 
- TAP-Lysis buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 7.5% Glycerol, 25 mM NaF, 0.2% NP-40
  (AppliChem), 1 mM Na3VO4 (Burckstummer et al., 2006) 
- 1x PBS (Phosphate buffered saline) 
- Sepharose A beads (Invitrogen, Life Technologies Corporation) crosslinked with 9E10 (anti-c-Myc
 antibody), Pan anti-mouse IgG Dynabeads (Invitrogen, Life Technologies Corporation), Sepharose A
 beads (Invitrogen, Life Technologies Corporation) crosslinked with 12CA5 (anti-HA antibody) 
- TEV protease (self-made) 
- TEV protease cleavage buffer: 10 mM Tris/HCl pH 7.4, 100 mM NaCl, 0.2% NP-40 
- 2x SDS sample buffer: 50 mM Tris/HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-mercapto-ethanol, 12.5 mM
 EDTA, 0.02% bromphenole blue 
Method 
Cells of one 80%-90% confluent 10cm petri dish were scraped off in 1x PBS and 
pelleted by centrifugation at 2000 rpm. After washing one time in 1x PBS the cells 
were resuspended in the adequate lysis buffer and lysed by sonication for 3 times 15 
seconds, 50% pulse. The lysate was spinned for 10’ at 14 000 rpm at 4°C. After 
spinning the supernatant for another 3’ at 14 000 rpm at 4°C an aliquot (10 µl) of the 
total lysate was saved. The cell lysate was incubated with IgG Dynabeads (constructs 
expressing truncated Filamin A), (25 µl/IP) or antibody-cross-linked beads (9E10 
coupled Sepharose A beads), (2.5 mg/IP) for 1-2h at 4°C. The beads were washed 
four times with lysis buffer and two times with TEV protease cleavage buffer. After 
resuspending the beads in 100µl reaction volume of TEV protease cleavage buffer an 
aliquot (10µl) was saved for analysis of 9E10 precipitation. The cleavage reaction 
with 1 µl TEV protease was done for 1h at 16°C. After the cleavage reaction the 
bead-supernatant was saved. Additionally the beads were washed another two times 
with lysis buffer, whereby the supernatants again were saved. After taking an aliquot 
of the cleaved product (10µl) the supernatant was loaded onto the second beads (9E10 
anti-MYC antibody coupled Sepharose A beads/ 12CA5 coupled Sepharose A beads), 
(2.5 mg - 5 mg/IP) and incubated for 1h at 4°C. The second beads were washed four 
to eight times with lysis buffer before resuspending in 2x SDS sample buffer and 
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heating for 5’ at 95°C. This protocol was modified from Burckstummer et al., 2006 
(Burckstummer et al., 2006). Samples from immunoprecipitations and tandem affinity 
purifications were analysed on 7.5%-17% gradient SDS PAGE gels and subsequent 
silver staining. 
 
 
3.6. SDS PAGE / Western Blotting 
 
Material 
 
-­‐ Separation gel (mix has to be prepared according to the size of proteins to be separated): 
30% acrylamide-mix (30:1 acrylamide/bis-acrylamide) (AppliChem GmbH), 1M Tris-HCl, pH 8.8, 
dH2O, 10% SDS, 10% APS, TEMED (AppliChem GmbH) 
-­‐ 2-propanol 
-­‐ Stacking gel stock: 3.6% acrylamide-mix, 110mM Tris-HCl pH 6.8, 0.1% SDS, 13% glycerol) + 10% 
APS, TEMED 
-­‐ 2x SDS sample buffer (220mM Tris-HCl pH 6.8, 1,8% SDS, 29% glycerol, 0.03% bromphenol-blue, 
0.03% β-mercaptoehtanol) 
-­‐ 1x SDS running buffer (25mM Tris-HCl, 190mM glycine, 0.1% SDS) 
-­‐ Coomassie staining: Coomassie brilliant blue, destaining solution (10% acetic acid, 20% MetOH) 
-­‐ Western blotting: 
Nylon membrane (Whatman), 5% milk in 1x TBS-T, 0.5% milk in 1x TBS-T, 2.5% milk in 1x TBS-T 
Primary antibodies: 9E10 tissue culture supernatant, diluted 1:1 in 0.5% milk / TBS-T 
Secondary antibodies diluted 1:10 000 in 0.5% milk/TBS-T (goat anti-mouse HRP, Axell/ goat anti-
mouse AP, Sigma) 
TBS-T (Tris buffered saline, AppliChem GmbH, containing 0.05% Triton X-100, Fluka) 
- Detection: AP-detection: Alkaline phosphatase buffer (100 mM NaCl, 100 mM  
    Tris pH 9.5, 50 mM MgCl2, 1% Tween 20)  
    NBT (Nitro blue tetrazolium chloride)   
    BCIP (5-Bromo-4-chloro-3-indolyl phosphate)  
  HRP-detection: ECL reagent (Pierce) 
Method 
Protein separation by molecular weight was performed by denaturing-polyacrylamide 
gel electrophoresis (SDS-PAGE). The gel matrix consists of a separation gel, 
containing different percentages of 30:1 acrylamide/bis-acrylamide mix according to 
the size of the proteins to be separated, and a stacking gel which concentrates 
negatively charged proteins to a thin boundary. Before loading the samples were 
dissolved in 2x SDS sample buffer and heated for 5’ at 95°C. Electrophoresis was 
carried out in 1x SDS running buffer at an electric current of 20 mA per gel. 
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Protein detection was done by either Coommassie brilliant blue staining or by 
Western blot analysis. For staining with Coomassie brilliant blue the gel was 
incubated for ca. 30’ with the staining solution and destained for 1h at room 
temperature. 
For Western blot analysis the separated proteins were transferred onto a nylon 
membrane by blotting for 1 h at 450 mA. After blotting, the membrane was incubated 
for 10’ with blocking solution (5% milk in TBS-T) and with the primary antibody, 
diluted in 0.5% milk in TBS-T (tissue culture supernatants were diluted 1:1, other 
primary antibodies were diluted following the manufacturers’ protocols) for 1h at RT. 
Before incubation with the secondary antibody (HRP coupled: 1:10 000 in 0.5% 
milk/TBS-T; AP coupled: 1:400) for 1h at RT, the membrane was washed three times 
for 5’ with 2.5% milk/TBS-T. For detection of the anti-c-MYC primary antibody, 
developed from mouse, secondary antibodies, developed from goat, were used, 
coupled with either horseradish peroxidase (HRP) or alkaline phosphatase (AP). After 
the secondary antibody incubation the membrane was again washed three times 5’ 
with TBS-T. For protein detection the membrane was incubated for 5’ with ECL 
reagent (HRP detection). Detection by alkaline phosphatase was done by incubation 
for 10’ with BCIP (1:300) and NBT (1:150) in alkaline phosphatase buffer. 
 
3.7. 7.5%-17% gradient SDS PAGE 
 
Material 
 
Acrylamide (29:1) (AppliChem GmbH), 1 M Tris/HCl, pH 8.8, dH2O, 50% Glycerol, 10% SDS, 10% APS, 
TEMED (AppliChem GmbH) 
 
Table 2) Reaction mix for big gradient SDS PAGE: 
7.5% Chemical 17% 
3.62 ml 30% Acrylamide 8.18 ml 
5.44 ml Tris/HCl pH 8.8 5.44 ml 
5.18 ml dH2O 0 
0.074 ml 50% Glycerol 0.738 ml 
0.132 ml 10% SDS 0.132 ml 
0.06 ml 10% APS 0.06 ml 
0.004 ml TEMED 0.004 ml 
 
 
 
	  40	  
3.8. Blum silver staining (Helmut Blum, 1987)6 
 
Material 
 
-­‐ 40% EtOH/ 10% acetic acid 
-­‐ 30% EtOH 
-­‐ dH2O 
-­‐ 0.02 % Sodium thiosulfate (Riedel-deHaën) 
-­‐ 0.1% Silver nitrate (SIGMA-ALDRICH®) 
-­‐ 3% Sodium carbonate/0.05% formaldehyde 
-­‐ 5% acetic acid (AppliChem) 
-­‐ 1% acetic acid (AppliChem) 
Method 
In this staining protocol the proteins separated on a polyacrylamide gel were fixed by 
shaking the gel for at least 1 h in 40% EtOH/10% acetic acid. After fixing the gel was 
washed two times with 30% EtOH and one time with dH2O, each time for 20’. After 
sensitizing with 0.02% sodium thiosulfate, the gel was incubated at 4°C with 0.1% 
silver nitrate for 20’. To develop the staining, the gel was incubated with 3% sodium 
carbonate containing 0.05% formaldehyde for 3-5 minutes. The reaction was stopped 
by washing for 5’ with 5% acetic acid and 3 times for 10’ with dH2O. Bands were cut 
out and sent for mass spectrometric analysis to the Max. F. Perutz Laboratories Mass 
Spectrometry Facility. 
 
3.9. Other methods used 
 
3.9.1. PCR (Polymerase Chain Reaction) 
Material 
PCR-reaction mixes: 
 
Taq-Polymerase:            GoTaq-Polymerase:      Dream Taq Polymerase: 
 
1 µl Primer 1 (100 ng)            1 µl Primer 1 (100 ng)         1 µl Primer 1 (100 ng)  
1 µl Primer 2 (100 ng)           1 µl Primer 2 (100 ng)          1 µl Primer 2 (100 ng)  
1.5 µl dNTPs (10 mM)   1.5 µl dNTPs (10 mM)      1 µl dNTPs (10 mM)  
1.25 / 2.5 µl MgCl2             5 µl 5x buffer         5 µl 10x Dream Taq buffer 
2.5 µl 10x buffer (NH4)2 SO4            1 µl DNA           1 µl DNA 
0.5 / 1 µl DNA             15 µl dH2O       40 µl dH2O 
17.25 / 16.75 / 16 / 15.5 µl dH2O         0.5 µl GoTaq polymerase (Promega)     1 µl Dream Taq polymerase  
1 µl Taq polymerase (Fermentas) 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  protocol	  obtained	  from	  the	  Max.	  F.	  Perutz	  Mass	  Spectrometry	  Facility	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All used primers were designed in Geneious Pro 5.1.7 and synthesized by Microsynth 
AG7, Switzerland. To generate N-terminally tagged proteins the sequence of interest 
was cloned downstream to the MYC-TEV-HA tag by BamHI restriction digestion. 
Sequences that had to be cloned upstream of the MYC-TEV-HA tag were flanked by 
a 5’ XhoI and a 3’ NheI restriction site to generate C-terminally tagged versions of the 
expressed protein.  
 
-­‐ Oligos, designed for cloning of TEV-HA tag into 6x myc containing vector 
(pcDNA):  
MJ2948 5‘-AATTTAGAAAATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGG-3‘ (F)8 
MJ2949 5‘-AATTCCGCGTAGTCTGGGACGTCGTATGGGTAACCCTGGAAATAGAGATTTTCTA-3‘ (R)9 
  
-­‐ Amplification of DSS1 for N-terminal tagging (MYC-TEV-HA tag): 
MJ2999 5‘-GAGGGGATCCAATGTCAGAGAAAAAGCAGCCGGTA-3‘ (F) 
MJ3000 5‘-GAGGGGATCCCTATGAAGTCTCCATCTTATAACC-3‘ (R)  
 
-­‐ Amplification of DSS1 for C-terminal tagging (MYC-TEV-HA tag): 
MJ2968 5'-GATTGCTAGCATGTCAGAGAAAAAG-3' (F) 
MJ2969 5'-GCTCCTCGAGTTGAAGTCTCCATCTTAT-3' (R)  
 
-­‐ Amplification of DDX15 for N-terminal tagging (MYC-TEV-HA tag): 
MJ3001 5‘-GAGGGGATCCAATGTCCAAGCGGCACCGGTTG-3‘ (F) 
MJ3002 5‘-GAGGGGATCCTCACCAAACCAGTACAAAGGA-3‘ (R) 
 
-­‐ Amplification of DDX15 for C-terminal tagging (MYC-TEV-HA tag): 
MJ2970 5'-ATTCGCTAGCATGTCCAAGCGGCAC-3' (F) 
MJ2971 5'-AGTCCTCGAGTCCAAACCAGTACAA-3' (R) 
 
-­‐ Amplification of RPS14 for N-terminal tagging (MYC-TEV-HA tag): 
MJ3003 5‘-GAGGGGATCCCATGGCACCTCGAAAGGGGAAGGAA-3‘ (F) 
MJ3004 5‘-GAGGGGATCCTCACAGACGGCGACCACGGCG-3‘ (R) 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 http://www.microsynth.ch/  
8 (F)...forward primer for PCR amplification 
9 (R)...reverse primer for PCR amplification	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-­‐ Amplification of RPS14 for C-terminal tagging (MYC-TEV-HA tag): 
MJ3005 5’-GATTGCTAGCATGGCACCTCGAAAGGGGAAGGAA-3’ (F) 
MJ3006 5’-GATTCTCGAGGCAGACGGCGACCACGGCGAC-3’ (R) 
 
-­‐ Amplification of SRSF9 for N-terminal tagging (MYC-TEV-HA tag): 
MJ3025 5'-GCGGGGATCCCATGTCGGGCTGGGCGGACGAGCGC-3' (F) 
MJ3026 5'-CCTGGGATCCTCAGTAGGGCCTGAAAGGAGAGAA-3' (R) 
 
-­‐ Amplification of SRSF9 for C-terminal tagging (MYC-TEV-HA tag): 
MJ3027 5'-GCTGGCTAGCCATGTCGGGCTGGGCGGACGAG-3' (F) 
MJ3028 5'-GCTCCTCGAGGGTAGGGCCTGAAAGGAGAGAA-3' (R)  
 
-­‐ Control primer for pcDNA 3.1 (-) Hygromycine vector: 
 MJ2712 5'-GACCCAAGCTGGCTAGCGT-3' (F) 
 MJ2431 5'-CGCAAATGGGCGGTAGGCGTG-3' (F) 
MJ2782 5'-TAGAAGGCACAGTCGAGG-3' (R) 
MJ2747 5'-CACAGTCGAGGCTGATCAGC-3' (R) 
 
3.9.2. Cycle Sequencing 
 
Material 
DNA (500 ng/µl):       1 µl 
Primer (0.8 pMol/µl):       4 µl 
2.5x Buffer:       1 µl 
Big Dye® Terminator v3.1 cycle sequencing kit (Applied Biosystems): 1 µl 
dH2O:        3 µl 
 
Method 
PCR program (25 cycles): rapid thermal ramp to 96°C     
   96°C for 10’’      
   rapid thermal ramp to 50°C     
   50°C for 5’’      
   rapid thermal ramp to 60°C     
   60°C for 4’ 
 
The cloned DNA constructs were sequenced using BigDye® Terminator v3.1 cycle 
sequencing kit according to manufacturers’ instructions. The Department of 
Systematic and Evolutionary Botany at the Faculty of Life Sciences, University of 
Vienna, performed analysis of prepared DNA samples. 
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3.9.3. Restriction analysis 
DNA oligomers were designed coding for a TEV-HA tag. After primer alignment the 
insert was cloned into a pcDNA 3.1 (-) vector downstream of a 6x MYC tag by EcoRI 
restriction sites while the 5’ EcoRI site got destroyed. The 6x MYC-TEV-HA tag was 
cloned into a pcDNA 3.1 (-) Hygromycin vector by PmeI-digestion. The different 
amplified inserts (candidates for ADAR impact factors, Dss1, Rps14, Ddx15, Srsf9) 
were cloned into the completed expression vector by BamHI (tagging the insert N-
terminally) and NheI/XhoI (tagging the insert C-terminally). Restriction digestions 
were done in a total reaction volume of 20 µl containing 1/10 reaction buffer plus 
RNAse A (20µg/ml per reaction) and BSA (bovine serum albumin) (100 µl/ml per 
reaction) for 1 h at 37°C. An aliquot of 5µl was analysed by DNA Gel electrophoresis 
(see DNA Gel electrophoresis). 
 
Used restriction enzymes:  
  
EcoRI (Fermentas GmbH, Thermo Fisher Scientific Inc.),     
restriction site10: 5’ ...G^AATTC... 3’ 
  3’ ...CTTAA^G... 5’      
    
PmeI (New England BioLabs® Inc.),       
restriction site11:  5’ ...GTTT^AAAC...3’       
  3’ ...CAAA^TTTG...5’ 
 
BamHI (Fermentas GmbH, Thermo Fisher Scientific Inc.)    
restriction site3: 5’ ...G^GATCC... 3’       
   3’ ...CCTAG^G...5’ 
 
XhoI (Fermentas GmbH, Thermo Fisher Scientific Inc.)     
restriction site3: 5’ ...C^TCGAG... 3’       
   3’ ...GAGCT^C... 5’ 
NheI (Fermentas GmbH, Thermo Fisher Scientific Inc.)      
restriction site3: 5’ ...G^CTAGC... 3’       
   3’ ...CGATC^G... 5’ 
 
 
 
3.9.4. DNA Gel electrophoresis 
Material 
-­‐ Agarose  
-­‐ 1x TAE buffer 
-­‐ Etidiumbromide (Roth) 
-­‐ 10x loading dye  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10	  http://www.fermentas.de/	  product	  information	  
11	  http://www.neb.com/	  products	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Method 
According to the size of the DNA fragments to be analysed the DNA gels were casted 
with different concentrations of agarose (peqlab) to maintain efficient separation (see 
table 1.). The agarose was mixed with the desired buffer, 1x TAE (Tris-acetate-
EDTA) or 1x TBE (Tris-borate-EDTA), (AppliChem), and heated up to solve the 
agarose. After cooling down the gel, Etidium bromide (Roth) was added (0.1 – 0.5 
µl/ml) to stain DNA fragments.  
 
Fragment length Agarose concentration (w/v) 
1 - 30 kb 0.5% 
0.8 – 12 kb 0.7% 
0.5 – 7 kb 1.0% 
0.4 – 6 kb 1.2% 
0.2 – 3 kb 1.5% 
0.1 – 2 kb 2.0% 
Table 3. Used agarose concentrations according to DNA fragment length 12 
 
3.9.5. DNA transformation into bacteria 
 
Material 
 
-­‐ 30µl – 50µl competent bacteria (E.coli: XL-1 blue) 
-­‐ 1-10 ng DNA  
-­‐ SOB media 
-­‐ Antibiotic plates 
Method 
The competent bacteria were thawn on ice and mixed with 1-10 ng of DNA. After 15’ 
on ice the cells were heat shocked by incubating them for 90’’ at 42°C and returning 
them back on ice for another 5’. In 300 µl of SOB medium the transformed cells 
shook at 37°C for > 1h. Finally 100-300 µl were plated on agar plates already 
containing the appropriate antibiotic.  
 
3.9.6. DNA preparations 
DNA preparations were done following standard methods 13 . 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12 Der Experimentator: Molekularbiologie/Genomics; 6. Auflage  (Mülhardt, 2009) 
13 Current Protocols in Molecular Biology, Chapter 2, Section I, Unit 2.1A	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4. Results 
 
4.1. ACTIVATORS AND INHIBITORS OF ADAR 
4.1.1. Generation of Expression Vectors for Tandem Affinity Purification14 
 
Primers have been designed in silico using Geneious Pro 5.1.7 for the amplification of 
the ADAR regulator candidates, DSS1, RPS14, DDX15 and SRSF9, from existing 
vectors or from cDNA generated from total RNA extracts (see 3.). The primers were 
designed to flank the inserts with restriction sites for cloning into the designed 
mammalian expression vector pcDNA 3.1 (-) Hygromycin containing a TAP-tag (6x 
c-MYC/TEV/HA) and a Hygromycin resistance gene. To generate C-terminally 
tagged inserts the PCR-product was cloned upstream of the c-MYC-TEV-HA tag by 
NheI/XhoI restriction digestion. For N-terminally tagged inserts the PCR-product was 
cloned downstream of the tag by BamHI restriction digestion. DSS1, DDX15 and 
RPS14 were successfully cloned to be C- and N-terminally tagged. For cloning of the 
SR protein SRSF9 cDNA was prepared from the mouse neuroblastoma cell line cN2A 
and from the human osteosarcoma cell line U2OS, using Trizol® Reagent 
(Invitrogen). The mouse N2A sequence differs from the human sequence in 
transitions in the wobble position of some amino acids, but in two cases the amino 
acid differs from the human sequence: at the N-terminus, at position V147, there 
appeared a Valine/Methionine substitution after sequencing. A second transition near 
the C-terminus, at position R197, leads to an Arginine/Glutamine substitution within 
the SR-rich domain.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
14	  For sequence details see Appendix 
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4.1.2. DSS1 
 
4.1.2.1. Transient Immunofluorescence staining: DSS1 
 
Dss1 is a small acidic protein known to be a subunit of the 26S proteasome complex 
(Funakoshi et al., 2004; Sone et al., 2004). After cloning of full-length Dss1 
(GenomeNet Accession number: NP_006295) in the generated pcDNA 3.1 (-) Hygro / 
6x c-MYC/TEV/HA TAP expression vector the DNA preparation was tested on its 
transfection efficiency by transient transfection of 3 µg DNA into the human cell line 
Hek293 and subsequent immunofluorescence staining, detecting the c-Myc antigen 
tag.   
 
 
 
   
   
 
Figure 12) Transient transfection of Dss1 N- and C-terminally tagged with a c-MYC-TEV-HA tag in 
Hek293. For testing the transfection efficiency of the generated mammalian expression vectors the plasmid 
preparations were transiently transfected into the human cell line Hek293. Detection of transiently transfected 
Dss1 by Alexa 488-coupled antibodies shows mainly nuclear localization of both variants, the C- and the N-
terminally tagged Dss1. Dss1 NTAP: Dss1 N-terminally tagged with a c-MYC-TEV-HA tag. Dss1 CTAP: Dss1 
C-terminally tagged with a c-MYC-TEV-HA tag. DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 
fluorescence staining. Scale bar: 20 µm. 
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In addition to an important function during protein degradation, DSS1 was also found 
to be involved in DNA repair, as it forms a stoichiometric complex with the DNA 
repair protein BRCA2 (Li et al., 2006). Thus, the transiently expressed tagged protein 
shows mainly nuclear localization pattern. Similar subcellular localization pattern was 
found for both versions of Dss1, C- and N-terminally tagged. Transfection 
efficiencies of about 30% to 40% were obtained with both generated vectors, 
encoding C- and N-terminally tagged versions of Dss1.  
 
 
4.1.2.2. Stable expression of DSS1: Immunofluorescence staining 
 
After testing the Dss1 expression vector on it’s transfect ability the generation of 
stable expressing cell lines was started.  Several cell lines were transfected with 5 -8 
µg of DNA. Twenty four to forty eight hours after transfection, selection was started, 
by growing the cells in DMEM medium containing 50 µg/ml – 200 µg/ml of the 
antibiotic Hygromycin B. During selection the transfected DNA gets randomly 
integrated into the genome. After ten days to three weeks of selection transfected cells 
start to form colonies. Picked stable clones were tested on their expression of Dss1 by 
immunofluorescence staining and western blot analysis. 
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Figure 13) HeLa cell line stably expressing Dss1 N-terminally tagged with a c-MYC-TEV-HA TAP-tag. 
After selection for stable random integration of the transfected DNA construct, the picked clones were tested on 
their homogeneity of stable protein expression by immunofluorescence staining. Tagged Dss1 was detected by an 
anti-c-MYC primary antibody and subsequent labelling with a goat anti-mouse secondary antibody, coupled to 
Alexa 488. In stable expressing cells, Dss1 was also mainly detected within the nucleus. About 50% of analysed 
cells show positive expression of Dss1 in immunofluorescence staining analysis. Dss1 NTAP: Dss1 N-terminally 
tagged with a MYC-TEV-HA tag. DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescence 
staining. Scale bar: 20 µm. 
 
Two picked HeLa clones were found to stably express N-terminally tagged DSS1. In 
immunofluorescence staining analysis about 50% of the cells show DSS1 expression, 
where DSS1 was mainly detected within the nucleus. The N-terminally tagged 
version of DSS1 was also stably expressed in the human osteosarcoma cell line 
U2OS. This clone shows inhomogeneity of DSS1 expression. About 30% of cells 
stained by immunofluorescence staining were found to express the protein. However, 
in this case DSS1 again shows nuclear localization pattern in positive cells. 
 
 
 
   
   
 
Figure 14) U2OS cell line stably expressing Dss1 N-terminally tagged with a c-MYC-TEV-HA TAP-tag. 
After selection for stable random integration of the transfected DNA construct, the picked clones were tested on 
their homogeneity of stable protein expression by immunofluorescence staining. Tagged Dss1 was detected using 
an anti-MYC primary antibody and subsequent labelling with a goat anti-mouse secondary antibody coupled to 
Alexa 488. In U2OS cells, stable expressed Dss1 shows nuclear localization in immunofluorescence staining 
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analysis. Dss1 NTAP: Dss1 N-terminally tagged with a c-MYC-TEV-HA tag. DAPI: nuclear staining. DIC: phase 
contrast. FITC: Alexa 488 fluorescence staining. Scale bar: 20 µm. 
 
The pcDNA 3.1 (-) Hygro TAP expression vector expressing C-terminally tagged 
DSS1 was also used for transfection and selection of stable cell lines. But to date, no 
stable expressing clones have been gained. 
 
 
 
4.1.2.3. Stable expression of DSS1: Western blot analysis 
 
To further test the level of protein expression of the picked stable clones, Western blot 
analysis was done, using an anti-c-Myc primary antibody for detection of TAP-tagged 
DSS1.  Visualization of the tagged protein was achieved by using a goat anti-mouse 
secondary antibody coupled to horseradish peroxidase. The human full-length DSS1 
shows a molecular weight of 8.27 kDa. Fused to a 6x c-Myc/TEV/HA tag, the protein 
has a molecular weight of about 35 kDa. 
 
 
 
 
Figure 15) Stable expression of Dss1: Western blot analysis. To check the expression level of N-terminally 
tagged Dss1 in HeLa clones, found to express Dss1 by immunofluorescence staining, Western blot analysis of the 
positive clones was done. Dss1 was detected by an anti-c-Myc primary antibody and visualization with a goat anti-
mouse secondary antibody coupled to HRP. TAP-tagged Dss1= 35 kDa. Ctrl = plane HeLa cell lysate; #4 = lysate 
of Dss1 in HeLa clone 4; #7 = lysate of Dss1 in HeLa clone 7.  
 
4.1.2.4. Immunoprecipitation / Tandem Affinity Purification: DSS1 
 
After testing the generated stable expressing DSS1 cell lines, anti-c-Myc 
Immunoprecipitation and Tandem Affinity Purification respectively was done. DSS1 
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expressing cells and control cells (empty) were lysed using 0.5x RIPA lysis buffer. 
After sonication the lysates were incubated with 9E10 anti-c-Myc cross-linked 
Sepharose A beads. The obtained samples were analysed on a 7.5% to 17% gradient 
SDS PAGE gel and subsequent silver staining. Protein bands specifically found in 
lysates prepared from DSS1 expressing cells were cut and sent for mass spectrometric 
analysis. After two rounds of tandem affinity purification two Dss1-specific protein 
bands, at a molecular weight of 30 kDa and 50 kDa, were obtained from stable 
expressing HeLa cells. Anti-c-Myc immunoprecipitation of Dss1 from stable 
expressing U2OS cells yielded a Dss1-specific protein band at a molecular weight of 
67 kDa. 
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Figure 16) Silver gels: Purification of Dss1. The N-terminally tagged version of Dss1 was stable expressed in the 
human cell lines HeLa (clone 3, clone 7) and U2OS. Tandem Affinity Purification was done with HeLa cells 
expressing Dss1. The first IP was done with Pan anti-mouse IgG Dynabeads coupled with an anti-c-Myc antibody 
(9E10). After TEV-cleavage from the first beads a second IP was done with Sepharose A beads coupled with an 
anti-HA antibody (12CA5). The samples were separated on a 7.5%-17% gradient SDS PAGE gel and stained by 
Blum’s silver staining protocol. A) TAP of Dss1, N-terminally tagged, expressed in HeLa, clone 7. Black arrow: 
band at 50 kDa B) TAP of Dss1 N-terminally tagged expressed in HeLa, clone 3. Black arrow: band at 30 kDa C) 
Anti-c-Myc-IP of Dss1, N-terminally tagged, expressed in U2OS. Black arrow: band at 67 kDa. Black arrows 
mark protein bands cut out and sent for mass spectrometric analysis. Input = total lysate; 9E10 IP = c-Myc 
immunoprecipitation; TEV Cl. = TEV cleavage reaction; 12CA5 IP = HA immunoprecipitation; TEV = TEV 
protease loading control; M = PAGE Ruler unstained protein ladder; Ctrl = lysate of empty cells; Dss1 = lysate of 
Dss1 expressing cells. 
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4.1.2.5. Mass spectrometry: DSS1 
 
Cut protein samples were digested and analysed by members of the mass 
spectrometry facility of the Max F. Perutz Laboratories. The following tables list 
proteins, pulled down specifically with N-terminally tagged DSS1 from the human 
cell lines HeLa and U2OS. Data labelled in bold was found to interact with DSS1. 
Not highlighted data are proteins, also detected in other analysed samples. Many 
ribosomal subunits and proteins involved in RNA-processing, like hnRNPs, were 
detected in the analysed samples (see Table 4). These proteins, acting on RNA, could 
be the missing link in the network of the stimulatory role of Dss1 on RNA-editing. 
Candidates for these linkers are highlighted in green. 
 
 
Table 4) Dss1-interacting proteins detected by mass spectrometric analysis. This table lists all proteins, 
detected in protein bands after precipitation of Dss1 from stable exressing HeLa and U2OS cells by mass 
spectrometric analysis. The identified protein, the number of analysed peptides and the percentage of coverage of 
the annotated sequence is listed. Proteins specifically pulled down with Dss1 are highlighted in bold. Green data 
marks possible candidates in the network of linking Dss1 to RNA-editing. Mw = molecular weight of identified 
protein in kDa. Sample = molecular weight of cut protein band. 
Dss1 interacting 
protein 
 
peptides 
 
coverage 
Mw 
(kDa) 
Sample 
(Mw, 
source) 
comments function references 
vimentin 20 45% 54 50 kDa HeLa 
also comes 
with DDX15 
Class-III intermediate 
filament; binding and 
stabilization of 
collagen mRNAs 
(Ferrari et al., 1986); 
(Challa and 
Stefanovic, 2011) 
hnRNP G 18 39% 47 
50 kDa 
HeLa/U2-
OS 
also comes 
with DDX15 
RNA-binding protein; 
associates with Pol II 
transcripts; regulates 
splice site selection 
(Soulard et al., 
1993); (Heinrich et 
al., 2009) 
26S proteasome 
non-ATPase 
regulatory 
subunit 6 
12 26% 46 50 kDa HeLa  
regulatory 26S 
proteasome subunit 
(ATP-dependent 
degradation of 
ubiquitinated 
proteins) 
(Ewing et al., 2007)  
ribosomal 
protein L8 2 8,10% 24 
50 kDa 
HeLa  
rRNA binding, part 
of 60S ribosome (Hanes et al., 1993) 
proteasome 
subunit p42 7 16% 44 
50 kDa 
HeLa  
proteasome 
regulatory protein 
(Fujiwara et al., 
1996) 
26S protease 
regulatory 
subunit 8 isoform 
2 
10 29% 45 50 kDa HeLa  
antigen processing  to 
generate class I MHC 
binding peptides 
(Akiyama et al., 
1995) 
40S ribosomal 
protein S3a 7 28% 30 
50 kDa 
HeLa  
Eukaryotic ribosomal 
protein 
(Vladimirov et al., 
1996) 
(Ewing et al., 2007) 
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interleukin 
enhancer-binding 
factor 2 
3 9,70% 43 50 kDa HeLa  
regulates 
transcription of IL2 
in T-cell activation/ 
formation of stable 
DNA-dependent 
protein kinase 
holoenzyme  
(Ting et al., 1998) 
(Satoh et al., 1999) 
(Reichman et al., 
2002) 
ribosomal 
protein S8 3 14% 27 
50 kDa 
HeLa  
Ribonucleoprotein of 
40S ribosome 
(Vladimirov et al., 
1996) 
TDP43 3 10% 45 50 kDa HeLa  
neurofilament mRNA 
binding protein 
Strong et al 
(unpublished data) 
ribosomal 
protein S4 2 5,70% 43 
50 kDa 
HeLa  
Ribonucleoprotein of 
40S ribosome (Zinn et al., 1994) 
erlin-2 isoform 1 2 7,10% 38 50 kDa HeLa 
also comes 
with edited 
BLCAP 
mediates ER-
associated degradation 
of activated IP3-
receptors 
 
(Browman et al., 
2006) 
hnRNP C 
isoform 1  2 7,30% 32 
50 kDa 
HeLa  
Nucleation of 40S 
hnRNP particles (Huang et al., 1994) 
hnRNP K 2 5,60% 51 67 kDa U2OS  Transcription factor 
 (Michelotti et al., 
1996) 
mitochondrial 
elongation factor 
Tu 
2 6,20% 50 50 kDa HeLa  
promotes binding of 
amino-acyl-tRNA to 
A site of ribosomes 
(Woriax et al., 
1995) 
hnRNP D 2 8,50% 41 50 kDa HeLa  
AU-rich element 
binding  (Nagata et al., 1999) 
ubiquinol-
cytochrome c 
reductase core 
protein II 
3 17% 28 50 kDa HeLa  
ubiquinol-cytochrome 
c reductase complex 
assembly 
(Hosokawa et al., 
1989) 
heat shock 60kDa 
protein 1 
(chaperonin) 
2 5,50% 41 67 kDa U2OS  
Mitochondrial 
protein import (Singh et al., 1990) 
26S proteasome 
subunit 9 2 4,50% 47 
50 kDa 
HeLa  
Chaperone during 
26S proteasome 
assembly 
(Kaneko et al., 
2009) 
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4.1.3. RPS14 
4.1.3.1. Transient Immunofluorescence staining: RPS14 
 
The second candidate for a regulator of ADAR activity was the ribosomal protein 
RPS14. After cloning of RPS14 (GenomeNet Accession number: NP_001020242) 
into the newly generated TAP-tag expression vector pcDNA 3.1 (-) Hygromycin with 
a c-MYC-TEV-HA tag, the plasmids containing C- and N-terminally tagged versions 
of RPS14 were tested on their transfection ability by transient transfection into the 
human cell line Hek293. The cells were transfected as described in 3.3. After 24 to 48 
hours, the transfection efficiency of the RPS14 expression vector DNA-preparation 
was tested by immunofluorescence staining. For detecting the expressed protein of 
interest a primary anti-c-MYC antibody was used. Detection of the primary antibody 
was conducted using a goat anti-mouse secondary antibody coupled with a fluorescent 
dye, Alexa 488. 
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Figure 17) Transient transfection of Rps14 N- and C-terminally tagged with a c-MYC-TEV-HA tag in 
Hek293. For testing the transfection efficiency of the generated mammalian expression vectors the plasmid 
preparations were transiently transfected into the human cell line Hek293. Transient transfected N-terminally 
tagged Rps14 shows nuclear localization, while C-terminally tagged Rps14 was mainly detected in nucleoli. Rps14 
NTAP: Rps14 N-terminally tagged with a c-MYC-TEV-HA tag. Rps14 CTAP: Rps14 C-terminally tagged with a 
c-MYC-TEV-HA tag. DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescence staining. Scale 
bar: 20 µm. 
 
The ribosomal protein RPS14 (Chen et al., 1986; Rhoads et al., 1986) is involved in 
the processing of ribosomal RNA (Ferreira-Cerca et al., 2005), thus was found to 
localize mainly in the nucleolus after transient transfection into the human cell line 
Hek293, if it was C-terminally tagged. N-terminally tagged Rps14 shows nuclear 
subcellular localization. With the N-terminally tagged Rps14 very low transfection 
efficiency was detected. However, the vector encoding the C-terminally tagged 
version of the ribosomal protein showed a transfection efficiency of about 40%, 
where the protein mainly localized to the nucleolus and nucleoplasm.  
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4.1.3.2. Stable expression of RPS14: Immunofluorescence staining 
 
Following the evaluation of transfection efficiency of the generated expression 
vectors expressing the ribosomal protein Rps14, various cell lines were transfected. 
Twenty four to forty eight hours later, selection for stable integration of the 
transfected DNA into the genome was started by adding 50 µg/ml to 200 µg/ml of the 
antibiotic Hygromycin B to the growth medium. After ten days up to three weeks 
surviving cells started growing in colonies. These colonies were picked and analysed 
for their expression of Rps14 by immunofluorescence staining and Western blot 
analysis.   
 
 
   
   
 
Figure 18) HeLa cell line stably expressing Rps14 N-terminally tagged with a c-MYC-TEV-HA TAP-tag. 
After selection for stable random integration of the transfected DNA construct, the picked clones were tested on 
their homogeneity of stable protein expression by immunofluorescence staining. Tagged Rps14 was detected by an 
anti-c-MYC primary antibody and adjacently labelling with a goat anti-mouse secondary antibody coupled to 
Alexa 488. N-termnally tagged Rps14 expressed in HeLa cells shows nuclear subcellular localization, but can also 
be found in the cytoplasm at a low level. Rps14 NTAP: Rps14 N-terminally tagged with a c-MYC-TEV-HA tag. 
DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescent staining. Scale bar: 20 µm. 
 
 
Also the C-terminally TAP tagged version of the ribosomal protein RPS14 was 
successfully expressed in the human osteosarcoma cell line U2OS. One stable 
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expressing clone was obtained. About 50% to 60% of the cells show stable expression 
of Rps14 in immunofluorescence staining analysis. Interestingly, like in transient 
immunofluorescence staining assays, the C-terminally tagged Rps14 shows a different 
subcellular localization pattern than the N-terminally tagged version does. While N-
terminally tagged Rps14, expressed in HeLa cells, shows nuclear localization, C-
terminally tagged Rps14 in U2OS cells shows a promintent nucleolar localization 
pattern. This observation is supposedly due to the TAP tag, as the position of the tag 
may influence protein folding and function. 
 
 
   
   
 
Figure 19) U2OS cell line stably expressing Rps14 C-terminally tagged with a c-MYC-TEV-HA TAP-tag. 
After selection for stable random integration of the transfected DNA construct, the picked clones were tested on 
their homogeneity of stable protein expression by immunofluorescence staining. Tagged Rps14 was detected using 
anti-c-MYC primary antibody and subsequent labelling with a goat anti-mouse secondary antibody coupled to 
Alexa 488. C-terminally tagged Rps14 expressed in U2OS cells shows a prominent nucleolar localization pattern 
in positive cells. Rps14 CTAP: Rps14 C-terminally tagged with a c-MYC-TEV-HA tag. DAPI: nuclear staining. 
DIC: phase contrast. FITC: Alexa 488 fluorescence staining. Scale bar: 20 µm. 
 
 
	   59	  
 
4.1.3.3. Stable expression of RPS14: Western blot analysis 
 
To further analyse the expression level of obtained RPS14 expressing clones, Western 
blot analysis was done. TAP-tagged RPS14 was detected using an anti-c-MYC 
primary antibody. The primary antibodies were visualized using goat anti-mouse 
secondary antibodies coupled to either alkaline phosphatase (RPS14 NTAP in HeLa) 
or horseradish peroxidase (RPS14 CTAP in U2OS).  
 
a)  b)  
 
Figure 20) Stable expression of RPS14, C- and N-terminally tagged: Western blot analysis. C- and N-
terminally tagged RPS14, expressed in HeLa and U2OS cells, was detected by Western blot analysis. The TAP-
tagged protein was detected using an anti-c-MYC primary antibody and secondary antibodies coupled to either 
alkaline phosphatase or horseradish peroxidase. a) N-terminally TAP-tagged RPS14 expressed in HeLa cells. Cell 
lysates were prepared, using 2x SDS sample buffer. N-terminally tagged RPS14 was detected using a goat anti-
mouse secondary antibody coupled to alkaline phosphatase. b) C-terminally TAP-tagged RPS14 expressed in 
U2OS cells. Cell lysates were prepared, using NET-2 lysis buffer. Samples from precipitated pellets and 
supernatants were analysed using an anti-c-Myc primary antibody and a goat anti-mouse secondary antibody 
coupled to horseradish peroxidase. Full-length RPS14 is of a molecular weight of 16.3 kDa. TAP tagged RPS14 is 
detected at a molecular weight of about 38 kDa. Ctrl = lysate of empty HeLA/U2OS cells; RPS14 NTAP = N-
terminally tagged RPS14; RPS14 CTAP = C-terminally tagged RPS14.  
 
N-terminally tagged RPS14 expressed in HeLa cells was detected using a goat anti-
mouse secondary antibody coupled to alkaline phosphatase after preparing the cell 
lysate, using 2x SDS sample buffer. U2OS cells, expressing C-terminally tagged 
RPS14, were lysed using NET-2 lysis buffer. Samples from precipitated pellets and 
supernatants of C-terminally tagged Rps14 expressing cells were analysed by Western 
blot analysis, using goat anti-mouse secondary antibodies coupled to horseradish 
peroxidase. This analysis showed that most of the C-terminally tagged protein was not 
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solubilized and precipitated in the pellet. However, at a low level RPS14 was also 
detected in the supernatant. 
 
 
4.1.3.4. Immunoprecipitation / Tandem Affinity Purification: RPS14 
 
Positive clones of HeLa and U2OS cells, that have shown adequate expression levels 
of C- and N-terminally tagged RPS14 in immunofluorescence staining tests and 
Western blot analysis, were expanded for immunoprecipitation and Tandem Affinity 
Purification of RPS14. So far most of the obtained precipitated protein samples have 
been obtained by anti-c-MYC immunoprecipitation assays as the Tandem Affinity 
Purification protocol for c-MYC-TEV-HA tagged proteins still needs to be improved, 
because the second purification step using anti-HA crosslinked Sepharose A beads 
yields high levels of background signal. N-terminally TAP tagged RPS14 expressed 
in HeLa cells, was purified by anti-c-MYC immunoprecipitation and Tandem Affinity 
Purification. By these methods, NTAP-Rps14-specific bands of a molecular weight of 
107 kDa and 52 kDa were purified. To date RPS14- specific protein bands (120 kDa, 
107 kDa and 41 kDa) after purification of C-terminally tagged RPS14 from U2OS 
cells were gained by immunoprecipitation, using anti-c-MYC cross-linked Sepharose 
A beads. Obtained samples were analysed on 7.5% to 17% gradient SDS PAGE gels 
and subsequent silver staining. Protein bands exclusively found in RPS14 containing 
lysates had been cut out and were sent for mass spectrometric analysis. 
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Figure 21) Silver gels: Purification of Rps14 I. The N-terminally tagged version of Rps14 was stable expressed 
in the human cell line HeLa. Anti-c-Myc immuno-precipitation and Tandem Affinity Purification were done with 
HeLa cells expressing Rps14. The samples were separated on a 7.5%-17% gradient SDS PAGE gel and stained by 
Blum’s silver staining protocol.  
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A) Anti-c-Myc IP of Rps14, N-terminally tagged, expressed in HeLa. Black arrow: band at 107 kDa  
B) Initial try of a TAP of Rps14, N-terminally tagged, expressed in HeLa. Black arrow: band at 47 kDa. Black 
arrows mark protein bands cut out and sent for mass spectrometric analysis. Input = total lysate; 9E10 IP = c-Myc 
immunoprecipitation; TEV Cl. = TEV cleavage reaction; 12CA5 IP = HA immunoprecipitation; Ctrl = lysate of 
empty cells; Rps14 = lysate of Rps14 expressing cells; M = PAGE Ruler unstained protein ladder. 
 
 
 
 
Figure 22) Silver gels: Purification of Rps14 II. The C-terminally tagged version of Rps14 was stable expressed 
in the human cell line U2OS. Anti-c-Myc immunoprecipitation was done with U2OS cells expressing Rps14. The 
samples were separated on a 7.5%-17% gradient SDS PAGE gel and stained by Blum’s silver staining protocol. a) 
Protein band at a molecular weight of 120 kDa. b) Protein band at a molecular weight of 100 kDa. c) Protein band 
at a molecular weight of 40 kDa. Black arrows mark cut protein bands sent for mass spectrometric analysis. Input 
= total lysate; 9E10 IP = c-Myc immunoprecipitation; Ctrl = lysate of empty cell line; Rps14 = lysate of Rps14 
expressing cell line; M = PAGE Ruler unstained protein ladder. 
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4.1.3.5. Mass spectrometry: RPS14 
 
The following tables list proteins, which were pulled down with RPS14 from HeLa 
and U2OS cell lysates by purification assays and subsequent mass spectrometric 
analysis. For each protein the number of unique peptides, the percentage of coverage 
with the full-length protein, the molecular weight and protein function is mentioned in 
the mass spectrometry data. Bold highlighted data depicts proteins, which were found 
to interact only with RPS14 in our data. Non-highlighted data indicates proteins, 
which have also been detected in other samples. 
 
 
Table 5) Rps14-interacting proteins, detected by mass spectrometric analysis I. This table lists all proteins, 
detected in protein bands after precipitation of N-termnally tagged Rps14 from stable exressing HeLa cells by 
mass spectrometric analysis. The identified protein, the number of analysed peptides and the percentage of 
coverage of the annotated sequence is listed. Proteins specifically pulled down with Rps14 are highlighted in bold. 
Mw = molecular weight of identified protein in kDa. Sample = molecular weight of cut protein band. 
RPS14 interacting 
protein 
unique 
peptides 
percent  
coverage 
Mw 
(kDa) 
Sample: 
Mw 
source 
comments function References 
desmocollin-1 
isoform Dsc1a 
preproprotein  
7 8,50% 100 52 kDa HeLa 
also comes with 
short edited 
FLNA 
Epidermal barrier 
function 
(Toulza et al., 
2007) 
protein S100-A8  2 19% 11 52 kDa HeLa  
Ca-binding 
protein 
(Lagasse and 
Clerc, 1988) 
small proline rich 
protein 2 31% 8 
100 kDa 
HeLa 
also comes with 
short edited 
FLNA 
Keratinocyte 
differentiation  
(Kartasova et 
al., 1988) 
arginase-1  2 6,80% 35 100 kDa HeLa  
Arginine 
metabolism/ urea 
cylcic enzyme 
(Haraguchi et 
al., 1987), 
(Takiguchi et 
al., 1988)  
apolipoprotein D 
precursor  2 9,50% 21 kDa 
100 kDa 
HeLa  Lipid transporter 
(Drayna et al., 
1986) 
 
The mass spectrometry data obtained from N-terminally tagged RPS14 purification 
did not yield any suitable information about RPS14 interaction partners. To begin 
with, no ribosomal proteins were pulled down with RPS14 although it is a known 
ribosomal protein and functions in the complex formation of the 40S ribosome 
(Rhoads et al., 1986).  Secondly none of the identified proteins correlates with the cut 
protein bands as they were cut at a different molecular weight height.  
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Mass spectrometry data after purification of C-terminally tagged Rps14 from U2OS 
cells is listed in table 6. Proteins, found only in one of the Rps14 cut samples are 
highlighted in bold. Identified proteins, which may be interesting for further analysis, 
are stained in green. 
 
Table 6) Rps14-interacting proteins detected by mass spectrometric analysis II. This table lists all proteins, 
detected in protein bands after precipitation of C-termnally tagged Rps14 from stable exressing U2OS cells by 
mass spectrometric analysis. The identified proteins, the number of analysed peptides, the molecular weight of the 
identified protein and of the cut sample are listed. Proteins specifically pulled down with Rps14 are highlighted in 
bold. Data highlighted in green are possible candidates for linking Rps14 to RNA-editing. Mw = molecular weight 
of identified protein in kDa. Sample = molecular weight of cut protein band. 
RPS14 interacting 
protein 
number of 
assigned spectra Mw (kDa) 
sample: 
Mw, 
source 
function reference 
nucleophosmin 
isoform 1  8 32,7 41 
ribosome biogenesis, chaperone during 
ribosome nuclear export, histone 
chaperone 
 (Okuwaki et al., 2001) 
(Maggi et al., 2008) 
(Swaminathan et al., 
2005)  
HIST1H4H protein 3 11,3 41 core component of nucleosomes RuleBase RU000528 
hnRNP A2/B1 3 37 41 hnRNP complex formation (Kozu et al., 1995) 
caspase-14 
precursor  3 27,6 120 cysteine-type endopeptidase InterPro 
 
In this run of purification of C-terminally tagged RPS14 just very low amounts of 
protein were detected by mass spectrometric analysis. Thus, high levels of keratin 
contamination may mask other interacting factors. Nevertheless, at least two of the 
identified proteins match the cut bands in their molecular weight, the nucleolar 
protein nucleophosmin and the hnRNP A2/B1.These two identified Rps14-interactors 
may be interesting for further analysis of Rps14 function in RNA-editing. 
 
 
4.1.4. DDX15 
4.1.4.1. Transient Immunofluorescence staining: DDX15 
 
The next candidate for an ADAR regulator was the RNA helicase DDX15 (Imamura 
et al., 1997). This RNA helicase (GemoneNet Accession number: NP_001349) was 
also cloned into the generated pcDNA TAP expression vector to be C- and N-
terminally tagged. By mistake, only a truncated version of DDX15 was cloned into 
the expressing vector. Cloning of full-length DDX15 is still in progress. DDX15 
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contains nuclear and nucleolar localization signal peptide sequences, which may help 
the protein traffic between different subcellular compartments (Fouraux et al., 2002). 
Transient transfection studies on the human cell line Hek293 have shown both, 
nuclear and in a high number of cells also nucleolar localization of the C- and N-
terminally tagged protein. However, transfection efficiency of both vectors was less 
than 30%. 
 
 
 
 
   
   
 
Figure 23) Transient transfection of DDX15 N- and C-terminally tagged with a c-MYC-TEV-HA tag in 
Hek293. For testing the transfection efficiency of the generated mammalian expression vectors the plasmid 
preparations were transiently transfected into the human cell line Hek293. Nuclear localization of C- and N-
terminally tagged truncated DDX15 was detected by Alexa 488 immunofluorescence staining of an anti-c-Myc 
primary antibody. Most of the analysed cells got damaged during the fixation procedure. DDX15 NTAP: DDX15 
N-terminally tagged with a c-MYC-TEV-HA tag. DDX15 CTAP: DDX15 C-terminally tagged with a c-MYC-
TEV-HA tag. DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescence staining. Scale bar: 20 
µm. 
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4.1.4.2. Stable expression of DDX15: Immunofluorescence staining 
 
Though the transfection efficiency of the RNA helicase DDX15 in transient 
transfection tests was very low, the two versions of the protein, the C- and the N-
terminally tagged DDX15, were used for the generation of stable expressing cell 
lines. We failed to stably express the C-terminally tagged version of DDX15 in any of 
the used cell lines. Nevertheless, we obtained one U2OS clone stably expressing N-
terminally tagged DDX15 although expression levels of DDX15 were found to be 
very low.  
 
 
 
    
   
 
Figure 24) U2OS cell line stably expressing DDX15 N-terminally tagged with a c-MYC-TEV-HA TAP-tag. 
After selection for stable random integration of the transfected DNA construct, the picked clones were tested on 
their homogeneity of stable protein expression by immunofluorescence staining. Tagged DDX15 was detected by 
an anti-c-MYC primary antibody and labelling with a goat anti-mouse secondary antibody coupled to Alexa 488. 
Stable expressed truncated DDX15 shows nucleolar/nucleoplasmic and granular cytoplasmic localization. DDX15 
NTAP: DDX15 C-terminally tagged with a c-MYC-TEV-HA tag. DAPI: nuclear staining. DIC: phase contrast. 
FITC: Alexa 488 fluorescence staining. Scale bar: 20 µm. 
 
As mentioned before, very few cells of the picked clones have shown positive 
expression of N-terminally tagged DDX15 in immunofluorescence staining tests. Like 
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in transient transfection assays, using the N-terminally tagged DDX15 expression 
vector, also stable expressing U2OS cells show mainly nuclear and nucleolar 
localization of the RNA helicase. 
 
4.1.4.3. Stable expression of DDX15: Western blot analysis 
 
Western blot analysis of the DDX15 expressing U2OS clone did not yield proper 
information about the expression of the truncated, N-terminally tagged, DDX15. The 
human full-length protein has a molecular weight of about 90 kDa. Tagged with a 6x 
c-Myc-TEV-HA tag, DDX15 is of about 120 kDa. The molecular weight of tagged 
truncated DDX15 is not known. Detected bands are due to a high background level 
after visualization of DDX15 with an anti-c-Myc primary antibody and a horseradish 
peroxidase coupled secondary antibody. 
 
 
Figure 25) Stable expression of truncated DDX15 in U2OS cells: Western blot analysis. To check the 
expression of N-terminally tagged truncated DDX15 in the U2OS clone, found to express the protein by 
immunofluorescence staining, Western blot analysis of the positive clone was done. DDX15 was detected by an 
anti-c-Myc primary antibody and subsequent visualization with a goat anti-mouse secondary antibody coupled to 
HRP. The protein band detected at a molecular weight of about 128 kDa is a background band. Thus the size of the 
truncated version of DDX15 is still unknown. TAP-tagged DDX15 = 120 kDa. Ctrl = plane U2OS cell lysate. 
DDX15 NTAP = U2OS clone expressing DDX15 tagged with a N-terminal tag for tandem affinity purification. 
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4.1.4.4. Immunoprecipitation: DDX15 
 
Although the overall expression levels of truncated DDX15 in the obtained U2OS 
clone were very low in immunofluorescence staining tests and not detectable in 
Western blot analysis, an initial experimental trial of anti-c-Myc immunoprecipitation 
was done with Sepharose A beads cross-linked with a 9E10 anti-c-Myc antibody. The 
samples were analysed on a 7.5% to 17% gradient SDS PAGE gel and subsequent 
silver staining. Data gained by DDX15 immunoprecipitation from U2OS cells is not 
significant, as the molecular weight of the truncated version of DDX15 itself was not 
known. However, one specific protein band was detected at a molecular weight of 65 
kDa. Additionally a prominent double band at 56 kDa and 58 kDa was detected. All 
three bands were sent for mass spectrometric analysis. 
 
 
 
 
Figure 26) Silver gels: Purification of truncated DDX15. The N-terminally tagged, truncated version of 
DDDX15 was stable expressed in the human cell line U2OS. Anti-c-Myc immunoprecipitation was done. The 
samples were separated on a 7.5%-17% gradient SDS PAGE gel and stained by Blum’s silver staining protocol. a) 
Protein band at a molecular weight of 65 kDa. b) Protein double band at a molecular weight of 58 kDa and 56 kDa. 
Black arrows mark cut protein bands stent for mass spectrometric analysis. The molecular weight of the expressed 
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truncated version of DDX15 is not known. This was an initial experimental trial. Input = total lysate; 9E10 IP = c-
Myc immunoprecipitation; M = PAGE Ruler unstained protein ladder; Ctrl = empty U2OS lysate; Ddx15 = 
DDX15 expressing U2OS lysate.  
 
 
4.1.4.5. Mass spectrometry: DDX15 
 
Table 7 lists proteins detected after immunoprecipitation using U2OS cells expressing 
a truncated version of DDX15. As the size of this protein is not known, this was just 
an experimental trial. It was also not known which localization signals are comprised 
in the sequence of the truncated protein. Very few proteins were found in the cut gel 
bands, what may be due to the truncation and low expression level of the DDX15 
itself in the cell line used for purification studies. Data labelled in bold was identified 
only in lysates, prepared from DDX15 expressing cells. 
 
 
Table 7) DDX15 interacting proteins detected by mass spectrometric analysis. This table lists all proteins, 
detected in protein bands after precipitation of N-termnally tagged truncated DDX15 from stable exressing U2OS 
cells by mass spectrometric analysis. The identified protein, the number of analysed peptides and the percentage of 
coverage of the annotated sequence is listed. Proteins specifically pulled down from the DDX15 lysate are 
highlighted in bold. Mw = molecular weight of identified protein in kDa. Sample = molecular weight of cut 
protein band. 
DDX15 
interacting 
protein 
unique 
peptides 
percent  
coverage 
Mw 
(kDa) 
Sample: 
Mw 
source 
comments function references 
alpha-2-
glycoprotein 1 2 11% 23 
50 kDa 
U2OS  
MCH class I 
protein 
(Kennedy et 
al., 2001) 
suprabasin 
isoform 1 
precursor  
2 6,10% 61 65 kDa U2OS 
also comes with 
unedited 
BLCAP 
epidermal barrier 
function 
(Toulza et al., 
2007) 
Tubulin, beta  2 6,10% 50 50 kDa U2OS  
microtubule 
subunit 
(Lee et al., 
1983) 
vimentin  34 65% 54 65 kDa U2OS 
also comes with 
DSS1 
Class-III 
intermediate 
filament; binding, 
stabilization of 
collagen mRNAs 
(Ferrari et al., 
1986), (Challa 
and Stefanovic, 
2011) 
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4.1.5. SRSF9 
4.1.5.1. Transient Immunofluorescence staining: SRSF9 
 
The last identified putative regulator of ADAR activity investigated in this thesis was 
the arginine/serine- rich splice factor SRSF9. For cloning of the SR protein, cDNA 
from the mouse neuroblastoma cell line N2A was prepared. Primers for amplification 
of the full-length SR sequence were designed in silico (UniProt Accession number: 
Q13242). The amplified sequence was cloned into the pcDNA (-) Hygro vector, 
designed for Tandem Affinity Purification. A C-terminally tagged version of SRSF9 
was obtained which showed adequate levels of transfection efficiency during transient 
transfection studies in the human cell line Hek293. No positive signals could be 
detected after transfection of N-terminally tagged SRSF9, raising the question on the 
suitability of the used construct. 
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Figure 27) Transient transfection of SRSF9 C-terminally tagged with a c-MYC-TEV-HA tag in Hek293, 
HeLa and U2OS. For testing the transfection efficiency of the generated mammalian expression vector expressing 
SRSF9, the plasmid preparations were transiently transfected into the human cell lines Hek293, HeLa and U2OS. 
In most of the cells nuclear localization of the TAP-tagged SRSF9 was observed. Though, in some of the positive 
cells SRSF9 was also detected within the cytoplasm. A similar subcellular localization pattern of C-terminally 
tagged SRSF9 was observed in all three investigated cell lines. SRSF9 CTAP: SRSF9 C-terminally tagged with a 
c-MYC-TEV-HA tag. DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescence staining. Scale 
bar: 20 µm. 
 
SRSF9 is an arginine/serine- rich splice factor involved in constitutive and alternative 
splicing (Screaton et al., 1995). Pre-mRNA splicing is a post-transcriptional 
processing mechanism, taking place in the nucleus (Misteli et al., 1997). Thus in 
transient transfection tests with SRSF9 we observed mainly nuclear localization 
pattern in three different human cell lines. However, in some transfected cells of all 
three investigated cell lines, SRSF9 was also found to localize within the cytoplasm. 
The generation of stable expressing cell lines was started with the C-terminally TAP-
tagged SRSF9. But to date no SRSF9 expressing positive clone was sustained. 
 
 
4.1. FILAMIN A 
 
The cytoskeletal cross-linker Filamin A (FLNA) is a large cytoplasmic protein 
involved in many cellular processes (Weihing, 1985). FLNA forms a high molecular 
weight dimer, mediated by its C-terminus, and cross-links actin filaments (Hartwig et 
al., 1980; Nakamura et al., 2007). In addition to the high avidity binding of FLNA to 
F-actin many other proteins have been identified to be interaction partners of Filamin. 
These partners can be grouped into cytoskeletal proteins, proteins involved in cell 
signalling and motility, and regulators of cellular mechanic stability, for detailed 
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information see following reviews: (Feng and Walsh, 2004; Popowicz et al., 2006; 
Stossel et al., 2001). A N-terminal actin binding domain (Hartwig, 1995) is followed 
by 24 antiparallel beta-barrels, forming IgG-like domains, separated by two calpain-
sensitive hinge regions (Gardel et al., 2006). This highly versatile protein was 
identified as one of the protein-coding targets of RNA editing. Here, editing of the 
Filamin A transcript leads to an amino acid substitution of a glutamine into an 
arginine within IgG-like repeat 22 (Levanon et al., 2005). This domain of the protein 
is known to interact with integrins (Travis et al., 2004) and small GTPases (Ohta et 
al., 1999). As mentioned in the introduction, the effect of this editing event, which 
changes the electrostatic properties of the protein, is not known. Thus mammalian 
expression vectors (pREP4 containing a Hygromycin resistance gene) were 
established in our lab, encoding the full-length versions of edited and unedited 
Filamin A tagged with a 3x c-Myc tag. Additionally, we were provided by Christina 
Godfried (Lehigh University, PA) with pCeMM expression vectors, encoding edited 
and unedited Filamin A IgG-like domains 20 to 24, tagged by a Protein G-TEV-MYC 
tag, C-terminally tagged Filamin, and a Protein G-TEV-SBP tag, N-terminally tagged 
Filamin, for tandem affinity purification. Using the listed expression vectors, we 
wanted to generate stable cell lines for purification studies under native conditions to 
investigate interaction profiles of edited and unedited Filamin A. 
 
4.2.1. Transient Immunofluorescence staining: Filamin A 
 
The pREP4 vectors and pCeMM vectors were transiently transfected into several 
mammalian cell lines to explore potential differences regarding localization pattern of 
edited and unedited Filamin A. In the following section pictures taken after transient 
transfections are shown. The c-Myc-tagged Filamins were detected using a 9E10 anti-
c-Myc primary antibody and goat anti-mouse secondary antibodies coupled to 
Alexa568/488 fluorescent dyes. We failed to detect short N-terminally tagged 
Filamins in transient transfection tests. Goat anti-mouse secondary antibodies coupled 
to different fluorescent dyes have been tried to detect the protein G-tag. Additionally, 
fluorescently labelled biotin was used to detect the SBP-tag without success.  
Due to the actin-cross-linking nature of Filamin, it shows cytoplasmic, filament-
associated localization pattern in all cell lines. However, in some of the transfected 
cell lines the edited version of full-length Filamin A seems to be more stress fibre 
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associated, e.g. in HeLa cells. No difference in localization pattern of edited and 
unedited Filamin A was found in transiently transfected SCaBER cells. 
 
Furthermore, we also used mouse cell lines for investigating subcellular localization 
pattern of Filamin A. Edited Filamin A was found to be stress fibre associated in the 
mouse myoblast cell line C2C12, similar to the localization pattern in HeLa cells. 
Transient transfection of Filamin A in the mouse neuroblastoma cell line cN2A 
revealed no obvious differences in localization of edited and unedited Filamin A. 
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Figure 28) Transient transfection of edited and unedited full-length Filamin A, in the human cell lines HeLa 
and SCaBER. For testing the transfection efficiency of the mammalian expression vector pREP4 expressing full-
length edited and unedited versions of Filamin A, the plasmid preparations were transiently transfected into the 
human cell lines HeLa and SCaBER. C-Myc-tagged FLNA was detected using a 9E10 antibody and a goat anti-
mouse secondary antibody coupled to Alexa 488. Due to FLNA’s role as a cytoskeletal cross-linker, transiently 
transfected FLNA shows cytoplasmic localization. In general, both versions of FLNA, the edited and the unedited 
protein, show filament-associated localization. Though, in transiently transfected HeLa cells, a more stress-fibre 
associated localization pattern of edited FLNA was observed, while in SCaBER cells, no obvious differences in 
localization behaviour of edited and unedited FLNA was found. FLNA = Filamin A, WT = unedited version of 
Filamin. DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescent staining. Scale bar: 20 µm. 
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Figure 29) Transient transfection of edited and unedited full-length Filamin A in the mouse cell lines C2C12 
and cN2A. For testing the transfection efficiency of the mammalian expression vector pREP4 expressing full-
length edited and unedited versions of Filamin A, the plasmid preparations were transiently transfected into the 
mouse myoblasts C2C12 and neuroblastoma cN2A. C-Myc-taged FLNA was detected using a 9E10 primary 
antibody and a goat anti-mouse secondary antibody coupled to Alexa 488. As a cytoskeletal cross-linker, 
transiently transfected FLNA shows cytoplasmic localization also in the mouse cell lines. In general, both versions 
of FLNA, the edited and the unedited protein, show filament-associated localization. Though, in transiently 
transfected C2C12 myoblasts, a more stress-fibre associated localization pattern of edited FLNA was observed, 
while in the neuroblastoma N2A, no obvious differences in localization behaviour of edited and unedited FLNA 
was found.  FLNA = Filamin A, WT = unedited version of Filamin. DAPI: nuclear staining. DIC: phase contrast. 
FITC: Alexa 488 fluorescent staining. Scale bar: 20 µm. 
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The pCeMM vectors for expression of edited and unedited Filamin A IgG-repeats 20 
to 24 are designed to be transfected into mammalian cells via virus-mediated 
transfection methods. These transfection procedures cannot be carried out in our 
laboratory facility. Thus we did transient transfection tests with the short Filamin A 
encoding expression vectors to investigate the transfection efficiencies obtained by 
nanoparticle mediated transfection techniques. This method was quite promising for 
the generation of stable cell lines expressing these pCeMM encoded short versions of 
Filamin A, as an transfection efficiency of about 30% to 40% in several cell lines was 
gained. Similar to the localization pattern of full-length Filamins, no obvious 
differences were found in the subcellular localization of short edited and unedited 
Filamin A in the squamous cell carcinoma cell line SCaBER. Nevertheless, in mouse 
myoblasts, C2C12, again a more stress fibre associated behaviour of edited truncated 
Filamin A was observed. 
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Figure 30) Transient transfection of truncated Filamin A (IgG-like repeats 20 to 24), edited and unedited, in 
the human cell line SCaBER and the mouse myoblast cell line C2C12. For testing the transfection efficiency of 
the mammalian expression vector pCeMM expressing C-terminally tagged truncated edited and unedited versions 
of Filamin A, the plasmid preparations were transiently transfected into the human cell line SCaBER and the 
mouse myoblasts C2C12. TAP-tagged truncated FLNA was detected, using an anti-c-Myc 9E10 primary antibody 
and a goat anti-mouse secondary antibody coupled to Alexa 488. Also the truncated versions of FLNA show a 
cytoplasmic staining pattern. Thoug no obvious differences in subcellular localization of short edited and unedited 
FLNA could be detected in transiently transfected SCaBER cells, in the mouse cell line C2C12 edited short FLNA 
again shows a more stress-fibre associated localization. FLNA = Filamin A, WT = unedited version of Filamin A. 
DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescent staining. Scale bar: 20 µm. 
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4.2.2. Stable expression of Filamin A: Immunofluorescence staining 
 
After investigating transfection efficiencies of the available Filamin A expression 
vectors, we started to generate stable cell lines, expressing full-length and truncated 
versions of edited and unedited Filamin A. The pREP4 vectors for the expression of 
full-length Filamin A, encodes a Hygromycin resistance gene. Two days after 
transfection, selection was started by adding the antibiotic Hygromycin B. After 10 
days up to three weeks of selection the cells started growing in colonies. These clones 
were picked and tested on their expression level of Filamin A by immunofluorescence 
staining and Western blot analysis. Up to now we were able to generate several stable 
cell lines expressing full-length versions of Filamin A. However, only in the human 
cell line Hek293 we were able to express both variants of the protein. Edited full-
length Filamin A was also stable expressed in the human cell lines U2OS and HeLa 
cells and in the mouse neuroblastoma cell line cN2A. Two clones of HeLa and U2OS 
were generated which show a highly heterogenous expression level of unedited full-
length Filmain A in immunofluorescence staining tests. Nevertheless, they were 
useless for purification studies as their Filamin A expression level was much lower 
than in the clones expressing the edited Filamin A. In order to complete the 
localization studies on Filamin A, the immunofluorescence pictures of several 
generated Filamin A expressing cell lines are depicted in the next section. 
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Figure 31) Stable expression of full-length Filamin A in the human cell line HeLa. After selection for stable 
random integration of the transfected DNA construct, the picked clones were tested on their homogeneity of stable 
protein expression by immunofluorescence staining. C-Myc-tagged full length Filamin A was detected by an anti-
MYC primary antibody and subsequent labelling with a goat anti-mouse secondary antibody coupled to Alexa 488. 
The full-length versions of edited and unedited FLNA show a cytobplasmic localization pattern in stable 
expressing HeLa cells. In contrast to transient transfection assays of full-length FLNA in HeLa cells, no obvious 
differences in filament-association of edited and unedited FLNA were observed in stable expressing HeLa cells. 
FLNA = Filamin A; WT = unedited Filamin A; DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 
fluorescence staining. Scale bar: 20 µm. 
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Figure 32) Stable expression of full-length Filamin A in the human cell line U2OS. After selection for stable 
random integration of the transfected DNA construct, the picked clones were tested on their homogeneity of stable 
protein expression by immunofluorescence staining. C-Myc-tagged full length Filamin A was detected by an anti-
MYC primary antibody and subsequent labelling with a goat anti-mouse secondary antibody coupled to Alexa 488. 
Also in the human cell line U2OS full-length FLNA is localized in the cytoplasm. Due to the spreading of these 
cells the association of FLNA with cortical actin fibres is easy to detect and nicely visible after 
immunofluorescence staining. No obvious differences in localization of edited and unedited FLNA are visible in 
stable expressing U2OS cells. FLNA = Filamin A; WT = unedited Filamin A; DAPI: nuclear staining. DIC: phase 
contrast. FITC: Alexa 488 fluorescent staining. Scale bar: 20 µm. 
 
 
   
 
Figure 33) Stable expression of edited full-length Filamin A in the mouse cell line cN2A. After selection for 
stable random integration of the transfected DNA construct, the picked clones were tested on their homogeneity of 
stable protein expression by immunofluorescence staining. C-Myc-tagged full-length Filamin A was detected by 
an anti-MYC primary antibody and subsequent labelling with a goat anti-mouse secondary antibody coupled to 
Alexa 488. In undifferentiated mouse N2A cells edited full-length FLNA was again detected in the cytoplasm by 
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immunofluorescence staining. FLNA = Filamin A; DAPI: nuclear staining. DIC: phase contrast. FITC: Alexa 488 
fluorescent staining. Scale bar: 20 µm. 
 
 
To generate stable cell lines expressing the truncated versions of edited and unedited 
Filamin A, the pCeMM expression vectors were co-transfected with a helper plasmid 
containing a Hygromycin resistance gene. After 10 days up to three weeks of 
selection, stable Filamin A expressing clones were picked and analysed by 
immunofluorescence staining and Western blot analysis. Up to now we successfully 
expressed edited and unedited truncated Filamin A in the human cell line Hek293. 
Additional U2OS clones have been obtained expressing the unedited form of Filamin 
A repeats 20 to 24. We failed to express both versions of the protein in other cell 
lines. Future studies on edited and unedited Filamin A will focus on the generation of 
stable expressing Filamin A clones in cell lines, where major differences in 
localization pattern of edited and unedited Filamin A have been detected in this study, 
like in HeLa cells and C2C12 mouse myoblasts. 
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Figure 34) Stable expression of edited and unedited Filamin A IgG-repeats 20 to 24 in the human cell line 
Hek293. After selection for stable random integration of the transfected DNA construct, picked clones were tested 
on their homogeneity of stable protein expression by immunofluorescence staining. C-terminally TAP-tagged 
short Filamin A (IgG-like repeats 20 to 24) was detected by an anti-c-MYC primary antibody and subsequent 
labelled with a goat anti-mouse secondary antibody coupled to Alexa 488. Due to the harming action of fixation 
reagent on Hek293 cells, detected positive cells are miss-shaped. Though, again an overall cytoplasmic 
localization of stable expressed short FLNA is visible FLNA = Filamin A; WT = unedited Filamin A; DAPI: 
nuclear staining. DIC: phase contrast. FITC: Alexa 488 fluorescent staining. Scale bar: 20 µm. 
 
4.2.3. Stable expression of Filamin A: Western blot analysis 
 
Western blot analysis of clones expressing full-length FLNA is not shown, as a high 
level of protein fragmentation was detected. Hek293 clones expressing edited and 
unedited FLNA were lysed using 2x SDS sample buffer and subsequent sonication. 
TAP-tagged C-terminally tagged truncated edited and unedited FLNA was detected 
using a 9E10 anti-c-MYC primary antibody and a goat anti-mouse secondary 
antibody coupled to horseradish peroxidase.  
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Figure 35) Stable expression of truncated C-terminally tagged edited and unedited FLNA: Western blot 
analysis. Hek293 cells, found to express truncated FLNA C-terminally tagged by immunofluorescence staining, 
were lysed in 2x SDS sample buffer and sonication. Samples were analysed using an anti-c-MYC primary 
antibody and a goat anti-mouse secondary antibody coupled to horseradish peroxidase. Truncated edited and 
unedited FLNA tagged by a Protein G/TEV/MYC TAP-tag shows a molecular weight of about 75 kDa. Ctrl = 
lysate of empty Hek293 cells; FLNA WT = lysate of Hek293 cells expressing truncated unedited FLNA, C-
terminally TAP-tagged; FLNA edited = lysate of Hek293 cells expressing truncated edited FLNA, C-terminally 
TAP-tagged. 
 
4.2.4. Immunoprecipitation / Tandem Affinity purification: Filamin A 
 
After testing the picked clones on their Filamin A expression immunoprecipitation 
assays were done using Sepharose A beads cross-linked to a 9E10 anti-c-Myc 
antibody. To date no specific protein bands have been obtained in purification assays 
of full-length Filamin A. Due to high levels of protein fragmentation and high 
background signal after 9E10-immunoprecipitation, sustained protein bands may 
mask Filamin A specific bands, thus the purification procedure for full-length Filamin 
A still has to be improved. The Hek293 cell line expressing edited and unedited 
Filamin A IgG- like repeats 20 to 24 was used for purification studies. 
Immunoprecipitation using 9E10 anti-c-Myc antibody coupled Sepharose A beads 
and Tandem Affinity Purification was done. The first purification step in the Tandem 
Affinity Purification procedure for Filamin A precipitation was conducted using pan 
anti-mouse IgG-magnetic beads. After the TEV cleavage reaction c-Myc tagged 
truncated Filamin A was pulled down by anti-c-Myc coupled Sepharose A beads. So 
far no FLNA-specific protein bands have been obtained by tandem affinity 
purification. IP-Obtained samples were examined by 7.5% to 17% SDS PAGE and 
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subsequent silver staining. Filamin A was purified under several conditions, using 
different lysis buffers to improve the overall yield of purified protein. 
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 Figure 36) Silver gels: Purification of short Filamin A tagged with a C-terminal TAP-tag. The C-terminally 
tagged edited and unedited versions of Filamin A IgG-like repeats 20 to 24 were stable expressed in the human 
cell line Hek293. Anti-c-Myc immuno-precipitation was done with Hek293 cells expressing edited and unedited 
Filamin A IgG-repeats 20-24. The samples were separated on a 7.5%-17% gradient SDS PAGE gel and stained by 
Blum’s silver staining protocol. a) Protein band at a molecular weight of > 200 kDa after IP of unedited short 
Filamin A. b) Protein band at a molecular weight of > 200 kDa from IP of short edited Filamin A c) Protein band 
at a molecular weight of 200 kDa from IP of short edited Filamin A. d) Protein band at a molecular weight of 47 
kDa. Black arrows mark cut protein bands sent for mass spectrometric analysis. Ctrl = Lysate of plane Hek293; wt 
= lysate of Hek293 expressing unedited short Filamin A; ed = lysate of Hek293 expressing edited short Filamin A; 
Input = total lysate; 9E10 IP = c-Myc immunoprecipitation; M = PAGE Ruler unstained protein ladder.  
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Figure 37) Silver gels: Purification of full length FLNA and short FLNA tagged with a C-terminal TAP-tag. 
The c-Myc tagged edited and unedited full length FLNA and the C-terminally tagged edited and unedited versions 
of FLNA IgG-like repeats 20 to 24 were stable expressed in the human cell line Hek293. Anti-c-Myc 
immunoprecipitation using the lysis buffer NET-2 was done with Hek293 cells expressing edited and unedited 
full-length FLNA and FLNA IgG-repeats 20-24. The samples were separated on a 7.5%-17% gradient SDS PAGE 
gel and stained by Blum’s silver staining protocol. a) Protein band at a molecular weight of > 24 kDa after IP of 
edited short FLNA b) Protein band at a molecular weight of > 22 kDa from IP of short edited FLNA c) Protein 
band at a molecular weight of 11 kDa from IP of short edited FLNA d) Protein band at a molecular weight of 26 
kDa from IP of full length edited FLNA. Black arrows mark cut protein bands sent for mass spectrometric 
analysis. Ctrl = Lysate of plane Hek293; wt = lysate of Hek293 expressing unedited full length and short Filamin 
A; ed = lysate of Hek293 expressing edited full-length and short Filamin A; Input = total lysate; 9E10 IP = c-Myc 
immunoprecipitation; M = PAGE Ruler unstained protein ladder. 
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Figure 38) Silver gels: Purification of full length FLNA and short FLNA tagged with a C-terminal TAP-tag. 
The c-Myc tagged edited and unedited full length FLNA and the C-terminally tagged edited and unedited versions 
of FLNA IgG-like repeats 20 to 24 were stable expressed in the human cell line Hek293. Anti-c-Myc 
immunoprecipitation using 0.5x RIPA buffer for cell lysis was done with Hek293 cells expressing edited and 
unedited full length FLNA and FLNA IgG-repeats 20-24. The samples were separated on a 7.5%-17% gradient 
SDS PAGE gel and stained by Blum’s silver staining protocol. a) Protein band at a molecular weight of > 156 kDa 
after IP of unedited short FLNA b) Protein band at a molecular weight of > 22 kDa from IP of short edited FLNA 
c) Protein band at a molecular weight of 11 kDa from IP of short edited FLNA d) Protein band at a molecular 
weight of 26 kDa from IP of full length edited FLNA. Black arrows mark cut protein bands sent for mass 
spectrometric analysis. Ctrl = Lysate of plane Hek293; wt = lysate of Hek293 expressing unedited full-length and 
short Filamin A; ed = lysate of Hek293 expressing edited full-length and short Filamin A; Input = total lysate; 
9E10 IP = c-Myc immunoprecipitation; M = PAGE Ruler unstained protein ladder. 
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4.2.5. Mass spectrometry: Filamin A 
 
We tried to purify full-length and truncated edited and unedited Filamin A in complex 
with its interaction partners under different conditions. Tables below list proteins 
pulled down by anti-c-Myc immunoprecipitation of truncated edited and unedited 
Filamin A. Proteins found to interact only with Filamins are listed in bold in two 
tables, separating interaction partners of unedited and edited Filamin A. In this sudy 
several proteins have been identified which only interact with short edited or unedited 
Filamin A. These interaction partners and other interesting identified proteins, like 
several histone variants, are highlighted in green. Furhter studies need to be done to 
verify mass spectrometry data gained in this project. 
 
 
Table 8) Interaction partners of unedited FLNA identified by mass spectrometric analysis I. Proteins, 
detected in protein bands after precipitation of C-termnally tagged truncated unedited FLNA from stable exressing 
Hek293 cells are listed in this table. The identified proteins, the numbers of analysed peptides, the molecular 
weight of the identified protein and of the cut sample are shown. Proteins specifically pulled down with unedited 
short FLNA are highlighted in bold. Data highlighted in green are proteins either specifically interacting with 
unedited FLNA (spectrin alpha) or nuclear proteins (histone H1.3), which may lead to new insights on FLNA 
localization and function in the cell. Mw = molecular weight of identified protein in kDa. Sample = molecular 
weight of cut protein band. 
WT FLNA-
interacting 
protein 
unique 
peptides 
percent  
coverage 
Mw  
(kDa) 
Sample: 
Mw 
(kDa) 
comments function reference 
filamin-A isoform 
1  34 16% 280  > 200  
 comes with 
edited FLNA 
cytoskeletal cross 
linker, signalling 
scaffold 
 (Stossel et al., 2001), 
(van der Flier and 
Sonnenberg, 2001)  
filamin-B isoform 
2  9 5,10% 278  > 200 
 comes with 
edited FLNA  
links actin 
cytoskeleton to 
membrane 
constituents 
(Stossel et al., 2001), 
(van der Flier and 
Sonnenberg, 2001) 
filamin-C isoform 
a  2 2,20% 291  > 200 
 comes with 
edited FLNA 
actin filament cross 
linker; muscle-
specific filamin 
(van der Ven et al., 
2000) 
histone H1.3  2 9,50% 22  > 200  comes with edited FLNA  
condensation of 
nucleosome DNA (Albig et al., 1991) 
spectrin, alpha, 
non-erythrocytic 
1  
3 1,30% 279  > 200  
 Ca2+ dependent 
movement of 
cytoskeleton 
(Moon and 
McMahon, 1990) 
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Table 9) Interaction partners of edited FLNA identified by mass spectrometric analysis I. Proteins, detected 
in protein bands after precipitation of C-termnally tagged truncated edited FLNA from stable exressing Hek293 
cells are listed in this table. The identified proteins, the numbers of analysed peptides, the molecular weight of the 
identified protein and of the cut sample are shown. Proteins specifically pulled down with edited short FLNA are 
highlighted in bold. Data highlighted in green are proteins either specifically interacting with edited FLNA 
(spectrin beta) or nuclear proteins (histone H1.3), which may lead to new insights on FLNA localization and 
function in the cell. Mw = molecular weight of identified protein in kDa. Sample = molecular weight of cut protein 
band. 
Edited FLNA- 
interacting 
protein 
unique 
peptides 
percent  
coverage 
Mw 
(kDa) 
Sample: 
Mw 
(kDa) 
comments function references 
filamin-A isoform 
1  22 11% 280  > 200 
comes with 
unedited 
FLNA 
cytoskeletal cross 
linker, signalling 
scaffold 
(Stossel et al., 2001; 
van der Flier and 
Sonnenberg, 2001) 
desmoglein-1 
preproprotein  3 4,00% 114  
47 
 
comes with 
Rps14 and 
DDX15 
component of 
intercellular 
desmosome 
junctions 
(Nilles et al., 1991) 
filamin-B isoform 
2  7 3,00% 
278 
kDa > 200 
comes with 
unedited 
FLNA 
links actin 
cytoskeleton to 
membrane 
constituents 
(Stossel et al., 2001), 
(van der Flier and 
Sonnenberg, 2001) 
glyceraldehyde-3-
phosphate 
dehydrogenase 
3 12% 36 kDa 47  
Dehydrogenase and 
nitrosylase 
activities 
(Hanauer and 
Mandel, 1984) 
histone H2A type 
1-B/E  2 12% 14 kDa 47  
core component of 
nucleosomes 
(Bonenfant et al., 
2006) 
filamin-C isoform 
a  5 3,00% 
291 
kDa > 200 
 comes with 
unedited 
FLNA  
actin filament cross 
linker; muscle-
specific filamin 
(van der Ven et al., 
2000) 
small proline rich 
protein 2 31% 6 kDA 47 
 comes with 
Rps14 
envelope protein of 
keratinocytes 
(Kartasova and van de 
Putte, 1988) 
spectrin beta 
chain, brain 1 
isoform 1  
2 0,89% 275 kDa > 200  
cytoskeletal 
protein, crosslinks 
actin 
(Byers and Branton, 
1985) 
histone H1.3  5 15% 22 kDa > 200  comes with edited FLNA 
condensation of 
nucleosome DNA (Albig et al., 1991) 
band-6-protein  2 2,80% 80 kDa 47  
constituent of 
desmosomes (Hatzfeld et al., 1994) 
PELOTA  2 6,20% 43 kDa 47  
Mitosis/genomic 
stability/ 
degradation of 
damaged mRNA 
(Shamsadin et al., 
2000) 
 
 
After anti-c-Myc immunoprecipitation of C-terminally tagged short edited and 
unedited FLNA from Hek293 cells, lysed by either NET-2 or RIPA lysis buffer, 
another set of cut protein bands was sent for mass spectrometric analysis. This time 
just a few peptides were detected. Nevertheless, most of these peptides were assigned 
to annotated protein sequences and are listed in the tables below. For these runs of 
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short Filamin A purification different lysis buffers were used, thus a different set of 
proteins was identified than in the first Filamin A purifications. This time several 
components of cell adhesion contacts, like subunits of desmosomes, have been 
identified to interact either with edited or unedited short Filamin A. Again one histone 
variant was identified to be an interacting partner of Filamin A (Histone H2B type 1-
K).  
 
Table 10) Interaction partners of unedited FLNA identified by mass spectrometric analysis II. Proteins, 
detected in protein bands after precipitation of C-termnally tagged truncated unedited FLNA from stable exressing 
Hek293 cells are listed in this table. Different lysis buffers have been used for this run of FLNA purification. The 
identified proteins, the numbers of analysed peptides, the molecular weight of the identified protein and of the cut 
sample are shown. Proteins specifically pulled down with unedited short FLNA are highlighted in bold. Data 
highlighted in green are proteins either specifically interacting with unedited FLNA (Desmoplakin) or nuclear 
proteins (Histone H2B type 1-K), which may lead to new insights on FLNA localization and function in the cell. 
Mw = molecular weight of identified protein in kDa. Sample = molecular weight of cut protein band. 
WT FLNA-interacting 
protein 
Nr. of assigned 
spectra Mw (kDa) 
Sample: 
Mw 
(kDa) 
function reference 
Desmoplakin 2 330 120 component of desmosomes (Green et al., 1990) 
Histone H2B type 1-K 2 14 120 histone binding protein (Lorain et al., 1998) 
 
 
Table 11) Interaction partners of edited FLNA identified by mass spectrometric analysis II. Proteins, 
detected in protein bands after precipitation of C-termnally tagged truncated edited FLNA from stable exressing 
Hek293 cells are listed in this table. The identified proteins, the numbers of analysed peptides, the molecular 
weight of the identified protein and of the cut sample are shown. Proteins specifically pulled down with edited 
short FLNA are highlighted in bold. Data highlighted in green are proteins either specifically interacting with 
edited FLNA (spectrin beta) or nuclear proteins (histone H1.3), which may lead to new insights on FLNA 
localization and function in the cell. Mw = molecular weight of identified protein in kDa. Sample = molecular 
weight of cut protein band. 
Edited FLNA-interacting 
protein 
Nr. of assigned 
spectra 
Mw 
(kDa) 
Sample:  
Mw 
(kDa) 
function reference 
Desmoglein-1 3 / 1 114 24 / 10  cadherin family protein (Wheeler et al., 1991) 
Serpin A12 3 47 24  adipocatokine (Hida et al., 2005) 
Serpin B3 2 44,6 24  squamous cell carcinoma antigen 
(Suminami et al., 
2000) 
Annexin A2 1 / 2 38,6 24 / 26  Ca2+ dependent membrane binding protein (Emans et al., 1993) 
Desmocollin-1 2 100 24  component of desmosomes (King et al., 1991) 
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Gamma-
glutamylcyclotransferase 2 21 24 cytochrome c releasing factor (Masuda et al., 2006) 
Four and a half LIM 
domains protein 3 2 31,2 22 
Zink-finger binding protein 
in sceletal muscle 
development 
(Morgan and 
Madgwick, 1999) 
Vinculin 2 123,8 24 actin binding protein (Le Clainche et al., 2010) 
Small proline-rich 
protein 2G 2 8,2 10 
regulation of barrier 
function (Cabral et al., 2001) 
14-3-3 protein epsilon 2 29 22  involved in cell cycle regulation (Conklin et al., 1995) 
Heat shock protein HSP 
90-beta 5 83 103  
involved in progesteron 
signalling (Chadli et al., 2006) 
 
4.3. BLCAP 
 
The bladder cancer associated protein BLCAP has been identified as another target 
for RNA editing (Levanon et al., 2005). Up to 11 editing events in the primary 
transcript have been reported where three of them lead to amino acid substitutions 
within the coding region. In silico studies have predicted two trans-membrane 
spanning regions in the primary sequence of BLCAP (Galeano et al., 2010). However, 
little is known about the function of this ubiquitously expressed protein. 
In our lab, vectors have been generated for stable expression of one edited and 
unedited version of BLCAP comprising 9x c-Myc tagged full-length variants of the 
protein and a Neomycin resistance gene.  
 
4.3.1. Transient Immunofluorescence staining: BLCAP 
 
To investigate the subcellular localization of BLCAP, transient transfection studies 
have been done in various mammalian cell lines. Edited and unedited BLCAP was 
transiently transfected and stained by a 9E10 anti-c-Myc primary antibody, visualized 
by a goat anti- mouse secondary antibody coupled to the fluorescence dye Alexa 488. 
An overall granular localization pattern of BLCAP was detected in all cell lines 
investigated. No differences were observed between unedited and edited BLCAP in 
any of the cell lines. 
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Figure 39) Transient Immunofluorescence staining of edited and unedited BLCAP in the human cell lines 
Hek293 and HeLa. 9x c-Myc tagged edited and unedited BLCAP, transiently transfected into Hek293 and HeLa 
cell lines, was detected by a 9E10 anti-c-Myc primary antibody from mouse. For visualization a goat anti-mouse 
secondary antibody was used coupled to the green fluorescence dye Alexa 488. In Hek293 and HeLa cells, edited 
and unedited BLCAP show cytoplasmic localization. Additionally, what can be seen from HeLa cells, transfected 
with edited and unedited BLCAP, an overall granular localization pattern can be observed. No differences in 
localization pattern between edited and unedited BLCAP are observed in immunofluorescence staining assays of 
transiently transfected BLCAP versions. DAPI = nuclear staining; DIC = phase contrast; FITC = localization of 
BLCAP, Alexa 488; Scale bar: 20 µm. 
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Figure 40) Transient Immunofluorescence staining of edited and unedited BLCAP in the human cell lines 
U2OS and SCaBER.  9x c-Myc tagged edited and unedited BLCAP, transiently transfected into U2OS and 
SCaBER cell lines, was detected by a 9E10 anti-c-Myc primary antibody from mouse. For visualization a goat 
anti-mouse secondary antibody was used, coupled to the green fluorescence dye Alexa 488. In both tested cell 
lines, edited and unedited BLCAP show cytoplasmic localization. Again an overall granular localization pattern 
can be observed, like in tests on other mammalian cell lines. No differences in localization pattern between edited 
and unedited BLCAP are observed in immunofluorescence staining assays of transiently transfected BLCAP 
versions in the investigated cell lines.  DAPI = nuclear staining; DIC = phase contrast; FITC = localization of 
BLCAP, Alexa 488; Scale bar: 20 µm. 
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Figure 41) Transient Immunofluorescence staining of edited and unedited BLCAP in the mouse 
neuroblastoma cell line cN2A. 9x c-Myc tagged BLCAP transiently transfected into the mouse neuroblastoma 
cell line N2A was detected by a 9E10 anti-c-Myc primary antibody from mouse. For visualization a goat anti-
mouse secondary antibody was used coupled to the green fluorescence dye Alexa 488. To investigate if and how 
the expression of BLCAP changes during differentiation, the cells have been starved after transfection culturing 
them over night in DMEM medium containing no FCS. Also in the murine cell line N2A BLCAP shows an overall 
granular, cytoplasmic localization pattern. After inducing differentiation in the neuroblastoma cell line, the cells 
start forming growth cones. Upon differentiation BLCAP seems to stay within the cell body, though also a low 
level of BLCAP is found in growing extensions. No obvious differences in localization pattern of edited and 
onedited BLCA were detected. DAPI = nuclear staining; DIC = phase contrast; FITC = localization of BLCAP, 
Alexa 488; Scale bar: 20 µm. 
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Figure 42) Transient Immunofluorescence staining of edited and unedited BLCAP in the human 
neuroblastoma cell line STANB (St. Anna Neuroblastoma). 9x c-Myc tagged BLCAP, transiently transfected 
into the human neuroblastoma cell line STANB, was detected by a 9E10 anti-c-Myc primary antibody from 
mouse. For visualization a goat anti-mouse secondary antibody was used, coupled to the green fluorescence dye 
Alexa 488. Also in the human neuroblastoma cell line BLCAP shows a cytoplasmic, granular localization, while 
no differences were detected in localization of edited and unedited BLCAP. DAPI = nuclear staining; DIC = phase 
contrast; FITC = localization of BLCAP, Alexa 488. 
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4.3.2. Stable expression of BLCAP: Immunofluorescence staining 
 
 
After testing the BLCAP expression vectors on their transfection efficiency, the 
constructs were transfected into several mammalian cell lines for the generation of 
stable expressing clones. To select for stable random integration the cells were 
cultivated in DMEM medium containing 100 µg/ml to 300 µg/ml of the antibiotic 
G418 (Geneticin). After one week to ten days of selection stable expressing clones 
were picked and tested on their BLCAP-expression level by immunofluorescence 
staining using 9E10 anti-c-Myc primary antibody and goat anti-mouse secondary 
antibodies coupled to Alexa fluorescence dyes. Both, the edited and the unedited 
version of the BLCAP protein were successfully expressed at high levels in two 
mammalian cell lines, the human cell line HeLa, and the mouse neuroblastoma cell 
line cN2A. Resembling the results of transient transfection studies, BLCAP shows an 
overall granular localization pattern in stable expressing cell lines. Again no obvious 
differences were detected between edited and unedited versions of the protein. 
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Figure 43) Stable expression of 9x c-Myc tagged BLCAP in the human cell line HeLa and the mouse 
neuroblastoma cell line cN2A. After selection for stable random integration of the transfected DNA construct, the 
picked clones were tested on their homogeneity of stable protein expression by immunofluorescence staining. C-
Myc-tagged BLCAP was detected by an anti-MYC primary antibody and subsequent labelling with a goat anti-
mouse secondary antibody coupled to Alexa 488. In both generated stable BLCAP expressing cell lines BLCAP 
was found to localise within the cytoplasm. Similar to observations from immunofluorescence staining assays of 
transiently transfected cell lines, a granular pattern of BLCAP localization was found in stable expressing cells. 
Additionally, no obvious differences in localization of edited and unedited BLCAP can be detected. BLCAP WT = 
unedited version of BLCAP; BLCAP edited = edited version of BLCAP. DAPI: nuclear staining. DIC: phase 
contrast. FITC: Alexa 488 fluorescence staining. Scale bar: 20 µm. 
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4.3.3. Stable expression of BLCAP: Western blot analysis 
 
As nothing is known on the protein function and properties of BLCAP, Western blot 
analysis was done after lysing stable expressing cells in lysis buffers containing 
different reagents for solubilisation. The cells were lysed by NET-2, Tris-Buffer 
containing 0.1% of deoxycholic acid DOC and one Tris-buffer containing 0.1% of the 
detergent Triton X-100. Treating the cells with Tris-buffer containing Triton X-100 
yielded high levels of BLCAP in solution after sonication. BLCAP was detected using 
a 9E10 anti c-Myc primary antibody and a goat anti-mouse secondary antibody 
coupled to alkaline phosphatase.  
 
 
 
Figure 44) Western Blot: BLCAP expression in Hek293. Hek293 cells expressing edited and unedited BLCAP 
were lysed using buffers of different compositions. After lysing the cells, cell debris were precipitated by 
centrifugation. Samples from total lysate and pellet were analysed by Western blot analysis, using anti-c-Myc 
primary antibodies and secondary antibodies coupled to alkaline phosphatase. DOX = Tris buffer containing 0.1% 
DOX, Triton = Tris buffer containing 0.1% Triton X-100, NET = NET-2 lysis buffer containing 0.02% Tween-20. 
BLCAP edited = lysate of Hek293 cells expressing edited BLCAP, BLCAP WT = lysate of Hek293 cells 
expressing unedited BLCAP, Hek293 = lysate of empty Hek293 cells; M = PAGE Ruler pre-stained protein 
ladder. 
This Western blot analysis shows, that most of the BLCAP protein is solubilized best 
after using a lysis buffer, containing 0.1% Triton X-100, as no protein was detected in 
the pellet. 
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4.3.4. Immunoprecipitation: BLCAP 
 
After testing the obtained stably expressing clones on their BLCAP-expression level, 
the cells were expanded for BLCAP-purification assays. Edited and unedited BLCAP 
was precipitated using Sepharose A beads cross-linked with 9E10 anti-c-Myc 
antibody. Gained samples were analysed on 7.5% to 17% gradient SDS PAGE gels 
and subsequent silver staining. To date BLCAP-specific pulled down bands had been 
obtained by immunopreciptiation of BLCAP expressed in HeLa cells. Protein bands 
were cut out from silver gels and sent for mass spectrometric analysis. 
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Figure 45) Silver gels: Immunoprecipitation of edited and unedited BLCAP from HeLa. Stable expressing 
HeLa cells were lysed using a Tris-lysis buffer containing 0.1% Triton X-100. 9E10 anti-c-Myc immuno-
precipitation was done using sepharose A beads cross-linked to 9E10 antibodies. Samples were analysed on 7.5% 
to 17% gradient SDS PAGE gels and subsequent silver staining. BLCAP specific bands were cut out and sent for 
mass spectrometric analysis. A) anti-c-Myc immunoprecipitation of 9x c-Myc tagged edited and unedited BLCAP 
from HeLa cells. Black arrow indicates cut protein band of 32 kDa from edited BLCAP pull down. B) anti-c-Myc 
immunoprecipitation of 9x c-Myc immunoprecipitation of 9x c-Myc tagged edited and unedited BLCAP from 
HeLa cells. Black arrows indicate cut protein bands from edited and unedited BLCAP pull down at a molecular 
weight of 47 kDa. Black arrows mark protein bands sent for mass spectrometric analysis. Input = total cell lysate; 
9E10 IP = anit-c-Myc immunoprecipitation; Ctrl = lysate of empty HeLa cells; wt = lysate of HeLa cells stably 
expressing unedited BLCAP; ed = lysate of HeLa cells stably expressing edited BLCAP; M = PAGE Ruler 
unstained protein ladder. 
 
4.3.5. Mass spectrometry: BLCAP 
 
Three BLCAP-specific protein bands have been pulled down by anti-c-Myc 
immunoprecipitation from BLCAP expressing HeLa cells. Mass spectrometry data of 
the gained BLCAP-interacting proteins is listed in the tables below. Little information 
about protein interactions of unedited BLCAP was gained from anti-c-Myc 
immunoprecipitation from HeLa cells. Nevertheless, some mitochondrial proteins 
were found to interact with edited BLCAP. Proteins, which interact only with BLCAP 
are highlighted in bold. Identified proteins, which give insights on BLCAP protein 
function are stained green. 
 
 
Table 12) Proteins interacting with unedited BLCAP identified by mass spectrometry. Proteins, detected in 
protein bands after precipitation of unedited BLCAP from stable expressing HeLa cells are listed in this table. The 
identified proteins, the numbers of analysed peptides, the percentage of coverage with annotated sequences, the 
molecular weight of the identified protein and of the cut sample are shown. Due to a high level of sample 
contamination with keratin, no bands were found specifically interacting with unedited BLCAP. It cannot be 
excluded, that the found protein, suprabasin isoform, is also a contamination. Mw = molecular weight of identified 
protein in kDa. Sample = molecular weight of cut protein band. 
Unedited BLCAP- 
interacting 
protein 
unique 
peptides 
percent  
coverage 
Mw 
(kDa) 
Sample: 
Mw 
(kDa) 
comments function references 
suprabasin isoform 
1 precursor  2 6,10% 61  47  
comes with 
DDX15 
epidermal barrier 
function 
(Toulza et al., 
2007) 
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Table 13) Proteins interacting with edited BLCAP identified by mass spectrometry. Proteins, detected in 
protein bands after precipitation of edited BLCAP from stable expressing HeLa cells are listed in this table. The 
identified proteins, the numbers of analysed peptides, the percentage of coverage with annotated sequences, the 
molecular weight of the identified protein and of the cut sample are shown. Several mitochondrial proteins have 
been detected in this study by mass spectrometry. All mitochondrial proteins identified, match cut sample size and 
thus are stained in green. Proteins, which interact only with edited BLCAP, are highlighted in bold. Mw = 
molecular weight of identified protein in kDa. Sample = molecular weight of cut protein band. 
Edited BLCAP- 
interacting 
protein  
unique 
peptides 
percent  
coverage 
Mw 
(kDa) 
Source: 
Mw 
(kDa) 
comments function references 
coiled-coil 
domain-
containing protein 
124 
8 30% 26  32  DNA-binding protein 
uniprot-database 
Q96CT7 
polyubiquitin 5 7,70% 68  32  
posttranslational 
modification 
(Komander et al., 
2009) 
erlin-2 isoform 1 2 7,10% 38  47 also comes with Dss1 
mediates ER-associated 
degradation of activated 
IP3 receptors 
(Yildirim et al., 
2011) 
7-de-hydro-
cholesterol 
reductase 7 
2 3,80% 54  47  cholesterol metabolism 
(Moebius et al., 
1998) 
solute carrier 
family 25, 
member 5 
2 7,20% 28  32  
ATP hydrolysis across 
mitochondrial 
membrane 
(De Marcos 
Lousa et al., 
2002) 
voltage-dependent 
anion channel 2 2 7,80% 34  32  
mitiochondrial anion 
channel  (Yu et al., 1995) 
mitochondrial 
glutamate carrier 
1 
3 9,00% 34  32  
mitochondrial glutamate 
transporter 
(Fiermonte et al., 
2002) 
 
 
4.3.6. BLCAP, a mitochondrial protein? 
 
According to the gained information after mass spectrometric analysis of BLCAP 
interacting proteins, BLCAP seems to be a mitochondrial protein. To confirm the 
mass spectrometry data, co-staining assays were done, detecting c-Myc-tagged 
BLCAP and a mitochondrial marker, cytochrome c. U2OS cells were transiently 
transfected with constructs expressing edited and unedited BLCAP. Twenty four to 
forty eight hours later the cells were fixed and stained by immunofluorescence 
staining. The c-Myc tagged BLCAP versions were detected using a 9E10 anti-c-Myc 
primary antibody developed from rabbit. The anti-c-Myc primary antibody was 
visualized using a goat anti-rabbit secondary antibody coupled to the fluorescence dye 
Alexa 488. As a control for mitochondrial localization of BLCAP an antibody binding 
the mitochondrial marker protein cytochrome c, developed from mouse, was used for 
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co-staining assays. This mitochondrial marker was visualized using a goat anti-mouse 
secondary antibody coupled to the fluorescence dye Alexa 568. Microscopy pictures 
from BLCAP localization (FITC) and mitochondrial cytochrome c (TRITC) were 
merged using Photoshop CS5. These immunofluorescence-staining assays showed, 
that localization of BLCAP almost completely overlaps with mitochondrial markers 
as cytochrome c.  
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Figure 46) Transient co-staining: BLCAP vs. Cytochrome C. The human cell line U2OS was transiently 
transfected with edited and unedited BLCAP. C-Myc-tagged BLCAP was visualized using a 9E10 anti-c-Myc 
primary antibody from rabbit, detected by a goat anti-rabbit Alexa 488 coupled secondary antibody. Cytochrome 
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C, a mitochondrial marker protein, was detected using a goat anti-mouse antibody, coupled to Alexa 568. In 
untransfected U2OS cells a high nuclear background staining of the used goat anti-rabbid secondary antibody was 
detected in FITC. Edited and unedited BLCAP show a similar granular, cytoplasmic localization pattern (FITC). 
Additionally, staining of the mitochondrial marker, Cytochrome c, shows a similar granular localization. Thus, 
merging the FITC of BLCAP figures and the TRITC of mitochondria localization, yields pictures where an almost 
completely colocalization of BLCAP with mitochondria was observed. Empty = untransfected cell line; BLCAP 
WT = U2OS cells expressing transiently transfected unedited BLCAP; BLCAP edited = U2OS cells expressing 
transiently transfected edited BLCAP; DAPI = nuclear staining; DIC = phase contrast; FITC = Alexa 488 green 
fluorescence staining; TRITC = Alexa 568 red fluorescence staining; Scale bar = 10 µm. 
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5. Discussion 
 
 
During this thesis we tried to establish stable cell lines expressing several proteins 
identified to be involved in RNA editing. These proteins can be separated into two 
groups. On the one hand we wanted to express regulators of ADAR activity, 
identified earlier in our lab by screening assays, in several mammalian cell lines. The 
second group of proteins involved in RNA editing, investigated in this thesis, were 
two protein-coding targets of ADAR, the cytoskeletal cross-linker Filamin A and the 
bladder cancer associated protein BLCAP. The aim of this project was to purify the 
listed proteins as complexes with interacting proteins by immunoprecipitation assays 
and Tandem Affinity Purification. Mass spectrometric analysis of these co-purified 
proteins should yield further insights into regulatory networks of RNA editing on the 
one hand. On the other hand, we wanted to explore effects of RNA editing on 
interaction profiles of the two investigated ADAR targets, Filmain A and BLCAP, as 
RNA editing leads to amino acid changes in their primary sequence. 
The first aim of this thesis was to generate expression vectors containing a TAP-
sequence for Tandem Affinity Purification, and an appropriate selection marker for 
stable expression of cloned, TAP-tagged inserts in mammalian cell lines. The 
candidate proteins for regulators of RNA editing were the small acidic protein DSS1, 
the RNA helicase DDX15, the ribosomal subunit RPS14 and the arginine/serine-rich 
splice factor SRSF9. Full-length versions of all four ADAR regulators were cloned 
into the TAP-expression vector to be C- and N-terminally tagged with a 6x c-
Myc/TEV/HA tag. We obtained stable clones of HeLa cells and U2OS cells, 
expressing N-terminally tagged DSS1. These clones have shown adequate expression 
levels of DSS1 in immunofluorescence staining assays and Western blot analysis. Till 
now, we failed to express the C-terminally tagged version of DSS1 in any of the 
tested cell lines. Immunoprecipitaion and following silver staining yielded three 
DSS1-specific protein bands with a molecular weight of 30 kDa, 50 kDa and 67 kDa. 
DSS1 is a regulatory subunit of the 26S proteasome (Funakoshi et al., 2004; Josse et 
al., 2006; Wilmes et al., 2008). As expected, we could identify several proteasome 
subunits as interaction partners of DSS1. What was astonishing is, that according to 
our mass spectrometry data, DSS1 also interacts with several ribosomal proteins and 
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heterogenous ribonucleoprotein particles (hnRNPs). On trial, we tried to co-purify 
Dss1 with ribosomes in an immunoprecipitation assay, but so far without success. 
However, our data may provide another indication for DSS1 to be involved in RNA 
processing mechanisms, because other groups already have linked this 
multifunctional protein to mRNA export processes (Wilmes et al., 2008). By binding 
to hnRNPs, ribosomes and other RNA-processing factors, Dss1 might destabilize 
their binding to the target RNA, what in turn would allow or facilitate binding of 
ADAR2. Thus, our data from mass spectrometric analysis might give hints for the 
missing link in the role of Dss1 as an activator of ADAR2 activity. 
The RNA helicase DDX15 was also stably expressed in the human cell line U2OS, as 
N-terminally TAP-tagged truncated version. But due to the low expression level of 
DDX15 in the obtained clone, no significant protein interactions have been identified 
after immunoprecipitation and following mass spectrometric analysis of gained 
protein bands. This lack in interaction partners may also be due to the truncation, as in 
the absence of nucleolar or nuclear localization peptide stretches, DDX15 may not 
localize correctly and thus a complete interaction profile cannot be provided. In the 
case of DDX15 we again failed to express the C-terminally tagged version of the 
protein in any of the tested cell lines, though both versions of the protein, the N- and 
C-terminally tagged construct, were successfully transfected transiently. Nevertheless, 
though we could not detect interaction partners of DDX15, that may explain its 
inhibitory action on ADAR2 activity, possibly just its RNA helicase activity may be a 
cause for a decrease in editing. Namely, if an RNA helicase, like DDX15, unwinds 
double-stranded RNA structures, ADAR2 may no longer be able to recognize its 
substrates. 
Another candidate for an ADAR regulator was the ribosomal protein RPS14. In this 
case we successfully generated cell lines stably expressing the C- and the N-
terminally tagged versions of the protein. Observations from immunofluorescence 
staining assays have shown that these two versions of RPS14 show a different 
subcellular localization pattern. N-terminally tagged RPS14 localizes mainly within 
the nucleoplasm of stable expressing HeLa cells, whereas the C-terminally tagged 
protein expressed in U2OS cells was detected in nucleoli. Initial purification studies 
were done by immunoprecipitation assays and Tandem Affinity Purification of N-
terminally tagged RPS14 expressed in HeLa cells. Mass spectrometric analysis of the 
cut protein bands, at a molecular weight of 107 kDa and 52 kDa, yielded no valuable 
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information about RPS14 interacting proteins. No ribosomal proteins were detected in 
N-terminally tagged RPS14 precipitates, though it is known to be a ribosomal protein 
(Chen et al., 1986; Ferreira-Cerca et al., 2005; Rhoads et al., 1986). Nevertheless, we 
also did anti-c-Myc immunoprecipitation of C-terminally tagged RPS14 expressed in 
U2OS cells. In this round of purification of RPS14 we could obtain just very low 
amounts of protein after the samples were analysed by gradient SDS PAGE and silver 
staining. Just few proteins were detected in these samples by mass spectrometry. 
Though one identified interaction partner from RPS14 precipitation seems to be 
interesting: we detected the histone chaperone nucleophosmin. Beside its function in 
chromatin remodelling (Swaminathan et al., 2005), nucleophosmin is also known to 
be involved during nuclear export of ribosomes (Maggi et al., 2008). Another hint for 
nucleophosmin to be a real RPS14 interacting protein is, that its deregulation is 
involved in the development of several variants of leukemia. On the one hand, 
aberrant localization of nucleophosmin was detected in a high number of patients 
suffering from acute myelogenous leukemia (AML) and myeloid sarcoma (Bolli et 
al., 2006; Falini et al., 2005). In other studies a chromosomal translocation, fusing 
parts of nucleophosmin to the retinoic acid receptor alpha, was detected in samples 
from patients suffering from acute promyelocytic leukemia (APL) (Redner et al., 
1996).  Another chromosomal translocation was detected in non-Hodgkin’s 
lymphoma, where nucleophosmin is fused to the gene of the tyrosine kinase ALK, 
what may have a strong impact on transformation of these lymphomas (Morris et al., 
1994). What links these molecular causes for leukemic diseases to our project is, that 
another translocation of the nucleophosmin gene, encoded on chromosome 5, to 
chromosome 3, leading to a fusion of nucleophosmin with a gene named 
myelodysplasia/myeloid leukemia factor 1 (MLF1) was linked to the development 
and progression of the myelodysplastic syndrome and acute myeloid leukemia 
(Yoneda-Kato et al., 1996). As mentioned in the introduction, haploinsufficiency of 
RPS14 was identified to be a main cause for the development of the myelodysplastic 
syndrome or 5q- syndrome where parts of chromosome 5 are deleted (Ebert et al., 
2008). However, we need to repeat this purification experiments to get more hints 
about interaction partners of RPS14 to declare its role during RNA editing. 
The last putative candidate for an inhibitor of RNA editing was the SR-protein 
SRSF9. As mentioned earlier the full-length sequence of SRSF9 amplified from 
mouse cDNA was cloned into the generated TAP-expression vector to be C- and N-
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terminally tagged. We failed to transfect the N-terminally tagged SRSF9 into 
mammalian cell lines in transient transfection tests, what may be due to cloning 
mistakes, leading to frame shifts. The C-terminally tagged version has shown a 
nuclear localization pattern in these tests. However, up to now we failed to stably 
express this version of SRSF9 in any of the tested cell lines. 
In the second part of this thesis we tried to establish stable cell lines expressing two 
targets for RNA editing, Filamin A and BLCAP. By immunoprecipitation assays and 
Tandem Affinity Purification under native conditions we tried to detect differences in 
protein interactions due to the editing events.  
Hek293 clones were obtained expressing edited and unedited versions of full-length 
Filamin A. Additionally we got clones of U2OS, HeLa and N2A cells, expressing 
either the edited or the unedited version of Filamin A. The method for purification of 
full-length Filamin A still has to be improved as high protein fragmentation and 
degradation was detected in samples obtained after anti-c-Myc precipitation.  
In addition to the full-length versions of Filamin A we were provided with TAP-
expression vectors encoding for truncated versions of Filamin A, comprising IgG-like 
repeats 20 to 24. We failed to conduct transient transfection studies and subsequent 
immunofluorescence staining with the constructs encoding for edited and unedited 
versions of N-terminally tagged Filamin A, as we were not able to detect the 
streptavidin binding protein tag. C-terminally tagged, edited and unedited Filamin A 
was successfully detected by anti-c-Myc antibodies. We also obtained two Hek293 
clones stably expressing C-terminally tagged edited and unedited Filamin A. Tandem 
affinity purification of short Filamin A was conducted. But, though after the second 
immunoprecipitation, TEV-cleaved Filamin A was detected, no Filamin A-specific 
protein bands were found in these precipitations. Different interacting proteins of 
Filamin A may bind under different conditions. Thus, the use of other lysis buffers 
may yield specific protein bands after Filamin A TAP. However, 
immunoprecipitation assays were done using beads coupled to anti-c-Myc antibodies. 
Mass spectrometric analysis of proteins co-purified with Filamin A have shown, that 
both versions, the edited and the unedited Filamin A, interact with Filamin A, Filamin 
B and Filamin C and the histone core protein H1.3. In addition to that, unedited 
truncated Filamin A was found to interact with non-erythrocytic spectrin alpha, 
whereas edited Filamin A interacts with spectrin beta. To date, this purification 
protocol, that yielded the listed mass spectrometry data was not repeated, thus the 
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spectrin-interaction pattern of edited and unedited Filamin A still needs to be proved. 
Additionally, very few peptides have been detected in some of the cut gel bands. Due 
to a high level of keratin contamination, some of the Filamin A-interacting proteins 
may be masked by this contamination. Several other proteins have been found to be 
pulled down with edited Filamin A, like the band-6-protein, a component of 
desmosomes, and nuclear proteins, like Histone H2A and the PELOTA protein. This 
data was quite surprising, because just few cytoskeletal and cell signalling proteins 
have been pulled down with Filamin A in the initial rounds of purification assays. In 
contrast to these purifications, in subsequent immunoprecipitation assays, other lysis 
buffers have been used to purify Filamin A. In these runs, several proteins, which are 
known to be involved in cell adhesion and cell-cell interactions, like subunits of 
desmosomes, were found in samples from either edited of unedited short Filamin A. 
Interestingly, many nuclear proteins were found to interact with the C-terminal part of 
Filamin A. There is some evidence for a nuclear localization of Filamin A. In studies 
on human skin fibroblasts and HeLa cells, Filmain A was found in the nucleus, where 
it is involved in DNA damage response by interacting with the DNA repair protein 
BRCA2 (Yuan and Shen, 2001). Additionally, could play a role during transcriptional 
regulation of FOXC1, as it was found to translocate into the nucleus as a complex 
with PBX1 (Berry et al., 2005). Nevertheless, a convincing proof for a translocating 
activity of Filamin A into the nucleus, where it may influence nuclear specific 
processes, is still missing. Our data may provide another hint for subsequent studies 
on Filamin A function in the nucleus. Till now, the Filamin A purifications have not 
been repeated. Further purification studies on several other cell lines expressing 
Filamin A are necessary to verify the obtained interaction maps of edited an unedited 
Filamin.  
The second protein-coding target of RNA editing, investigated in this project, is the 
bladder cancer associated protein, BLCAP. Very view is known about the function of 
this highly conserved protein. But, BLCAP is known to be edited at many positions 
(Galeano et al., 2010; Gromova et al., 2002; Levanon et al., 2005). During this work 
we successfully expressed one edited and one completely unedited version of BLCAP 
in the mammalian cell lines HeLa and N2A. First purification studies have been done 
on Hek293 clones also expressing both versions. So far, results after anti-c-Myc 
immunoprecipitation of BLCAP from HeLa cells were obtained. Our mass 
spectrometry data lists several mitochondrial proteins as interacting proteins of edited 
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BLCAP, the member 5 of the mitochondrial solute carrier family 25, the voltage-
dependent anion channel 2 and the mitochondrial glutamate carrier 1. To proof the 
obtained data, we did co-staining assays on cells, transiently transfected with edited 
and unedited BLCAP. In these tests we found, that localization of BLCAP in the cell 
is associated with mitochondria as a nearly completely overlap of BLCAP with the 
mitochondrial marker cytochrome C was detected by immunofluorescence staining. 
Thus, we conclude that BLCAP is a mitochondrial protein. 
 
In this thesis we successfully established stable cell lines expressing proteins involved 
in RNA editing. Data obtained from purification assays and subsequent mass 
spectrometric analysis provides some hints on the effect of editing on the two 
investigated proteins, Filamin A and BLCAP. Additionally DSS1, a putative activator 
of RNA editing, was found to interact with ribosomal proteins, what may be another 
link for a role of DSS1 as an activator of editing activity. However, we came up with 
several issues. To date, we still do not have stable clones, expressing the SR-protein, 
SRSF9, or the C-terminally tagged versions of Dss1 and DDX15, what may be due to 
cloning mistakes. Additionally, mass spectrometric analysis of pulled down proteins 
yielded high levels of keratin contamination in the samples. These high levels of 
keratin peptides may mask peptides of other interacting proteins. Thus, several control 
experiments need to be done to verify the obtained information on protein interactions 
of the investigated candidates.  
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Appendix 
 
Detailed Sequence information 
 
pcDNA 3.1 (-) Hygromycin MYC-TEV-HA TAP vector:  
TEV/HA sequence was cloned after 6xMYC tag by EcoRI, destroying the 5’ restriction site after 
cloning. MYC-TEV-HA tag was cloned by PmeI. 
 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGC
CGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCG
AGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTT
AGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGAT
TATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGA
GTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCG
CCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGA
CGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATA
TGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCC
AGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTAT
TACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG
GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAA
CGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGT
GTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTAC
TGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAAC
GGGCCCTCTAGACTCGAGGTCGACGGTATCGATCAGCCATGGAGCAAAAGCTCATTTCTG
AAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATG
GAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAA
GAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGA
GAGCTTGGGCGACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATTTAGA
AAATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGGAATTCCACCACACT
GGACTAGTGGATCCGAGCTCGGTACCAAGCTTAAGTTTAAACCGCTGATCAGCCTCGACT
GTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGA
AGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGT
AGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGA
AGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAAC
CAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGG
TGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTC
GCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG
GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAG
GGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGG
AGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTC
GGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAG
CTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGG
AAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGC
AACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCT
CAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCC
AGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGG
CCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTT
TTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATG
AGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGT
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GGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGT
GTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCC
CTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCT
TGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAA
GTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGG
CTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAG
CGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATG
ATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGC
GCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCA
TGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACC
GCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGG
CTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTAT
CGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGA
CGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTT
CGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGA
GTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGC
ATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACT
CATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCA
TGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAG
CCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTG
CGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAAT
CGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACT
GACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTA
ATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCA
GCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCC
CCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGAC
TATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCT
GCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGC
TCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG
AACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCC
GGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGA
GGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA
GAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTA
GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTTTTTTTGTTTGCAAGCAGCAGAT
TACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGC
TCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTT
CACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAA
ACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTAT
TTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTT
ACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTT
ATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAAT
AGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTA
TGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTG
CAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGT
GTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGA
TGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGAC
CGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAA
AAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTT
GAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTC
ACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAG
GGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTAT
CAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATA
GGGGTTCCGCGCACATTTCCCCGAAAAGTG 
6 x MYC HA PmeI restriction site 
 
 
 
 
DSS1 C-terminally tagged in pcDNA 3.1 (-) Hygro/ MYC-TEV-HA: cloned by NheI/XhoI: 
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CTGGCTAGCATGTCAGAGAAAAAGCAGCCGGTAGACTTAGGTCTGTTAGAGGAAGACGAC
GAGTTTGAAGAGTTCCCTGCCGAAGACTGGGCTGGCTTAGATGAAGATGAAGATGCACAT
GTCTGGGAGGATAATTGGGATGATGACAATGTAGAGGATGACTTCTCTAATCAGTTACGA
GCTGAACTAGAGAAACATGGTTATAAGATGGAGACTTCAACTCGAGGTCGACGGTATCGA
TCAGCCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTC
ATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAAT
GAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATT
TCTGAAGAGGACTTGAATGAAATGGAGAGCTTGGGCGACCTCACCATGGAGCAAAAGCTC
ATTTCTGAAGAGGACTTGAATTTAGAAAATCTCTATTTCCAGGGTTACCCATACGACGTCC
CAGACTACGCGGAATTCCAC 
 
NheI restriction site XhoI restriction site DSS1 full-length sequence 6x MYC HA 
 
 
 
DSS1 N-terminally tagged in pcDNA 3.1 (-) Hygromycin/ MYC-TEV-HA, cloned by BamHI: 
 
GCGTTTAAACGGGCCCTCTAGACTCGAGGTCGACGGTATCGATCAGCCATGGAGCAAAAG
CTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTG
AATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCT
CATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAA
TGAAATGGAGAGCTTGGGCGACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTT
GAATTTAGAAAATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGGAATTC
CACCACACTGGACTAGTGGATCCAATGTCAGAGAAAAAGCAGCCGGTAGACTTAGGTCTG
TTAGAGGAAGACGACGAGTTTGAAGAGTTCCCTGCCGAAGACTGGGCTGGCTTAGATGAA
GATGAAGATGCACATGTCTGGGAGGATAATTGGGATGATGACAATGTAGAGGATGACTTC
TCTAATCAGTTACGAGCTGAACTAGAGAAACATGGTTATAAGATGGAGACTTCATAGGGA
TCCGAGCTCGGTACCAAGCTTAAGTTTAAAC 
 
BamHI restriction site Dss1 full-length sequence 6x MYC HA 
 
 
 
DDX15 C-terminally tagged in pcDNA 3.1 (-) Hygromycin/ MYC-TEV-HA, cloned by NheI, 
XhoI: 
 
AAGCTGGCTAGCATGTCCAAGCGGCACCGGTTGGACCTAGGGGAGGATTACCCCTCTGGC
AAGAAGCGTGCGGGGACCGATGGGAAGGATCGAGATCGAGACCGGGATCGTGAAGATCG
GTCTAAAGATCGAGACCGAGAACGTGATAGAGGAGATAGAGAGCGAGAGAGGGAGAAA
GAAAAGGAGAAGGAGTTGCGAGCTTCAACAAATGCTATGCTTATCAGTGCTGGATTACCA
CCTTTGAAAGCTTCCCATTCAGCTCACTCAACCCACTCAGCACATTCAACGCATTCAACAC
ATTCTGCTCATTCAACGCATGCCGGACATGCAGGTCACACGTCACTTCCACAGTGCATTAA
TCCGTTCACCAACTTACCCCATACTCCTCGATACTATGATATTCTAAAGAAACGTCTTCAG
CTCCCTGTTTGGGAATACAAGGATAGGTTTACAGATATTCTGGTTAGACATCAGTCCTTTG
TACTGGTTTGGCTCGAGGTCGACGGTATCGATCAGCCATGGAGCAAAAGCTCATTTCTGA
AGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGG
AGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAG
AGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAG
AGCTTGGGCGACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATTTAGAA
AATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGGAATTCCACC 
 
NheI restriction site XhoI restriction site DDX15 N-terminal truncation 6x MYC HA 
 
 
 
DDX15 N-terminally tagged in pcDNA 3.1 (-) Hygromycin/ MYC-TEV-HA, cloned by BamHI: 
 
AAACGGGCCCTCTAGACTCGAGGTCGACGGTATCGATCAGCCATGGAGCAAAAGCTCATT
TCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAA
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ATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCT
GAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAAT
GGAGAGCTTGGGCGACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATTT
AGAAAATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGGAATTCCACCA
CACTGGACTAGTGGATCCAATGTCCAAGCGGCACCGGTTGGACCTAGGGGAGGATTACCC
CTCTGGCAAGAAGCGTGCGGGGACCGATGGGAAGGATCGAGATCGAGACCGGGATCGTG
AAGATCGGTCTAAAGATCGAGACCGAGAACGTGATAGAGGAGATAGAGAGCGAGAGAGG
GAGAAAGAAAAGGAGAAGGAGTTGCGAGCTTCAACAAATGCTATGCTTATCAGTGCTGG
ATTACCACCTTTGAAAGCTTCCCATTCAGCTCACTCAACCCACTCAGCACATTCAACGCAT
TCAACACATTCTGCTCATTCAACGCATGCCGGACATGCAGGTCACACGTCACTTCCACAGT
GCATTAATCCGTTCACCAACTTACCCCATACTCCTCGATACTATGATATTCTAAAGAAACG
TCTTCAGCTCCCTGTTTGGGAATACAAGGATAGGTTTACAGATATTCTGGTTAGACATCAG
TCCTTTGTACTGGTTTGGTGAGGATCCGAGCTCGGT 
 
BamHI restriction site DDX15 N-terminal truncation 6x MYC HA 
 
 
 
RPS14 C-terminally tagged in pcDNA 3.1 (-) Hygromycin/ MYC-TEV-HA, cloned by NheI, 
XhoI: 
 
GGGAGACCCAAGCTGGCTAGCATGGCACCTCGAAAGGGGAAGGAAAAGAAGGAAGAAC
AGGTCATCAGCCTCGGACCTCAGGTGGCTGAAGGAGAGAATGTATTTGGTGTCTGCCATA
TCTTTGCATCCTTCAATGACACTTTTGTCCATGTCACTGATCTTTCTGGCAAGGAAACCATC
TGCCGTGTGACTGGTGGGATGAAGGTAAAGGCAGACCGAGATGAATCCTCACCATATGCT
GCTATGTTGGCTGCCCAGGATGTGGCCCAGAGGTGCAAGGAGCTGGGTATCACCGCCCTA
CACATCAAACTCCGGGCCACAGGAGGAAATAGGACCAAGACCCCTGGACCTGGGGCCCA
GTCGGCCCTCAGAGCCCTTGCCCGCTCGGGTATGAAGATCGGGCGGATTGAGGATGTCAC
CCCCATCCCCTCTGACAGCACTCGCAGGAAGGGGGGTCGCCGTGGTCGCCGTCTGCCTCG
AGGTCGACGGTATCGATCAGCCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGA
AATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTC
TGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAAT
GGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGAGCTTGGGCGACCTCAC
CATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATTTAGAAAATCTCTATTTCCAGGGT
TACCCATACGACGTCCCAGACTACGCGGAATTCCACCACACTGGACTAGTGGATCCGAGC
TCGGTACCAAGCTTAAGTTT 
 
NheI restriction site XhoI restriction site RPS14 full-length sequence 6x MYC HA 
 
 
 
RPS14 N-terminally tagged in pcDNA 3.1 (-) Hygromycin/ MYC-TEV-HA, cloned by BamHI: 
 
GCCCTCTAGACTCGAGGTCGACGGTATCGATCAGCCATGGAGCAAAAGCTCATTTCTGAA
GAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGA
GCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGA
GGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGA
GCTTGGGCGACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATTTAGAAA
ATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGGAATTCCACCACACTGG
ACTAGTGGATCCCATGGCACCTCGAAAGGGGAAGGAAAAGAAGGAAGAACAGGTCATCA
GCCTCGGACCTCAGGTGGCTGAAGGAGAGAATGTATTTGGTGTCTGCCATATCTTTGCATC
CTTCAATGACACTTTTGTCCATGTCACTGATCTTTCTGGCAAGGAAACCATCTGCCGTGTG
ACTGGTGGGATGAAGGTAAAGGCAGACCGAGATGAATCCTCACCATATGCTGCTATGTTG
GCTGCCCAGGATGTGGCCCAGAGGTGCAAGGAGCTGGGTATCACCGCCCTACACATCAAA
CTCCGGGCCACAGGAGGAAATAGGACCAAGACCCCTGGACCTGGGGCCCAGTCGGCCCTC
AGAGCCCTTGCCCGCTCGGGTATGAAGATCGGGCGGATTGAGGATGTCACCCCCATCCCC
TCTGACAGCACTCGCAGGAAGGGGGGTCGCCGTGGTCGCCGTCTGTGAGGATCCGAGCTC
GGTACCAAGCTTAAGTTTAAA 
 
BamHI restriction site RPS14 full-length sequence 6x MYC HA 
	  136	  
 
 
 
SRSF9 C-terminally tagged in pcDNA 3.1 (-) Hygromycin/ MYC-TEV-HA, cloned by NheI, 
XhoI: 
 
AGCTGGCTAGCCATGTCGGGCTGGGCGGACGAGCGCGGCGGCGAGGGCGACGGGCGCAT
CTACGTGGGGAACCTTCCGACCGACGTGCGCGAGAAGGACTTGGAGGACCTGTTCTACAA
GTACGGCCGCATCCGCGAGATCGAGCTCAAGAACCGGCACGGCCTCGTGCCCTTCGCCTT
CGTGCGCTTCGAGGACCCCCGAGATGCAGAGGATGCTATTTATGGAAGAAATGGTTATGA
TTATGGCCAGTGTCGGCTTCGTGTGGAGTTCCCCAGGACTTATGGAGGTCGGGGTGGGTG
GCCCCGTGGTGGGAGGAATGGGCCTCCTACAAGAAGATCTGATTTCCGAGTTCTTGTTTCA
GGACTTCCTCCGTCAGGCAGCTGGCAGGACCTGAAGGATCACATGCGAGAAGCTGGGGAT
GTCTGTTATGCTGATGTGCAGAAGGATGGAGTGGGGATGGTCGAGTATCTCAGAAAAGAA
GACATGGAATATGCCCTGCGTAAACTGGATGACACCAAATTCCGCTCTCATGAGGGTGAA
ACTTCCTACATCCGAGTTTATCCTGAGAGAAGCACCAGCTATGGCTACTCACGGTCTCGGT
CTGGGTCAAGGGGCCGTGACTCTCCATACCAAAGCAGGGGTTCCCCACACTACTTCTCTCC
TTTCAGGCCCTACCCTCGAGGTCGACGGTATCGATCAGCCATGGAGCAAAAGCTCATTTCT
GAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAAT
GGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGA
AGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGG
AGAGCTTGGGCGACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATTTAG
AAAATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGGAATTCCACCACAC
TGGA 
 
NheI restriction site XhoI restriction site SRSF9 full-length sequence 6x MYC HA 
 
 
 
SRSF9 N-terminally tagged in pcDNA 3.1 (-) Hygromycin/ MYC-TEV-HA, cloned by BamHI: 
 
AAACGGGCCCTCTAGACTCGAGGTCGACGGTATCGATCAGCCATGGAGCAAAAGCTCATT
TCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAA
ATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCT
GAAGAGGACTTGAATGAAATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATGAAAT
GGAGAGCTTGGGCGACCTCACCATGGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATTT
AGAAAATCTCTATTTCCAGGGTTACCCATACGACGTCCCAGACTACGCGGAATTCCACCA
CACTGGACTAGTGGATCCCATGTCGGGCTGGGCGGACGAGCGCGGCGGCGAGGGCGACG
GGCGCATCTACGTGGGGAACCTTCCGACCGACGTGCGCGAGAAGGACTTGGAGGACCTGT
TCTACAAGTACGGCCGCATCCGCGAGATCGAGCTCAAGAACCGGCACGGCCTCGTGCCCT
TCGCCTTCGTGCGCTTCGAGGACCCCCGAGATGCAGAGGATGCTATTTATGGAAGAAATG
GTTATGATTATGGCCAGTGTCGGCTTCGTGTGGAGTTCCCCAGGACTTATGGAGGTCGGGG
TGGGTGGCCCCGTGGTGGGAGGAATGGGCCTCCTACAAGAAGATCTGATTTCCGAGTTCT
TGTTTCAGGACTTCCTCCGTCAGGCAGCTGGCAGGACCTGAAGGATCACATGCGAGAAGC
TGGGGATGTCTGTTATGCTGATGTGCAGAAGGATGGAGTGGGGATGGTCGAGTATCTCAG
AAAAGAAGACATGGAATATGCCCTGCGTAAACTGGATGACACCAAATTCCGCTCTCATGA
GGGTGAAACTTCCTACATCCGAGTTTATCCTGAGAGAAGCACCAGCTATGGCTACTCACG
GTCTCGGTCTGGGTCAAGGGGCCGTGACTCTCCATACCAAAGCAGGGGTTCCCCACACTA
CTTCTCTCCTTTCAGGCCCTACTGAGGATCCGAGCTCGGTACCAAGCTTAAGTTTAAA 
 
BamHI restriction site SRSF9 full-length sequence 6x MYC HA 
 
FLNA in Expression vector pCeMM-CTAP(GS) 
 
Start codon 
Protein G 
TEV cleavage site 
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SBP 
myc 
Restriction sites 
Insert (FLNA) 
 
atggaattcggtttaaaccaggatatgacagcccaggtgaccagcccatcgggcaagacc 
 M  E  F  G  L  N  Q  D  M  T  A  Q  V  T  S  P  S  G  K  T  
catgaggccgagatcgtggaaggggagaaccacacctactgcatccgctttgttcccgct 
 H  E  A  E  I  V  E  G  E  N  H  T  Y  C  I  R  F  V  P  A  
gagatgggcacacacacagtcagcgtgaagtacaagggccagcacgtgcctgggagcccc 
 E  M  G  T  H  T  V  S  V  K  Y  K  G  Q  H  V  P  G  S  P  
ttccagttcaccgtggggcccctaggggaagggggagcccacaaggtccgagctgggggc 
 F  Q  F  T  V  G  P  L  G  E  G  G  A  H  K  V  R  A  G  G  
cctggcctggagagagctgaagctggagtgccagccgaattcagtatctggacccgggaa 
 P  G  L  E  R  A  E  A  G  V  P  A  E  F  S  I  W  T  R  E  
gctggtgctggaggcctggccattgctgtcgagggccccagcaaggctgagatctctttt 
 A  G  A  G  G  L  A  I  A  V  E  G  P  S  K  A  E  I  S  F  
gaggaccgcaaggacggctcctgtggtgtggcttatgtggtccaggagccaggtgactac 
 E  D  R  K  D  G  S  C  G  V  A  Y  V  V  Q  E  P  G  D  Y  
gaagtctcagtcaagttcaacgaggaacacattcccgacagccccttcgtggtgcctgtg 
 E  V  S  V  K  F  N  E  E  H  I  P  D  S  P  F  V  V  P  V  
gcttctccgtctggcgacgcccgccgcctcactgtttctagccttcA/Gggagtcagggcta 
 A  S  P  S  G  D  A  R  R  L  T  V  S  S  L  Q/R  E  S  G  L  
aaggtcaaccagccagcctcttttgcagtcagcctgaacggggccaagggggcgatcgat 
 K  V  N  Q  P  A  S  F  A  V  S  L  N  G  A  K  G  A  I  D  
gccaaggtgcacagcccctcaggagccctggaggagtgctatgtcacagaaattgaccaa 
 A  K  V  H  S  P  S  G  A  L  E  E  C  Y  V  T  E  I  D  Q  
gataagtatgctgtgcgcttcatccctcgggagaatggcgtttacctgattgacgtcaag 
 D  K  Y  A  V  R  F  I  P  R  E  N  G  V  Y  L  I  D  V  K  
ttcaacggcacccacatccctggaagccccttcaagatccgagttggggagcctgggcat 
 F  N  G  T  H  I  P  G  S  P  F  K  I  R  V  G  E  P  G  H  
ggaggggacccaggcttggtgtctgcttacggagcaggtctggaaggcggtgtcacaggg 
 G  G  D  P  G  L  V  S  A  Y  G  A  G  L  E  G  G  V  T  G  
aacccagctgagttcgtcgtgaacacgagcaatgcgggagctggtgccctgtcggtgacc 
 N  P  A  E  F  V  V  N  T  S  N  A  G  A  G  A  L  S  V  T  
attgacggcccctccaaggtgaagatggattgccaggagtgccctgagggctaccgcgtc 
 I  D  G  P  S  K  V  K  M  D  C  Q  E  C  P  E  G  Y  R  V  
acctatacccccatggcacctggcagctacctcatctccatcaagtacggcggcccctac 
 T  Y  T  P  M  A  P  G  S  Y  L  I  S  I  K  Y  G  G  P  Y  
cacattgggggcagccccttcaaggccaaagtcacaggcccccgtctcgtcagcaaccac 
 H  I  G  G  S  P  F  K  A  K  V  T  G  P  R  L  V  S  N  H  
agcctccacgagacatcatcagtgtttgtagactctctgaccaaggccacctgtgccccc 
 S  L  H  E  T  S  S  V  F  V  D  S  L  T  K  A  T  C  A  P  
cagcatggggccccgggtcctgggcctgctgacgccagcaaggtggtggccaagggcctg 
 Q  H  G  A  P  G  P  G  P  A  D  A  S  K  V  V  A  K  G  L  
gggctgagcaaggcctacgtaggccagaagagcagcttcacagtagactgcagcaaagca 
 G  L  S  K  A  Y  V  G  Q  K  S  S  F  T  V  D  C  S  K  A  
ggcaacaacatgctgctggtgggggttcatggcccaaggaccccctgcgaggagatcctg 
 G  N  N  M  L  L  V  G  V  H  G  P  R  T  P  C  E  E  I  L  
gtgaagcacgtgggcagccggctctacagcgtgtcctacctgctcaaggacaagggggag 
 V  K  H  V  G  S  R  L  Y  S  V  S  Y  L  L  K  D  K  G  E  
tacacactggtggtcaaatggggggacgagcacatcccaggcagcccctaccgcgttgtg 
 Y  T  L  V  V  K  W  G  D  E  H  I  P  G  S  P  Y  R  V  V  
gtgccctggccggccgagcagaagcttatctccgaggaggatctcatggacgagaagacc 
 V  P  W  P  A  E  Q  K  L  I  S  E  E  D  L  M  D  E  K  T  
accgggtggcggggcggccacgttgtggagggtctcgctggcgagctggagcagctcagg 
 T  G  W  R  G  G  H  V  V  E  G  L  A  G  E  L  E  Q  L  R  
gcccgcttggagcaccatccccaggggcaacgcgagcctatcgatgaaaatctgtacttc 
 A  R  L  E  H  H  P  Q  G  Q  R  E  P  I  D  E  N  L  Y  F  
caggggatcgatgagaacctgtactttcaggggggtagtaccccggccgtgacgacctac 
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 Q  G  I  D  E  N  L  Y  F  Q  G  G  S  T  P  A  V  T  T  Y  
aagctggtgatcaacggcaagaccctgaagggcgagaccacaaccaaggccgtggacgct 
 K  L  V  I  N  G  K  T  L  K  G  E  T  T  T  K  A  V  D  A  
gaaaccgcagagaaggccttcaagcagtacgccaacgacaatggcgtggacggagtgtgg 
 E  T  A  E  K  A  F  K  Q  Y  A  N  D  N  G  V  D  G  V  W  
acctacgacgatgccaccaagaccttcaccgtgaccgaggttaacacccccgcagtcacc 
 T  Y  D  D  A  T  K  T  F  T  V  T  E  V  N  T  P  A  V  T  
acatacaaactggtgatcaacggaaaaacgctgaagggcgaaactacgaccaaggctgtg 
 T  Y  K  L  V  I  N  G  K  T  L  K  G  E  T  T  T  K  A  V  
gacgcggagacggccgaaaaggcgttcaaacagtatgccaacgataacggtgtagacggc 
 D  A  E  T  A  E  K  A  F  K  Q  Y  A  N  D  N  G  V  D  G  
gtctggacatatgacgacgcgacaaagactttcactgtcactgaatagctcga 
 V  W  T  Y  D  D  A  T  K  T  F  T  V  T  E  -     
601 gggccggcgc gccgcggccg ctacgtaaat tccgcccctc tccctccccc ccccctaacg 
661 ttactggccg aagccgcttg gaataaggcc ggtgtgcgtt tgtctatatg ttattttcca 
721 ccatattgcc gtcttttggc aatgtgaggg cccggaaacc tggccctgtc ttcttgacga 
781 gcattcctag gggtctttcc cctctcgcca aaggaatgca aggtctgttg aatgtcgtga 
841 aggaagcagt tcctctggaa gcttcttgaa gacaaacaac gtctgtagcg accctttgca 
901 ggcagcggaa ccccccacct ggcgacaggt gcctctgcgg ccaaaagcca cgtgtataag 
961 atacacctgc aaaggcggca caaccccagt gccacgttgt gagttggata gttgtggaaa 
1021gagtcaaatg gctctcctca agcgtattca acaaggggct gaaggatgcc cagaaggtac 
1081cccattgtat gggatctgat ctggggcctc ggtgcacatg ctttacatgt gtttagtcga 
1141ggttaaaaaa cgtctaggcc ccccgaacca cggggacgtg gttttccttt gaaaaacacg 
1201atgataatat ggccacaacc atggtgagca agggcgagga gctgttcacc ggggtggtgc 
1261ccatcctggt cgagctggac ggcgacgtga acggccacaa gttcagcgtg tccggcgagg 
1321gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc accggcaagc 
1381tgcccgtgcc ctggcccacc ctcgtgacca ccctgaccta cggcgtgcag tgcttcagcc 
1441gctaccccga ccacatgaag cagcacgact tcttcaagtc cgccatgccc gaaggctacg 
1501tccaggagcg caccatcttc ttcaaggacg acggcaacta caagacccgc gccgaggtga 
1561agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg 
1621acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac gtctatatca 
1681tggccgacaa gcagaagaac ggcatcaagg tgaacttcaa gatccgccac aacatcgagg 
1741acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcggc gacggccccg 
1801tgctgctgcc cgacaaccac tacctgagca cccagtccgc cctgagcaaa gaccccaacg 
1861agaagcgcga tcacatggtc ctgctggagt tcgtgaccgc cgccgggatc actcacggca 
1921tggacgagct gtacaagtaa agcgccagca cagtggtcga gatccggatt agtccaattt 
1981gttaaagaca ggatatcagt ggtccaggct ctagttttga ctcaacaata tcaccagctg 
2041aagcctatag agtacgagcc atagataaaa taaaagattt tatttagtct ccagaaaaag 
2101gggggaatga aagaccccac ctgtaggttt ggcaagctag cttaagtaac gccattttgc 
2161aaggcatgga aaaatacata actgagaata gagaagttca gatcaaggtc aggaacagat 
2221ggaacagctg aatatgggcc aaacaggata tctgtggtaa gcagttcctg ccccggctca 
2281gggccaagaa cagatggaac agctgaatat gggccaaaca ggatatctgt ggtaagcagt 
2341tcctgccccg gctcagggcc aagaacagat ggtccccaga tgcggtccag ccctcagcag 
2401tttctagaga accatcagat gtttccaggg tgccccaagg acctgaaatg accctgtgcc 
2461ttatttgaac taaccaatca gttcgcttct cgcttctgtt cgcgcgcttc tgctccccga 
2521gctcaataaa agagcccaca acccctcact cggggcgcca gtcctccgat tgactgagtc 
2581gcccgggtac ccgtgtatcc aataaaccct cttgcagttg catccgactt gtggtctcgc 
2641tgttccttgg gagggtctcc tctgagtgat tgactacccg tcagcggggg tctttcacac 
2701atgcagcatg tatcaaaatt aatttggttt tttttcttaa gtatttacat taaatggcca 
2761tagtattgaa aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt 
2821tttgcggcat tttgccttcc tgtttttgct cacccagaaa cgctggtgaa agtaaaagat 
2881gctgaagatc agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag 
2941atccttgaga gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg 
3001ctatgtggcg cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata 
3061cactattctc agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat 
3121ggcatgacag taagagaatt atgcagtgct gccataacca tgagtgataa cactgcggcc 
3181aacttacttc tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg 
3241ggggatcatg taactcgcct tgatcgttgg gaaccggagc tgaatgaagc cataccaaac 
3301gacgagcgtg acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact 
3361ggcgaactac ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa 
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3421gttgcaggac cacttctgcg ctcggccctt ccggctggct ggtttattgc tgataaatct 
3481ggagccggtg agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaagccc 
3541tcccgtatcg tagttatcta cacgacgggg agtcaggcaa ctatggatga acgaaataga 
3601cagatcgctg agataggtgc ctcactgatt aagcattggt aactgtcaga ccaagtttac 
3661tcatatatac tttagattga tttaaaactt catttttaat ttaaaaggat ctaggtgaag 
3721atcctttttg ataatctcat gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg 
3781tcagaccccg tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc 
3841tgctgcttgc aaacaaaaaa accaccgcta ccagcggtgg tttgtttgcc ggatcaagag 
3901ctaccaactc tttttccgaa ggtaactggc ttcagcagag cgcagatacc aaatactgtc 
3961cttctagtgt agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac 
4021ctcgctctgc taatcctgtt accagtggct gctgccagtg gcgataagtc gtgtcttacc 
4081gggttggact caagacgata gttaccggat aaggcgcagc ggtcgggctg aacggggggt 
4141tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt 
4201gagctatgag aaagcgccac gcttcccgaa gggagaaagg cggacaggta tccggtaagc 
4261ggcagggtcg gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt 
4321tatagtcctg tcgggtttcg ccacctctga cttgagcgtc gatttttgtg atgctcgtca 
4381ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt 
4441tgctggcctt ttgctcacat gttctttcct gcgttatccc ctgattctgt ggataaccgt 
4501attaccgcct ttgagtgagc tgataccgct cgccgcagcc gaacgaccga gcgcagcgag 
4561tcagtgagcg aggaagcgga agagcgccca atacgcaaac cgcctctccc cgcgcgttgg 
4621ccgattcatt aatgcagctg gcacgacagg tttcccgact ggaaagcggg cagtgagcgc 
4681aacgcaatta atgtgagtta gctcactcat taggcacccc aggctttaca ctttatgctt 
4741ccggctcgta tgttgtgtgg aattgtgagc ggataacaat ttcacacagg aaacagctat 
4801gaccatgatt acgccaagct tgactagtta ttaatagtaa tcaattacgg ggtcattagt 
4861tcatagccca tatatggagt tccgcgttac ataacttacg gtaaatggcc cgcctggctg 
4921accgcccaac gacccccgcc cattgacgtc aataatgacg tatgttccca tagtaacgcc 
4981aatagggact ttccattgac gtcaatgggt ggagtattta cggtaaactg cccacttggc 
5041agtacatcaa gtgtatcata tgccaagtac gccccctatt gacgtcaatg acggtaaatg 
5101gcccgcctgg cattatgccc agtacatgac cttatgggac tttcctactt ggcagtacat 
5161ctacgtatta gtcatcgcta ttaccatgca tggtgatgcg gttttggcag tacatcaatg 
5221ggcgtggata gcggtttgac tcacggggat ttccaagtct ccaccccatt gacgtcaatg 
5281ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac aactccgccc 
5341cattgacgca aatgggcggt aggcgtgtac ggtgggaggt ctatataagc agagctcaat 
5401aaaagagccc acaacccctc actcggcgcg ccagtcctcc gattgactga gtcgcccggg 
5461tacccgtgta tccaataaac cctcttgcag ttgcatccga cttgtggtct cgctgttcct 
5521tgggagggtc tcctctgagt gattgactac ccgtcagcgg gggtctttca tttgggggct 
5581cgtccgggat cgggagaccc ctgcccaggg accaccgacc caccaccggg aggtaagctg 
5641gccagcaact tatctgtgtc tgtccgattg tctagtgtct atgactgatt ttatgcgcct 
5701gcgtcggtac tagttagcta actagctctg tatctggcgg acccgtggtg gaactgacga 
5761gttcggaaca cccggccgca accctgggag acgtcccagg gacttcgggg gccgtttttg 
5821tggcccgacc tgagtccaaa aatcccgatc gttttggact ctttggtgca ccccccttag 
5881aggagggata tgtggttctg gtaggagacg agaacctaaa acagttcccg cctccgtctg 
5941aatttttgct ttcggtttgg gaccgaagcc gcgccgcgcg tcttgtctgc tgcagcatcg 
6001ttctgtgttg tctctgtctg actgtgtttc tgtatttgtc tgaaaatatg ggcccgggcc 
6061agactgttac cactccctta agtttgacct taggtcactg gaaagatgtc gagcggatcg 
6121ctcacaacca gtcggtagat gtcaagaaga gacgttgggt taccttctgc tctgcagaat 
6181ggccaacctt taacgtcgga tggccgcgag acggcacctt taaccgagac ctcatcaccc 
6241aggttaagat caaggtcttt tcacctggcc cgcatggaca cccagaccag gtcccctaca 
6301tcgtgacctg ggaagccttg gcttttgacc cccctccctg ggtcaagccc tttgtacacc 
6361ctaagcctcc gcctcctctt cctccatccg ccccgtctct cccccttgaa cctcctcgtt 
6421cgaccccgcc tcgatcctcc ctttatccag ccctcactcc ttctctaggc gcccccatat 
6481ggccatatga gatcttatat ggggcacccc cgccccttgt aaacttccct gaccctgaca 
6541tgacaagagt tactaacagc ccctctctcc aagctcactt acaggctctc tacttagtcc 
6601agcacgaagt ctggagacct ctggcggcag cctaccaaga acaactggac cgaccggtgg 
6661tacctcaccc ttaccgagtc ggcgacacag tgtgggtccg ccgacaccag actaagaacc 
6721tagaacctcg ctggaaagga ccttacacag tcctgctgac cacccccacc gccctcaaag 
6781tagacggcat cgcagcttgg atacacgccg cccacgtgtt aatacgactc actataggga 
6841aggctgccga ccccgggggt ggaccatcct ctagactgcc  
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FLNA in Expression vector pCeMM-NTAP(GS) 
ORIGIN       
Start codon 
Protein G 
TEV cleavage site 
SBP 
Restriction sites 
Insert (FLNA) 
 
 
catgggcacccccgcagtcaccacctacaagctggtcattaacggcaagactctgaagggc 
  M  G  T  P  A  V  T  T  Y  K  L  V  I  N  G  K  T  L  K  G  
gagaccaccaccaaggccgtggacgcagaaaccgcggaaaaggcgttcaagcagtacgcg 
 E  T  T  T  K  A  V  D  A  E  T  A  E  K  A  F  K  Q  Y  A  
aacgacaacggggtggacggagtctggacctacgatgacgctacaaaaacgttcaccgtg 
 N  D  N  G  V  D  G  V  W  T  Y  D  D  A  T  K  T  F  T  V  
accgaggttaacacccccgctgtgactacgtacaagctggtgatcaatgggaagaccctg 
 T  E  V  N  T  P  A  V  T  T  Y  K  L  V  I  N  G  K  T  L  
aagggcgagaccaccacgaaagctgtagacgccgagacagccgagaaggccttcaagcag 
 K  G  E  T  T  T  K  A  V  D  A  E  T  A  E  K  A  F  K  Q  
tacgccaatgacaacggcgtggatggcgtgtggacctatgacgacgccacgaagacattc 
 Y  A  N  D  N  G  V  D  G  V  W  T  Y  D  D  A  T  K  T  F  
actgtgactgagatcgatgagaacctctacttccagggcggcagtatggacgagaagacc 
 T  V  T  E  I  D  E  N  L  Y  F  Q  G  G  S  M  D  E  K  T  
accggctggagaggcggccacgtggtcgagggactggccggtgagctggagcagctacgg 
 T  G  W  R  G  G  H  V  V  E  G  L  A  G  E  L  E  Q  L  R  
gcccgccttgagcaccacccccaggggcagcgcgagccgggccggccggcgcgccatatg FseI 
 A  R  L  E  H  H  P  Q  G  Q  R  E  P  G  R  P  A  R  H  M  
gctagcggccatcaaacaagtttgtactcgagccaggatatgacagcccaggtgaccagc XhoI 
 A  S  G  H  Q  T  S  L  Y  S  S  Q  D  M  T  A  Q  V  T  S  
ccatcgggcaagacccatgaggccgagatcgtggaaggggagaaccacacctactgcatc 
 P  S  G  K  T  H  E  A  E  I  V  E  G  E  N  H  T  Y  C  I  
cgctttgttcccgctgagatgggcacacacacagtcagcgtgaagtacaagggccagcac 
 R  F  V  P  A  E  M  G  T  H  T  V  S  V  K  Y  K  G  Q  H  
gtgcctgggagccccttccagttcaccgtggggcccctaggggaagggggagcccacaag 
 V  P  G  S  P  F  Q  F  T  V  G  P  L  G  E  G  G  A  H  K  
gtccgagctgggggccctggcctggagagagctgaagctggagtgccagccgaattcagt 
 V  R  A  G  G  P  G  L  E  R  A  E  A  G  V  P  A  E  F  S  
atctggacccgggaagctggtgctggaggcctggccattgctgtcgagggccccagcaag 
 I  W  T  R  E  A  G  A  G  G  L  A  I  A  V  E  G  P  S  K  
gctgagatctcttttgaggaccgcaaggacggctcctgtggtgtggcttatgtggtccag 
 A  E  I  S  F  E  D  R  K  D  G  S  C  G  V  A  Y  V  V  Q  
gagccaggtgactacgaagtctcagtcaagttcaacgaggaacacattcccgacagcccc 
 E  P  G  D  Y  E  V  S  V  K  F  N  E  E  H  I  P  D  S  P  
ttcgtggtgcctgtggcttctccgtctggcgacgcccgccgcctcactgtttctagcctt 
 F  V  V  P  V  A  S  P  S  G  D  A  R  R  L  T  V  S  S  L  
cA/Gggagtcagggctaaaggtcaaccagccagcctcttttgcagtcagcctgaacggggcc 
 Q/R  E  S  G  L  K  V  N  Q  P  A  S  F  A  V  S  L  N  G  A  
aagggggcgatcgatgccaaggtgcacagcccctcaggagccctggaggagtgctatgtc 
 K  G  A  I  D  A  K  V  H  S  P  S  G  A  L  E  E  C  Y  V  
acagaaattgaccaagataagtatgctgtgcgcttcatccctcgggagaatggcgtttac 
 T  E  I  D  Q  D  K  Y  A  V  R  F  I  P  R  E  N  G  V  Y  
ctgattgacgtcaagttcaacggcacccacatccctggaagccccttcaagatccgagtt 
 L  I  D  V  K  F  N  G  T  H  I  P  G  S  P  F  K  I  R  V  
ggggagcctgggcatggaggggacccaggcttggtgtctgcttacggagcaggtctggaa 
 G  E  P  G  H  G  G  D  P  G  L  V  S  A  Y  G  A  G  L  E  
ggcggtgtcacagggaacccagctgagttcgtcgtgaacacgagcaatgcgggagctggt 
 G  G  V  T  G  N  P  A  E  F  V  V  N  T  S  N  A  G  A  G  
gccctgtcggtgaccattgacggcccctccaaggtgaagatggattgccaggagtgccct 
	   141	  
 A  L  S  V  T  I  D  G  P  S  K  V  K  M  D  C  Q  E  C  P  
gagggctaccgcgtcacctatacccccatggcacctggcagctacctcatctccatcaag 
 E  G  Y  R  V  T  Y  T  P  M  A  P  G  S  Y  L  I  S  I  K  
tacggcggcccctaccacattgggggcagccccttcaaggccaaagtcacaggcccccgt 
 Y  G  G  P  Y  H  I  G  G  S  P  F  K  A  K  V  T  G  P  R  
ctcgtcagcaaccacagcctccacgagacatcatcagtgtttgtagactctctgaccaag 
 L  V  S  N  H  S  L  H  E  T  S  S  V  F  V  D  S  L  T  K  
gccacctgtgccccccagcatggggccccgggtcctgggcctgctgacgccagcaaggtg 
 A  T  C  A  P  Q  H  G  A  P  G  P  G  P  A  D  A  S  K  V  
gtggccaagggcctggggctgagcaaggcctacgtaggccagaagagcagcttcacagta 
 V  A  K  G  L  G  L  S  K  A  Y  V  G  Q  K  S  S  F  T  V  
gactgcagcaaagcaggcaacaacatgctgctggtgggggttcatggcccaaggaccccc 
 D  C  S  K  A  G  N  N  M  L  L  V  G  V  H  G  P  R  T  P  
tgcgaggagatcctggtgaagcacgtgggcagccggctctacagcgtgtcctacctgctc 
 C  E  E  I  L  V  K  H  V  G  S  R  L  Y  S  V  S  Y  L  L  
aaggacaagggggagtacacactggtggtcaaatggggggacgagcacatcccaggcagc 
 K  D  K  G  E  Y  T  L  V  V  K  W  G  D  E  H  I  P  G  S  
ccctaccgcgttgtggtgccctga 
 P  Y  R  V  V  V  P  -   
   gcggc cgctacgtaa  Not1 
NotI   
601 attccgcccc tctccctccc ccccccctaa cgttactggc cgaagccgct tggaataagg 
661 ccggtgtgcg tttgtctata tgttattttc caccatattg ccgtcttttg gcaatgtgag 
721 ggcccggaaa cctggccctg tcttcttgac gagcattcct aggggtcttt cccctctcgc 
781 caaaggaatg caaggtctgt tgaatgtcgt gaaggaagca gttcctctgg aagcttcttg 
841 aagacaaaca acgtctgtag cgaccctttg caggcagcgg aaccccccac ctggcgacag 
901 gtgcctctgc ggccaaaagc cacgtgtata agatacacct gcaaaggcgg cacaacccca 
961 gtgccacgtt gtgagttgga tagttgtgga aagagtcaaa tggctctcct caagcgtatt 
1021caacaagggg ctgaaggatg cccagaaggt accccattgt atgggatctg atctggggcc 
1081tcggtgcaca tgctttacat gtgtttagtc gaggttaaaa aacgtctagg ccccccgaac 
1141cacggggacg tggttttcct ttgaaaaaca cgatgataat atggccacaa ccatggtgag 
1201caagggcgag gagctgttca ccggggtggt gcccatcctg gtcgagctgg acggcgacgt 
1261gaacggccac aagttcagcg tgtccggcga gggcgagggc gatgccacct acggcaagct 
1321gaccctgaag ttcatctgca ccaccggcaa gctgcccgtg ccctggccca ccctcgtgac 
1381caccctgacc tacggcgtgc agtgcttcag ccgctacccc gaccacatga agcagcacga 
1441cttcttcaag tccgccatgc ccgaaggcta cgtccaggag cgcaccatct tcttcaagga 
1501cgacggcaac tacaagaccc gcgccgaggt gaagttcgag ggcgacaccc tggtgaaccg 
1561catcgagctg aagggcatcg acttcaagga ggacggcaac atcctggggc acaagctgga 
1621gtacaactac aacagccaca acgtctatat catggccgac aagcagaaga acggcatcaa 
1681ggtgaacttc aagatccgcc acaacatcga ggacggcagc gtgcagctcg ccgaccacta 
1741ccagcagaac acccccatcg gcgacggccc cgtgctgctg cccgacaacc actacctgag 
1801cacccagtcc gccctgagca aagaccccaa cgagaagcgc gatcacatgg tcctgctgga 
1861gttcgtgacc gccgccggga tcactcacgg catggacgag ctgtacaagt aaagcgccag 
1921cacagtggtc gagatccgga ttagtccaat ttgttaaaga caggatatca gtggtccagg 
1981ctctagtttt gactcaacaa tatcaccagc tgaagcctat agagtacgag ccatagataa 
2041aataaaagat tttatttagt ctccagaaaa aggggggaat gaaagacccc acctgtaggt 
2101ttggcaagct agcttaagta acgccatttt gcaaggcatg gaaaaataca taactgagaa 
2161tagagaagtt cagatcaagg tcaggaacag atggaacagc tgaatatggg ccaaacagga 
2221tatctgtggt aagcagttcc tgccccggct cagggccaag aacagatgga acagctgaat 
2281atgggccaaa caggatatct gtggtaagca gttcctgccc cggctcaggg ccaagaacag 
2341atggtcccca gatgcggtcc agccctcagc agtttctaga gaaccatcag atgtttccag 
2401ggtgccccaa ggacctgaaa tgaccctgtg ccttatttga actaaccaat cagttcgctt 
2461ctcgcttctg ttcgcgcgct tctgctcccc gagctcaata aaagagccca caacccctca 
2521ctcggggcgc cagtcctccg attgactgag tcgcccgggt acccgtgtat ccaataaacc 
2581ctcttgcagt tgcatccgac ttgtggtctc gctgttcctt gggagggtct cctctgagtg 
2641attgactacc cgtcagcggg ggtctttcac acatgcagca tgtatcaaaa ttaatttggt 
2701tttttttctt aagtatttac attaaatggc catagtattg aaaaaggaag agtatgagta 
2761ttcaacattt ccgtgtcgcc cttattccct tttttgcggc attttgcctt cctgtttttg 
2821ctcacccaga aacgctggtg aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg 
2881gttacatcga actggatctc aacagcggta agatccttga gagttttcgc cccgaagaac 
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2941gttttccaat gatgagcact tttaaagttc tgctatgtgg cgcggtatta tcccgtattg 
3001acgccgggca agagcaactc ggtcgccgca tacactattc tcagaatgac ttggttgagt 
3061actcaccagt cacagaaaag catcttacgg atggcatgac agtaagagaa ttatgcagtg 
3121ctgccataac catgagtgat aacactgcgg ccaacttact tctgacaacg atcggaggac 
3181cgaaggagct aaccgctttt ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt 
3241gggaaccgga gctgaatgaa gccataccaa acgacgagcg tgacaccacg atgcctgtag 
3301caatggcaac aacgttgcgc aaactattaa ctggcgaact acttactcta gcttcccggc 
3361aacaattaat agactggatg gaggcggata aagttgcagg accacttctg cgctcggccc 
3421ttccggctgg ctggtttatt gctgataaat ctggagccgg tgagcgtggg tctcgcggta 
3481tcattgcagc actggggcca gatggtaagc cctcccgtat cgtagttatc tacacgacgg 
3541ggagtcaggc aactatggat gaacgaaata gacagatcgc tgagataggt gcctcactga 
3601ttaagcattg gtaactgtca gaccaagttt actcatatat actttagatt gatttaaaac 
3661ttcattttta atttaaaagg atctaggtga agatcctttt tgataatctc atgaccaaaa 
3721tcccttaacg tgagttttcg ttccactgag cgtcagaccc cgtagaaaag atcaaaggat 
3781cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc 
3841taccagcggt ggtttgtttg ccggatcaag agctaccaac tctttttccg aaggtaactg 
3901gcttcagcag agcgcagata ccaaatactg tccttctagt gtagccgtag ttaggccacc 
3961acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaatcctg ttaccagtgg 
4021ctgctgccag tggcgataag tcgtgtctta ccgggttgga ctcaagacga tagttaccgg 
4081ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac acagcccagc ttggagcgaa 
4141cgacctacac cgaactgaga tacctacagc gtgagctatg agaaagcgcc acgcttcccg 
4201aagggagaaa ggcggacagg tatccggtaa gcggcagggt cggaacagga gagcgcacga 
4261gggagcttcc agggggaaac gcctggtatc tttatagtcc tgtcgggttt cgccacctct 
4321gacttgagcg tcgatttttg tgatgctcgt caggggggcg gagcctatgg aaaaacgcca 
4381gcaacgcggc ctttttacgg ttcctggcct tttgctggcc ttttgctcac atgttctttc 
4441ctgcgttatc ccctgattct gtggataacc gtattaccgc ctttgagtga gctgataccg 
4501ctcgccgcag ccgaacgacc gagcgcagcg agtcagtgag cgaggaagcg gaagagcgcc 
4561caatacgcaa accgcctctc cccgcgcgtt ggccgattca ttaatgcagc tggcacgaca 
4621ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat taatgtgagt tagctcactc 
4681attaggcacc ccaggcttta cactttatgc ttccggctcg tatgttgtgt ggaattgtga 
4741gcggataaca atttcacaca ggaaacagct atgaccatga ttacgccaag cttgactagt 
4801tattaatagt aatcaattac ggggtcatta gttcatagcc catatatgga gttccgcgtt 
4861acataactta cggtaaatgg cccgcctggc tgaccgccca acgacccccg cccattgacg 
4921tcaataatga cgtatgttcc catagtaacg ccaataggga ctttccattg acgtcaatgg 
4981gtggagtatt tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt 
5041acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc ccagtacatg 
5101accttatggg actttcctac ttggcagtac atctacgtat tagtcatcgc tattaccatg 
5161catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg 
5221atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg 
5281ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt 
5341acggtgggag gtctatataa gcagagctca ataaaagagc ccacaacccc tcactcggcg 
5401cgccagtcct ccgattgact gagtcgcccg ggtacccgtg tatccaataa accctcttgc 
5461agttgcatcc gacttgtggt ctcgctgttc cttgggaggg tctcctctga gtgattgact 
5521acccgtcagc gggggtcttt catttggggg ctcgtccggg atcgggagac ccctgcccag 
5581ggaccaccga cccaccaccg ggaggtaagc tggccagcaa cttatctgtg tctgtccgat 
5641tgtctagtgt ctatgactga ttttatgcgc ctgcgtcggt actagttagc taactagctc 
5701tgtatctggc ggacccgtgg tggaactgac gagttcggaa cacccggccg caaccctggg 
5761agacgtccca gggacttcgg gggccgtttt tgtggcccga cctgagtcca aaaatcccga 
5821tcgttttgga ctctttggtg cacccccctt agaggaggga tatgtggttc tggtaggaga 
5881cgagaaccta aaacagttcc cgcctccgtc tgaatttttg ctttcggttt gggaccgaag 
5941ccgcgccgcg cgtcttgtct gctgcagcat cgttctgtgt tgtctctgtc tgactgtgtt 
6001tctgtatttg tctgaaaata tgggcccggg ccagactgtt accactccct taagtttgac 
6061cttaggtcac tggaaagatg tcgagcggat cgctcacaac cagtcggtag atgtcaagaa 
6121gagacgttgg gttaccttct gctctgcaga atggccaacc tttaacgtcg gatggccgcg 
6181agacggcacc tttaaccgag acctcatcac ccaggttaag atcaaggtct tttcacctgg 
6241cccgcatgga cacccagacc aggtccccta catcgtgacc tgggaagcct tggcttttga 
6301cccccctccc tgggtcaagc cctttgtaca ccctaagcct ccgcctcctc ttcctccatc 
6361cgccccgtct ctcccccttg aacctcctcg ttcgaccccg cctcgatcct ccctttatcc 
6421agccctcact ccttctctag gcgcccccat atggccatat gagatcttat atggggcacc 
6481cccgcccctt gtaaacttcc ctgaccctga catgacaaga gttactaaca gcccctctct 
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6541ccaagctcac ttacaggctc tctacttagt ccagcacgaa gtctggagac ctctggcggc 
6601agcctaccaa gaacaactgg accgaccggt ggtacctcac ccttaccgag tcggcgacac 
6661agtgtgggtc cgccgacacc agactaagaa cctagaacct cgctggaaag gaccttacac 
6721agtcctgctg accaccccca ccgccctcaa agtagacggc atcgcagctt ggatacacgc 
6781cgcccacgtg ttaatacgac tcactatagg gaaggctgcc gaccccgggg gtggaccatc 
6841ctctagactg ccatggaatt 
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